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CHAPTER 1 
General Introduction and 
Scope of the Thesis
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The Erasmus MC University Medical Center has a longstanding tradition in fundamental 
and clinical research in the field of lysosomal storage diseases with a special focus on 
Pompe disease. The pioneering work of our research group has resulted in the successful 
implementation of enzyme replacement therapy (ERT) for patients with Pompe disease, 
turning it into the first treatable hereditary neuromuscular disorder. In 2007, the Center 
for Lysosomal and Metabolic diseases at Erasmus MC (formerly known as ‘Pompe Cen-
ter’) was appointed by the Dutch health authority as the Center of Excellence for this 
particular disease. In this function, the center coordinates the care of all patients com-
bined with basic and clinical research. The research performed at the center is denoted 
by its translational character, as basic research and clinical research go hand in hand. 
The studies described in this thesis follow the tradition of combining patient care 
with translational research. This introductory chapter provides background information 
on Pompe disease with subjects like: clinical manifestations, natural disease course, di-
agnosis, pathogenesis, and treatment. The chapter ends with a description of the study 
aims and the content of the thesis. 
PomPe Disease
Pompe disease derives its name from the Dutch pathologist Johannes Cassianus Pompe. 
In 1932 he published a case of a 7-month-old girl who was thought to have died from 
pneumonia, however the autopsy revealed an enormous heart and other enlarged or-
gans.1 Studying post mortem tissues using light microscopy, he found massive vacuolar 
storage of glycogen in most organs, called it ‘generalized’ glycogenosis and concluded 
that the disease could be due to a defect in the infant’s glycogen metabolism. Accord-
ingly, Pompe disease belongs to the glycogenoses, a group of metabolic disorders caused 
by deficiencies of one or another enzyme associated with glycogen metabolism. In 1952, 
a classification was made of the different glycogen storage diseases and Pompe disease 
was classified as glycogen storage disease type II.2 About a decade later Hers and cowork-
ers demonstrated deficiency of the lysosomal enzyme acid α-glucosidase in five infants 
with Pompe disease.3 4 The enzyme cleaves both the α-1,4 as well as the α-1,6 glycosidic 
bonds at acid pH and thereby degrades the glucose polymer glycogen into glucose. Pompe 
disease became the first lysosomal storage disorder with a known enzymatic defect, and 
many other lysosomal enzyme deficiencies were subsequently discovered (Figure 1).5 
The discovery of the responsible deficient enzyme has given rise to the denominations 
acid α-glucosidase deficiency or acid maltase deficiency. In the following years, acid 
α-glucosidase deficiency was also identified as the cause of slowly progressive muscular 
weakness in children and adults, and therefore is one of the neuromuscular diseases.6-8 
Hence, the clinical spectrum of Pompe expanded from infants with severe muscle weak-
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ness and cardiomegaly to patients with onset of slowly increasing muscle weakness in 
late adulthood. In children and adults Pompe disease usually manifests itself as a limb-
girdle myopathy, as pathological changes are most prominent in the skeletal muscles of 
the trunk and proximal limbs.9 10 
There are over 600 hundred different neuromuscular diseases. Often it concerns 
genetic conditions having a low prevalence.11 Nevertheless, it is estimated that in total 
about 200.000 – 400.000 people in the Netherlands have a neuromuscular disease.12 
For Pompe disease, worldwide estimates vary from one in 40.000 to one in 300.000 live 
births.13-16 In the Netherlands, the overall incidence is 1 in 40.000 live births, stratified for 
phenotype the classic infantile form accounts for a predicted frequency of 1 in 138.000 
and the childhood and adult form for a predicted frequency of 1 in 57.000.14 Due to its 
low prevalence and severe nature, Pompe disease meets the criteria for classification as 
an orphan disease.17
From 1999 on, more patients have been referred to our center, as it was designated as 
the Center of Excellence for Pompe disease in the Netherlands. To date, we know of 26 
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Figure 1 Pathways of glycogen metabolism and effect of GAA deficiency 
Glycogen, a polymer of glucose, is transported to the lysosomes by autophagy and is used to store energy 
within the cells. When energy is needed, the intra-lysosomal glycogen is degraded into glucose by acid 
α-glucosidase (GAA). In case the enzyme is absent or deficient, glycogen accumulates in the lysosomes, 
which increase, swell and finally rupture. This causes cellular damage and finally loss of function. This 
figure was adapted from the publication by Raben et al. entitled ‘Autophagy and mitochondria in Pompe 
disease: nothing is so new as what has long been forgotten’ in the American Journal of Medical Genetics 
2012, by permission of John Wiley and Sons. 
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patients with the classic infantile phenotype and of 135 patients with non-classic Pompe 
disease, 22 of whom were diagnosed in childhood and 113 in adulthood. 
clinical sPectrum, manifestations anD Disease course
clinical spectrum
The first reported cases of Pompe disease were infants who died of cardiorespiratory 
failure within the first year of life.1 18 19 With increasing knowledge of the symptomatol-
ogy of the disease, the clinical spectrum has expanded and actually comprises patients 
with first symptoms at any age and widely differing rates of disease progression.10 20-23 
All phenotypes together form a continuous clinical spectrum (Figure 2).24 The clinically 
severest and rapid progressive classic infantile phenotype is situated on the one end of 
the spectrum. It is characterized by onset of symptoms within the first six months of life 
and by a hypertrophic cardiomyopathy.25 26 The rest of the spectrum encompasses more 
slowly progressive forms with onset of symptoms in childhood or adulthood with only 
rarely, or no signs of cardiac involvement.27-30 There is no consensus among experts on 
the nomenclature used for the different clinical subtypes of Pompe disease. Recently, the 
following nomenclature was proposed, which uses a mixture of old and new terminol-
ogy and is practical for the use of reporting data: 1) classic infantile Pompe disease as 
defined above; 2) childhood Pompe disease for patients lacking the hypertrophic cardio-
myopathy and possessing residual enzyme activity and with onset of symptoms from 
birth till adolescence; and 3) adult Pompe disease for patients similar as described in 2), 
but with onset of symptoms from adolescence to late adulthood.24 
Born with
Pompe disease
Classic
infantile
Childhood Adult
Non-classic
Age (years)
0 1 16 80
Figure 2 The clinical spectrum of Pompe disease
The figure was adapted from the publication written by Güngör and Reuser entitled ‘How to describe the 
clinical spectrum in Pompe disease?’ in the American Journal of Medical Genetics 2013, by permission of 
John Wiley and Sons. 
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clinical manifestations and natural course in classic infantile Pompe disease
Patients with classic infantile Pompe disease almost always present with obvious 
symptoms within the first three months after birth. The symptoms consist of feeding 
difficulties, generalized muscle hypotonia (floppy infant), muscular weakness, failure to 
thrive and respiratory insufficiency predisposing for respiratory infections.25 26 A minority 
of infants suffer shortly after birth from cardiac failure or cardiac arrhythmias. Due to 
rapidly progressive muscular weakness, the motor development is evidently delayed or 
even absent, patients do not learn to roll over or sit. Other symptoms and findings are 
macroglossia, moderate hepato(spleno)megaly, and hearing deficits due to the accumu-
lation of glycogen in the sensory cells of the cochlea.31 Untreated patients decease on 
average between six and seven months old due to cardiorespiratory failure.25 26
clinical manifestations and natural course in childhood and adult Pompe disease
The initial symptoms in children and adults with Pompe disease can appear at any age 
from early infancy to late adulthood (range first to seventh decade) and comprise dif-
ficulties with running, performing sports, walking, climbing stairs or standing up from 
a chair.20 21 28 32-37 The disease develops as a slowly progressive symmetrical limb-girdle 
myopathy without clinical signs of cardiac involvement. The disease also affects the 
respiratory muscles and diaphragm. In a cross-sectional study in the Dutch population 
about three quarter of the patients had some degree of pulmonary dysfunction and 
38% had obvious diaphragmatic weakness (defined as an inability to endure testing in 
supine position, a large drop in VC upon changing posture (>25%), or decreased MIP).38 
About 10% of patients experienced presenting symptoms attributable to respiratory 
dysfunction, such as shortness of breath, disrupted sleep, or morning headaches. In 2% 
of the patients, the development of acute respiratory failure leads to the diagnosis of 
Pompe disease.33 36 39 Fatigue was mentioned by a quarter of the patients as one of the 
earliest symptoms, and 76-85% of the patients report disproportional levels of fatigue.32 
40 41 Pain, mainly experienced in the legs, can also be an initial symptoms and is reported 
during the course of disease by 33-36% of the patients.28 32 42
Neurological examination often reveals less well known features of Pompe disease, 
which are sometimes symptomatic of other neuromuscular diseases, e.g. asymmetric 
ptosis,43-46 bulbar weakness,43 47 48 scoliosis,48-50 and severe scapular winging.27 48 Less 
frequently encountered features of the disease are macroglossia 51-53 and rigid spine.54-56 
It was shown in our cohort that these occurred in a considerable number of patients.10
The natural history is characterized by gradual progression of muscle weakness that 
in the majority (60-70%) of patients leads to wheelchair and ventilator dependency.21 36 
In general, the degree of skeletal muscle involvement is associated with the degree of 
pulmonary dysfunction, but there are patients with fairly limited motor problems who 
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are dependent on invasive ventilation.32 34 38 The severity of disease usually relates to the 
disease duration, but the pace of decline may vary among patients, even among affected 
siblings.23 33 57 58 About a quarter of the children that are diagnosed under the age of 15 
years seem to have a relative severe and fast progressive form of Pompe disease.21 
The life expectancy of children and adults with Pompe disease is shorter than the 
average normal for the general population.59 Respiratory failure, sometimes associated 
with pneumonia and complications of immobility are often the cause of death.36 60
Diagnosis
Differential diagnosis
Because this thesis has its focus on patients with non-classic forms of Pompe disease, 
the differential diagnosis of classic-infantile Pompe disease will not be discussed in this 
paragraph. 
Most often the initial symptoms in non-classic Pompe disease are related to limb-
girdle weakness. This gives rise to an extensive differential diagnosis, as a lot of defects 
in the peripheral nervous system can cause limb-girdle weakness: examples are defects 
in cell bodies located in the spinal cord (anterior horns cells), the nerve roots and nerve 
plexus, peripheral nerves, neuromuscular junction and the skeletal muscles (Figure 3). 
Alternative diagnoses causing these defects are for instance hereditary limb-girdle mus-
cular dystrophies, myotonic dystrophy type II (PROMM) or other metabolic myopathies. 
Table I lists examples of diseases that are included in the differential diagnosis of child-
hood and adult onset Pompe disease. For instance, besides limb-girdle weakness, ptosis, 
bulbar weakness, scoliosis, macroglossia, rigid spine, lumbar lordosis, and severe scapu-
lar winging, are among the clinical features that Pompe disease shares with other neu-
romuscular diseases. With regard to ptosis, the differential diagnosis can be narrowed 
down to disorders like myasthenia gravis, oculopharyngeal muscular dystrophy (OPMD), 
myotonic dystrophy (DM) type 1 and mitochondrial myopathy; with regard to bulbar 
weakness, to Kennedy disease, myasthenia gravis, mitochondrial myopathy, OPMD, and 
DM type I; with regard to macroglossia, to Becker muscular dystrophy, amyloid myopathy 
in primary amyloidosis, and hypothyroidism; with regard to rigid spine, to rigid spinal 
muscular dystrophy (selonopathy-related myopathy / selenoprotein N1-related myopa-
thy [SEPN1RM]), or rigid spine syndrome, but, rigid spine is also seen in different stages 
of various other myopathies;61 with regard to scoliosis, to FSHD, polymyositis, dermato-
myositis, sporadic inclusion body myositis (sIBM), OPMD, dystrophinopathy; and with 
respect to scapular winging, especially to facioscapulohumeral dystrophy (FSHD), and 
also to limb-girdle muscular dystrophy (LGMD) 2A and spinal accessory nerve lesions.11 
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Figure 3  Neuromuscular diseases and the lower motor neuron
The lower motor neuron (anterior horn cells) receives input from the central nervous system to initiate 
contraction in the skeletal muscles by innervating several muscle fibers. The dendrites at one end of the 
nerve cell carry the signal (action potential) toward the cell body of the neuron via the neuron axon onto 
the axon terminals. Subsequently, acetylcholine, a small molecule excitatory neurotransmitter, diffuses 
through the synapse and binds nicotinic acetylcholine receptors on the plasma membrane of the muscle 
fiber, also known as the sarcolemma. The binding of acetylcholine to the receptor can depolarize the 
muscle fiber, causing a cascade that eventually results in muscle contraction. For several neuromuscular 
disorders, the location is indicated where the pathologic mechanisms affect the peripheral nervous 
system (PNS). The figure was adapted from the publication written by N.C. Notermans and P.A. van Doorn 
entitled ‘Polyneuropathie: diagnostiek en beleid’, in the Nederlands Tijdschrift voor Geneeskunde 1997, by 
permission of Bohn Stafleu van Loghum.
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Diagnostic process
In children and adults with limb-girdle muscular weakness the diagnostic guideline 
of the Dutch Neuromuscular Research Center ISNO (Interuniversitair Steunpunt Neu-
romusculair Onderzoek) entitled ‘diagnosis of limb-girdle weakness’ is very helpful 
for structuring the diagnostic workup.62 The guideline recommends performing acid 
α-glucosidase testing in all patient with limb-girdle weakness of whom the family his-
tory is not indicative of another neuromuscular disease given that neurogenic, endocri-
nological and iatrogenic causes are unlikely or ruled out. This prominent position within 
the diagnostic work-up of adult patients with limb-girdle weakness can be explained 
by the fact that it is relatively easy to diagnose by enzymatic and DNA testing and also 
Table I Differential diagnosis of childhood and adult Pompe disease a
Toxic/endocrine causes
- Endocrinological disorders, e.g. hypothyroidism
- Myotoxic medication, e.g. statins, corticosteroids, interferon
- Toxic myopathy, e.g. red yeast rice, alcohol
Myopathies and muscular dystrophies
- Duchenne muscular dystrophy
- Becker muscular dystrophy
- Limb-Girdle Muscular Dystrophies (LGMD type 1 and 2; autosomal dominant and recessive)
- Emery-Dreifuss muscular dystrophy 
- FacioScapuloHumeral Dystrophy (FSHD)
- OculoPharyngeal Muscular Dystrophy (OPMD)
- Myotonic Dystrophy (DM)  type 1 and DM type 2 (PROMM)
- Glycogen Storage Diseases (GSDs) 
          - GSD type V / muscle phosphorylase deficiency / McArdle disease
          - GSD type VII / muscle phosphofructokinase deficiency / Tauri disease
- Mitochondrial myopathies
- Amyloidosis
- Rigid spine syndrome 
- Bethlem’s myopathy
- Myofibrillar myopathy
- Myositis
          - Dermatomyositis
          - Polymyositis
          - Sporadic Inclusion Body Myositis (sIBM)
Disorders of the neuromuscular junction
- Myasthenia Gravis (MG)
- Lambert-Eaton Myasthenic Syndrome (LEMS)
Disorders of the spinal cord
- Spinal Muscular Atrophy (SMA) type II, III and IV 
- Kennedy disease (spinal and bulbar muscular atrophy)
a The presented differential diagnosis does not pretend to be entirely complete
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because Pompe disease currently is the only inherited neuromuscular disorder for which 
a disease-specific treatment is available.
Enzymatic and molecular diagnosis
When a diagnosis of Pompe disease is suspected, first an enzyme assay in leucocytes is 
performed, as this is a rapid and decisive way for making the diagnosis. This assay uses 
either the natural substrate glycogen or the artificial substrate 4-methylumbellifery-
alpha-D-glucopyraniside(4-MU) for measuring the acid α-glucosidase activity. In both 
cases the addition of acarbose to the incubation mixture is mandatory to eliminate the 
activity of glucoamylase.63  The acid α-glucosidase activity as measured in cultured skin 
fibroblasts obtained by skin biopsy is the most reliable assay, but it takes more time. 
The assay is suitable for accurately measuring the level of enzyme activity and in most 
cases distinguishes patients with classic infantile Pompe disease from those with less 
progressive clinical phenotypes (Reuser Expert Opinion). 
The test can also be performed using dried bloodspots, but requires more than other 
tests confirmation by alternative assay procedures.35 The dried blood spot assay has 
its greatest value when used for screening purposes in patient populations at risk for 
Pompe disease or for neonatal screening.64-66 Just as in dried blood spots, the quantifica-
tion of glycogen-filled vacuoles in peripheral blood lymphocytes using PAS staining is an 
inexpensive and rapid test to support a diagnosis of Pompe disease.67 
To complete the diagnostic work-up after the demonstration of an acid α-glucosidase 
deficiency, DNA analysis is performed.68 This information is also needed for facilitating 
genetic counseling of patients and their family. By DNA analysis the pathogenic sequence 
variations in GAA gen are detected, provided that each of them is located on another GAA 
allele.68 The latter can be confirmed by establishing the parental segregation pattern. In 
case a diagnosis is made through DNA analysis, it is highly recommended to confirm the 
diagnosis by enzymatic testing.  
(Co-incidental) findings of several tests may prompt suspicion of Pompe disease. Rou-
tine blood tests can be of supportive value. Patients with classic infantile Pompe disease, 
but also older children and adults - although not always-, have elevated serum levels 
of creatine-kinase (CK), transaminases (AST and ALT), and lactate dehydrogenase (LDH). 
Normal CK values are most often encountered in patients with advanced disease, and 
seldom in the early stages of the disease.10 26 36 69 70 
Given that clinical symptoms are due to muscle weakness and that elevated serum 
CK levels occur in Pompe patients, muscle biopsy is frequently used in the diagnostic 
process. The muscle biopsy of a patient with Pompe disease usually shows a vacuolar 
myopathy (Figure 4; see also the paragraph about pathology). The vacuoles have in-
creased glycogen contents, which can be visualized by PAS-staining, and are identified as 
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lysosomes by the positive reaction for acid phosphatase. The acid phosphatase staining 
is the most sensitive stain for showing the vacuolar myopathy (Figure 4B), as in adult 
Pompe disease this stain can show pathologic changes, while the PAS-staining does not. 
It is important to know that a normal muscle biopsy does not rule out a diagnosis of 
Pompe disease, since approximately up to 30% of adult patients’ muscle biopsies can be 
non-pathological.33
Hence, when  the differential diagnosis on beforehand includes Pompe disease, the 
first step should be to apply for an enzyme assay, as this is a less invasive and quicker 
method for diagnostic confirmation.
Figure 4 Muscle biopsies of a healthy control and patients with Pompe disease
A shows a Haematoxylin-Eosin (HE) stain of a cross section of a muscle biopsy from muscle tissue of a 
healthy individual. The muscle architecture is normal and there are no signs of myopathic changes. B 
is an acid phosphatase staining and C is a HE staining of a cross section of muscle biopsy of an adult 
patient with a confirmed diagnosis of Pompe disease. Multiple muscle fibers show small vacuoles (arrow), 
typical for a vacuolar myopathy. In Pompe disease these vacuoles are enlarged lysosomes, filled with 
glycogen, which show on the Periodic Acid-Schiff (PAS) staining (D) as a deep purple color. In B-D muscle 
cell morphology is essentially preserved, except for some variance in muscle fiber size, which indicates 
slight myopathic changes. E shows a HE staining of a severely affected classic-infantile patient showing 
the clear variation in muscle fiber size and vacuolar myopathy. F shows a PAS staining of a muscle biopsy 
from a severely affected classic-infantile patient, the deposition of glycogen has massively destructed the 
muscle morphology, and only very few fibers are well preserved. Muscle fibers contain multiply enlarged 
lysosomes. 
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Pathogenesis
Pompe disease is caused by pathogenic sequence variations in the gene coding for 
acid α-glucosidase, which is located on chromosome 17q25.2-q25.3 (Online Mendelian 
Inheritance in Man [OMIM] number 232300).71 The pattern of inheritance is autosomal-
recessive, this means that both GAA alleles need to carry a pathogenic mutation before 
the disease develops. Patients have inherited a pathogenic mutation from each parent. 
The mutations can be the same or different. In the latter case the patients are compound 
heterozygotes. Parents are true carriers in virtually all family situations, and carriers of 
Pompe disease are unaffected.35 In very rare situations one of the two parents carries 
a second pathogenic mutation next to the one transmitted to the child and can be af-
fected too. Thus far over 400 sequence variants in the GAA gene have been described 
(see www.pompecenter.nl), 70% of these are pathogenic. Most mutations are very rare, 
but some prevail within ethnic groups.
The sequence variants in the GAA gene vary by severity. Due to degenerate codons 
some nucleotide changes do not have any effect on the nature of the encoded amino 
acid. Missense mutations substitute one amino acid for another and have, in extremo, no 
effect at all or lead to total loss of protein function. Frame shift mutations, stop codons, 
and large deletions/insertion are mostly detrimental for protein function. Thus, the kind 
and combination of mutations in each of the two copies of the GAA genes determines 
how much of either catalytically active or inactive acid α-glucosidase is produced in the 
cells of a patient with Pompe disease.   
The patients with classic infantile Pompe disease have virtually no acid α-glucosidase 
activity left, whereas patients with first symptoms in adulthood have in general residual 
acid α-glucosidase activity up to 25% of normal. 
The most common and most severe pathogenic GAA sequence variants in the Dutch 
population are: c.2481+102_2646del (delexon18; p.Gly828_Asn882del), c.525del 
(delT525; p.Glu176fsX45), and c.925 G>A (p.Gly309Arg).22 The most common mutation 
in patients with onset of symptoms in childhood or adulthood is: c.-32-13T>G (IVS1), a 
mutation located in intron 1 of the GAA gene reducing the fidelity of correct splicing to 
10-20% of average normal, which reduces the acid α-glucosidase production to the same 
extent.72-75
Thus, there is a scale of residual acid α-glucosidase activities along the clinical spectrum 
of Pompe disease; very low in early onset disease and higher in later onset phenotypes. 
However, some patients with onset of symptoms in late adulthood were demonstrated 
to have very low acid α-glucosidase activity, which points to the rather strong effect 
that secondary factors can have on the clinical expression of Pompe disease. Phenotypic 
diversity has also been reported within families.35 57 76 
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Pathology
When there is virtually no acid α-glucosidase activity left, as in classic infantile Pompe 
disease, the lysosomal glycogen degradation is completely blocked. Lysosomal glycogen 
starts to accumulate rapidly in all tissues, although symptoms arise mainly from the 
accumulation in skeletal, cardiac and smooth muscle.20 22 In children and adults with 
Pompe disease, the lysosomal glycogen accumulation has primarily pathogenic conse-
quences in the muscle fibers of the proximal muscles. The reduced pulmonary function 
is mainly caused by weakness of the diaphragm.38 Cerebral or thoracic aneurysms or 
dissections can occur due to accumulation of lysosomal glycogen in the smooth muscle 
cells of the vascular wall.77-81
The process by which lysosomal glycogen storage leads to loss of muscle contractile 
function is still a point of interest as knowing the precise mechanism may open the way 
to new treatment options. 
Cytoplasmic glycogen stores in liver and muscle tissue and serves as quickly available 
energy resources, but lysosomal glycogen turnover does not seem to be of crucial im-
portance for energy supply. Unlike patients with McArdle disease, patients with Pompe 
disease do not suffer from cramps or muscle pain during exercise and they have a normal 
glycogen metabolism during exercise.82 Mechanical distortion of muscle contraction was 
demonstrated to be the more likely mechanism of muscle weakness in Pompe disease. 
In the early phase of the disease process, glycogen-filled lysosomes may settle in be-
tween the myofibrils and reduce contractile force.83 When lysosomal glycogen storage 
continues, the number of lysosomes increases as well as their size. They may ultimately 
rupture thereby releasing lytic enzymes into the cytoplasm.84 Along with lysosomal 
dysfunction, and probably as a result of it, the autophagic pathway is derailed.85 This 
leads to deposition of non-contractile cellular debris disrupting muscle architecture and 
muscle contractibility.49 As a consequence the muscle performance decreases and the 
muscle fibers become atrophic. Finally, the muscle fibers are replaced by connective and 
adipose tissue, and irreversible damage has occurred. Figure 4B-D show different stain-
ings of a cross section of a muscle biopsy of an adult patient, showing the picture of a 
mild vacuolar myopathy, where multiple muscle fibers show small vacuoles. Figure 4F 
shows a Periodic Acid-Schiff (PAS) staining of a muscle biopsy from a severely affected 
classic-infantile patient. The deposition of glycogen has caused massive destruction of 
the muscle tissue, and only very few fibers are well preserved. 
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treatment
The treatment of patients with Pompe disease can be divided into disease-specific and 
supportive treatment. Enzyme replacement therapy with alglucosidase alfa is currently 
the only registered disease-specific treatment, nevertheless the following treatment 
options are among the strategies currently being studied: alternative formulas of 
recombinant human α-glucosidase with improved efficacy; gene-modified autologous 
hematopoietic stem-cell therapy; and pharmacological chaperone therapies. These new 
treatment strategies will be addressed in the general discussion of this thesis.  
supportive treatment
Before the introduction of ERT, supportive care for the classical-infantile patients was 
mainly targeted at respiratory support, providing adequate nutrition and alleviating 
symptoms, and had a less multidisciplinary character than the supportive care for 
children and adults with the disease. With the advent of ERT, however, classic-infantile 
patients live longer and exhibit a new phenotype with residual morbidity also creating a 
need for multidisciplinary care. 
The multidisciplinary team, often consists of a pediatrician (children) or internist 
(adults), (child)neurologist, pulmonologist, and a rehabilitation physician. Because the 
clinical manifestations and course of Pompe disease in children and adults are fairly 
variable, supportive management and rehabilitation should be individualized. The re-
habilitation program is targeted at preserving and optimizing motor and respiratory 
function. Therefore the following services should be available: physical therapy, occu-
pational therapy, speech therapy with dysphagia evaluation, nutritionist, orthotics, and 
psychological support.
For patients with symptomatic pulmonary dysfunction mechanical ventilatory 
support ought to be timely installed. As diaphragmatic weakness is a hallmark of the 
disease, patients often suffer from nocturnal hypoventilation and sleep-disordered 
breathing.86 By installing nightly non-invasive ventilation, patients’ general well-being 
will significantly improve and safeguard the patient from acute respiratory failure.39 87  
enzyme replacement therapy 
In the 1960s unsuccessful attempts were made to treat patients with intravenous in-
fusions of acid α-glucosidase preparations from human placenta and from Aspergillus 
niger. As we know now, the dosage was far too low and the preparations did not have the 
proper characteristics.88-92 Since 1984 our research group at Erasmus MC has worked on 
the development of ERT for Pompe disease. By cloning the GAA gene and unraveling the 
biosynthesis, processing and lysosomal targeting of acid α-glucosidase, the production 
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of recombinant human α-glucosidase became feasible.93-98 Two production lines were 
simultaneously explored: in genetically modified CHO cells (Chinese hamster ovary) 
and in the milk of transgenic rabbit. After proof of principle in animal models of Pompe 
disease, clinical application of ERT finally ushered at the turn of the twenty-first century. 
In 2006, approval from both the European and US regulatory authorities (EMA and FDA) 
was obtained for the use of alglucosidase alfa (Myozyme®) as long-term treatment for 
patients with a confirmed diagnosis of Pompe disease, and the treatment costs in the 
Netherlands were also reimbursed by the Dutch Health Insurance Companies (CVZ/CTG). 
In 2013, the Ministry of Health decided to prolong reimbursement based on the results 
of the randomized-controlled trial, of the open-label prospective study on the effects 
and safety of ERT in children and adults, and the study on survival in treated adults,99-101 
as well as the results of the farmaco-economic study. 
Enzyme replacement therapy in classic infantile Pompe disease
Clinical trials of ERT with recombinant human α-glucosidase started in 1999.102-109 
Patients with classic infantile Pompe disease were treated first. They demonstrated im-
proved survival, diminished cardiac hypertrophy, and gain in motor milestones. Several 
patients learned to roll over, stand and walk.25 26 Today, there is over 15 year of experience 
with treating classic-infantile patients with ERT. Experiences collected over the entire 
period showed that about one third of treated patients learned to walk, but that about 
the same percentage of patients did not survive beyond the age of four years or became 
ventilator dependent. From these results we have learned that clinical outcome can be 
improved by an early start of treatment - when the patient is still in a relatively good 
condition - and higher dosing of alglucosidase alfa (40 mg/kg every week instead of 20 
mg/kg every other week (eow)). Factors that adversely affect treatment outcome are 
a lack of Cross Reacting Immunological Material (CRIM), which is in essence any form 
of endogenous acid α-glucosidase, and a strong immunologic response to the admin-
istered recombinant enzyme.104 109-113 Presently, measures are being taken to prevent or 
counteract these negative factors as much as possible.114-117 With the implementation of 
an early treatment start, optimized dosing and immune tolerance protocols, the benefi-
cial effects of ERT have substantially increased in patients with classic infantile Pompe 
disease as compared to the earlier days. However, variations in treatment responses are 
still observed and in the majority of patients some form of residual disease remains.118-120
Enzyme replacement therapy in children and adults with Pompe disease
The first pilot study in non-classic Pompe disease that started in 1999 at the Erasmus 
MC included two children and one adult patient. At start of treatment all three patients 
were severely affected: all were wheelchair bound and two of them used mechanical 
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ventilator support. They were initially treated with enzyme extracted from the milk of 
transgenic rabbits and switched in 2002 to enzyme derived from genetically modified 
CHO cells. Over 8 years of therapy, positive effects were observed on muscle strength and 
muscle function. The effects of ERT were minimal in the eldest patient who was almost 
paralytic at the start of treatment, but it was remarkable in the youngest, 11-year-old 
and least affected, patient. He learned to walk and has at present, after 15 years of ERT, 
virtually no symptoms. All three patients were less fatigued and experienced an improved 
quality of life.121 122 The effects observed in classical infantile patients together with the 
positive results in the first observational studies performed in children and adults with 
Pompe disease,121-126 led to the design of the first and only performed placebo-controlled 
clinical trial, named Late-Onset Treatment Study (LOTS).101 This study evaluated the ef-
ficacy and safety of alglucosidase in 90 patients aged between 10 and 70 years of whom 
60 received treatment and 30 placebo over an 18-month follow-up period. The study 
provided proof of efficacy, as treated patients showed improvement of walking distance 
and stabilization of pulmonary function and the results differed significantly from the 
placebo group. Results for the other outcome measures were also in favor of the treat-
ment group, but statistical significance was only reached for improvement of maximal 
expiratory pressure (MEP). Patients in the treatment group and placebo group had 
similar frequencies of adverse events. Anaphylactic reactions occurred only in patients 
who received alglucosidase alfa (5%). All treated patients developed anti-alglucosidase 
alfa antibodies, but no consistent effect on treatment outcome or association with the 
occurrence of infusion-associated reactions was found.  
The overall conclusion that can be drawn from the clinical studies summarized in Table 
III of the general discussion (Chapter 5) is that about 60-90% of the patients receiving 
ERT experience stabilization or improvement of skeletal muscle strength, motor function 
and pulmonary function, even though effects are modest. Considering the progressive 
nature of the disease clinical stabilization should be regarded as a positive outcome.127 
The latest important finding is that ERT prolongs the survival of affected adults.100 
As in classic infantile Pompe disease, some children and adults respond far better to 
ERT than others. The reason why is a challenging subject for future research. By monitor-
ing the long-term treatment effects and determining prognostic factors for treatment 
outcome, the goal is to optimize treatment efficacy and develop proper treatment guide-
lines, thereby further improving patients’ perspectives. 
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scoPe
When enzyme-replacement therapy was about to become available for patients with 
Pompe disease, our research activities were strongly focused on data collection from 
untreated patients to enable later comparison of the clinical course before and after 
treatment. In 2004, just before enzyme replacement therapy became available, the 
Dutch nationwide prospective observational study on the natural course and the effects 
of enzyme replacement therapy in children and adults with Pompe disease started at 
Erasmus MC. In addition, information on level of handicap, quality of life and fatigue is 
gathered through questionnaires. The latter activity is conducted via the IPA (Interna-
tional Pompe Association)/Erasmus MC Pompe survey, an ongoing international survey 
that already started in 2002. In this survey, patients from around the world participate 
and are yearly questioned.
Up to now, our center has coordinated the care for 160 Pompe patients, of whom 
136 received enzyme replacement therapy. In the context of the nationwide prospective 
cohort study, all patients are followed on fixed regular intervals using a large set of as-
sessments (Appendix A).
The results described in this thesis are predominantly based on patient-related data 
collected in the Erasmus MC natural course prospective cohort study, and on the subse-
quent study on the effects of ERT in adults with Pompe disease. Chapter 2.2 and Chapter 
4.3 report on data collected in the context of the IPA/Erasmus MC Pompe survey.
study aims
The aims of the studies described in this thesis were as follows: 
1. To investigate and to describe the clinical features of adults with Pompe disease and 
follow how these features develop over time.
2. To study the effects of enzyme replacement therapy and to identify prognostic factors 
related to treatment response. 
3. To investigate the impact of adverse events and antibody response to recombinant 
human acid α-glucosidase in adults affected by Pompe disease.
4. To study whether continued enzyme replacement therapy during pregnancy and 
lactation is safe for mother and child.
5. To study the impact of fatigue in neuromuscular diseases with a focus on Pompe 
disease and to evaluate the effect of enzyme replacement therapy on fatigue in 
adults with Pompe disease.
26   |    Chapter 1
Chapter
 1
outline of the thesis
Chapter 1 is an introductory chapter providing elementary information on Pompe dis-
ease. Besides the clinical features, the spectrum of the disease, enzymatic and molecular 
background, muscle pathology, and diagnostic tools, aspects of treatment with enzyme-
replacement therapy are described. Chapter 2.1 delineates the natural disease course 
in 94 adults with Pompe disease. Chapter 2.2 deals more specifically with survival, and 
reports the survival data of a large international cohort of untreated patients. Chapter 3 
is dedicated to enzyme replacement therapy. The effects of enzyme replacement therapy 
and prognostic factors for treatment outcome are described in part 3.1; the role of 
antibody response and the occurrence of infusion-associated reactions are highlighted 
in part 3.2 and part 3.3; while part 3.4 is about enzyme-replacement therapy during 
pregnancy and lactation. Chapter 4 explores the causes of fatigue and the burden of 
fatigue in neuromuscular disorders with special emphasis on Pompe disease. The effect 
of enzyme replacement therapy on fatigue in Pompe disease is described at the end.
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abstract
Background Due partly to physicians’ unawareness, many adults with Pompe disease 
are diagnosed with great delay. Besides, it is not well known which factors influence the 
rate of disease progression, and thus disease outcome. We delineated the specific clinical 
features of Pompe disease in adults, and mapped out the distribution and severity of 
muscle weakness, and the sequence of involvement of the individual muscle groups. 
Furthermore, we defined the natural disease course and identified prognostic factors for 
disease progression.
Methods We conducted a single-center, prospective, observational study. Muscle 
strength (manual muscle testing, and hand-held dynamometry), muscle function (quick 
motor function test), and pulmonary function (forced vital capacity in sitting and supine 
positions) were assessed every 3–6 months and analyzed using repeated-measures 
ANOVA.
Results Between October 2004 and August 2009, 94 patients aged between 25 and 75 
years were included in the study. Although skeletal muscle weakness was typically dis-
tributed in a limb-girdle pattern, many patients had unfamiliar features such as ptosis 
(23%), bulbar weakness (28%), and scapular winging (33%). During follow-up (average 
1.6 years, range 0.5–4.2 years), skeletal muscle strength deteriorated significantly 
(mean declines of -1.3% point/year for manual muscle testing and of -2.6% points/year 
for hand-held dynamometry; both p<0.001). Longer disease duration (>15 years) and 
pulmonary involvement (forced vital capacity in sitting position <80%) at study entry 
predicted faster decline. On average, forced vital capacity in supine position deteriorated 
by 1.3% points per year (p=0.02). Decline in pulmonary function was consistent across 
subgroups. Ten percent of patients declined unexpectedly fast.
Conclusions Recognizing patterns of common and less familiar characteristics in adults 
with Pompe disease facilitates timely diagnosis. Longer disease duration and reduced 
pulmonary function stand out as predictors of rapid disease progression, and aid in 
deciding whether to initiate enzyme replacement therapy, or when.
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backgrounD
Pompe disease is a rare autosomal recessive metabolic disorder, whereby mutations in 
the GAA gene lead to partial or total absence of the lysosomal enzyme acid α-glucosidase. 
The disease presents as a spectrum of phenotypes, ranging from a rapidly fatal phenotype 
in infants1 to slower progressive phenotypes in older children and adults.2,3 Many adults 
with Pompe disease are diagnosed late in life, when they are already in an advanced 
stage of the disease. While this may be due to clinicians’ unawareness, it may also be 
explained by similarities in clinical presentation with other ‘limb-girdle’ diseases such as 
the limb-girdle muscular dystrophies (LGMD), Becker muscular dystrophy, or metabolic 
myopathies.4 Our first objective was to optimize future diagnosis in this patient group by 
classifying their specific clinical features, and by delineating the distribution and severity 
of muscle weakness and the sequential involvement of individual muscle groups during 
the course of the disease.
Since 2006, enzyme replacement therapy (ERT) with recombinant human acid 
α-glucosidase has been approved for the treatment of Pompe disease. In infants, treat-
ment generally improves cardiorespiratory function and motor function, and prolongs 
survival.5-8 In older children and adults ERT was shown to improve or stabilize skeletal 
muscle strength, muscle function and respiratory function. However, the magnitude of 
the therapeutic response varies between individual patients.9-14 To fully assess the ef-
fects of enzyme therapy, and to decide whom to treat and when to start treatment, it is 
necessary to be optimally informed about the course of disease prior to treatment, and 
about factors influencing disease progression. We thus prospectively studied the natural 
disease course, and aimed to identify prognostic factors for faster disease progression 
and poor outcome in a large cohort of adult Pompe patients.
methoDs
Participants and study design
We performed a single-center, prospective, cohort study, in which participation was open 
to all adults diagnosed with Pompe disease who had not yet received treatment with 
enzyme replacement therapy. Their diagnosis was confirmed by acid α-glucosidase assay 
in leukocytes or fibroblasts and by mutation analysis. All patients were seen between 
October 2004 and August 2009 at Erasmus MC University Medical Center, the designated 
center of expertise for Pompe disease in the Netherlands. The interval between visits 
was three to six months. Patients were recruited either through neuromuscular centers 
in the Netherlands and Belgium, through the Dutch neuromuscular patient organiza-
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tion, or were referred to our Center by their treating physicians. The research protocol 
was approved by the Central Committee on Research Involving Human Subjects in the 
Netherlands (CCMO). All patients provided written informed consent.
Seven patients participated in the placebo arm of the randomized, placebo controlled 
trial on the safety and efficacy of alglucosidase alfa in late-onset Pompe disease.13 Data 
on these patients collected during this period are included in the present analyses. We 
have previously reported long-term retrospective data on muscle strength and pulmo-
nary function in 16 patients with Pompe disease.15 While 12 of these patients partici-
pated in the current study, the present analyses were based solely on new, prospectively 
obtained data.
Procedures
We gathered information on the following: 1) the nature of first symptoms and the age 
at which these had presented; 2) the age at which the diagnosis had been made; 3) 
duration of disease since onset of first symptoms; 4) the presence of specific clinical 
features such as scoliosis, bulbar involvement (defined as weakness of muscles involved 
in speech, chewing and swallowing), winging of the scapula (defined as a clearly visible 
protrusion of the scapula when the patient was in a resting position or was lifting the 
arms anteriorly or sidewards), muscle atrophy, or ptosis; 5) the use of a wheelchair or 
walking aids; 6) skeletal muscle strength; 7) the use of mechanical ventilatory support; 
8) the number of hours of ventilatory support per day; 9) pulmonary function; 10) cardiac 
function; 11) acid α-glucosidase activity in leukocytes and fibroblasts; 12) serum creatine 
kinase (CK); and 13) type of GAA mutation.
Skeletal muscle strength and muscle function
By manual muscle testing using the Medical Research Council (MRC) grading scale16 
(range 0–5; all patients were examined by NvdB or JdV), we measured 25 different 
muscle groups throughout the body to define the distribution of skeletal muscle weak-
ness and the severity of involvement of the separate muscle groups. We calculated a 
sumscore (range 0–130) for the muscle groups that were involved most: neck extensors, 
neck flexors, and bilateral shoulder adductors, shoulder abductors, shoulder exorotators, 
shoulder endorotators, elbow flexors, elbow extensors, hip extensors, hip flexors, hip 
abductors, hip adductors, knee flexors and knee extensors. This score was subsequently 
converted to a percentage of the maximum possible score. Although the abdominal 
muscles and trunk muscles were frequently involved, we did not include these muscle 
groups in the MRC sumscore since they were difficult to grade.
Hand-held dynamometry (HHD) (Cytec dynamometer, Groningen, the Netherlands) 
was used as a second measure of muscle strength to examine the following muscle 
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groups: neck extensors, neck flexors and bilateral shoulder abductors, elbow flexors, 
elbow extensors, hip flexors, hip abductors, knee flexors and knee extensors. The value 
(Newton) measured in each muscle group was expressed as a percentage of the median 
strength of healthy females and males17, and then combined into a sumscore by averag-
ing these for all 16 muscle groups, producing a score between 0 and 100 percent.
Muscle function was assessed using the Quick Motor Function Test (QMFT).18 A total 
score (range 0–64) was obtained by adding the scores of all items. This was then ex-
pressed as a percentage of the maximum score.
Pulmonary function 
Forced vital capacity (FVC) was measured using a Lilly type pneumograph (Viasys Health-
care, Würzburg, Germany) or the KoKo spirometry system (Ferraris Respiratory, Louis-
ville, USA) with the patient in upright seated and supine positions, according to ATS/
ERS standards.19 Results were expressed as a percentage of predicted normal values.20 
A measured value below 80% of the predicted value was considered to be abnormally 
low. Seven male patients who were invasively ventilated were artificially allotted a FVC 
value of 10% – just below the least observed value – since their omission might have led 
to biased results. These seven patients were however excluded from the longitudinal 
analysis.
statistical analysis
Baseline characteristics are summarized using descriptive statistics. Differences between 
males and females, and between patients with and without scapular winging, were as-
sessed using χ2 tests (wheelchair use, use of mechanical ventilation, and presence of 
scoliosis, bulbar muscle weakness, scapular winging or ptosis) or Mann-Whitney tests 
(strength of individual muscle groups, MRC sumscore, HHD sumscore, QMFT sumscore, 
and FVC measured in sitting and supine positions). We used the Spearman’s rank cor-
relation coefficient (ρ) to calculate the relationships between residual enzyme activity 
and rate of decline in muscle strength and pulmonary function, and between serum CK 
activity and age, muscle atrophy and disease duration. Longitudinal analysis of muscle 
strength and pulmonary function was performed using repeated measures ANOVA 
(random coefficient models). The annual changes are expressed in absolute percentage 
points (pp/y). For subgroup analyses, patients were divided into groups on the basis of 
gender (male, female); wheelchair use (yes, no); use of mechanical ventilation (yes, no); 
age at first study visit (<50 or ≥50 years; taking the median as the cut-off point); disease 
duration (<15 or ≥15 years; taking the median as the cut-off point); MRC/HHD sumscore 
at study entry (categorization in tertiles); and FVC in sitting position at study entry (<80 
or ≥80 % predicted). Analyses were performed with SPSS for Windows (version 15, SPSS 
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Inc., Chicago, IL) or SAS (version 9.1, SAS Institute Inc., Cary, NC). A p-value of ≤0.05 was 
considered statistically significant.
results
study population 
In order of referral, we included 91 adult Pompe patients from the Netherlands – rep-
resenting virtually all known patients in the Netherlands – and three patients from 
Belgium. On average, there was a seven-year delay between the first noted symptoms of 
Pompe disease and the actual diagnosis. The characteristics of the study population are 
summarized in Table I.
Table I Characteristics of the study population (n=94)a
General characteristics
Gender (males) 48 (51%)
Age at first study visit (years) 51.1 (38.3–60.6)
Age at onset of symptoms (years) 32.0 (25.5–40.0)
       - < 18 years 10 (11%)
       - ≥ 18 years 84 (89%)
Age at diagnosis (years) 40.2 (32.7–50.2)
Disease duration since onset of first symptoms at first study visit (years) 15.3 (7.7–24.7)
Time since diagnosis at first study visit (years) 9.2 (0.6–16.0)
       - 0 to 5 years 41 (44%)
       - 5 to 10 years 15 (16%)
       - 10 to 15 years 10 (11%)
       - > 15 years 28 (30%)
Use of walking aids 14 (15%)
Wheelchair use 30 (32%)
Age at start of wheelchair use (years) 49.0 (43-56)
Use of mechanical ventilation b 27 (29%)
Age at start of mechanical ventilation (years) 48 (38.5–57.5)
First symptoms noted c 
Skeletal muscle weakness 93 (99%)
       - Difficulty running 30 (32%)
       - Difficulty performing sports 22 (23%)
       - Difficulty climbing stairs 24 (26%)
       - Difficulty walking 15 (16%)
       - Difficulty rising from an armchair 11 (12%)
       - Difficulty rising from a lying position 9 (10%)
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baseline measurements
Characteristic clinical features
A substantial number of patients had less familiar features of Pompe disease, such as 
bulbar muscle weakness (28%), prominent scapular winging (33%, Figure 1B), or ptosis – 
not accompanied by external eye-movement disturbances (23%; Figure 1C). Seventy-one 
percent of patients with scapular winging had bulbar muscle weakness, against 37% 
without scapular winging (p=0.001).
Table I Continued
First symptoms noted c 
Fatigue 17 (18%)
Muscle soreness / cramps 16 (17%)
Respiratory failure 1 (1%)
Clinical features
Ptosis 22 (23%)
Bulbar muscle weaknessd 26 (28%)
Scapular wingingd 31 (33%)
Scoliosis 22 (23%)
Increased lumbar lordosis 62 (66%)
Prominent muscle atrophy 53 (56%)
       - Shoulder girdle / upper arms 25 (27%)
       - Trunk muscles 27 (29%)
       - Pelvic girdle / Upper leg (Figure 1A) 40 (43%)
Laboratory parameters
CK (U/l)
       - Males 449 (279–1040)
       - Females 493 (237–715)
α-glucosidase activity in leukocytes (nmol glucose/h/mg protein) e 1.2 (0.4–2.2)
α-glucosidase activity in fibroblasts (nmol 4-MU/h/mg protein) f 13.0 (11.0–15.0)
Genotype
       - c.-32-13T>G / very severe or potentially less severe pathogenic mutation 92 (98%)
       - c.671G>A / c.525del 1 (1%)
       - unknown 1(1%)
4-MU=4-methylumbelliferyl-α-D-glucopyranoside
a Data are number (%) or median (IQR). b More men then women used mechanical ventilation (p=0.009). 
c Two or more complaints were counted if these occurred within the same year. d More men than women 
had scapular winging and bulbar muscle weakness (p=0.001 and p=0.05). e control range 48 to 215 nmol 
glucose/h/mg protein. f control range 45 to 180 nmol 4-MU/h/mg protein.
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Clinical distribution and severity of muscle weakness, and sequence of muscle involvement 
during the disease course
Shoulder abductors, abdominal muscles, paraspinal muscles, hip flexors, hip exten-
sors, hip adductors, and hip abductors were affected in more than 80% of all patients 
(Figure 2A). The strength of the quadriceps muscle was reduced in only 55% of patients. 
The muscles of the hands and feet were relatively spared, being affected in under 10% 
of patients. Abdominal muscles, paraspinal muscles – with exception of the neck exten-
sors and neck flexors –, hip flexors, hip extensors, hip adductors and hip abductors were 
the most severely affected muscles (Figure 2B). The pattern of muscle weakness was 
symmetrical in 95% of patients, and the distribution of weakness did not differ between 
males and females. Relative to patients without scapular winging, patients with scapu-
lar winging had more severe involvement of the shoulder girdle musculature (trapezius 
muscle, deltoid muscle, pectoral muscle, shoulder exorotators, and shoulder endorota-
tors; all p<0.02). The ‘limb-girdle’ and trunk muscles were affected early in the course of 
Figure 1 Clinical features in Pompe disease
Atrophy of the quadriceps muscle (A), scapular winging (B), and ptosis (C) as notable clinical features in 
adults with Pompe disease. Photographs are printed with permission of the patients.
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Figure 2 Muscle weakness in adults with Pompe disease
Distribution of skeletal muscle weakness (A), severity of muscle weakness of the individual muscle groups 
(B), and involvement of the individual muscles over time (C) in 94 adults with Pompe disease.
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the disease, while the distal muscle groups – if they were involved at all – were affected 
late in the course of the disease (Figure 2B).
cardiac evaluation
In a subset of 51 patients cardiac evaluation was performed, comprising electrocardi-
ography, Holter monitoring, two-dimensional echocardiography, low-dose dobutamine 
stress echocardiography, and tissue Doppler imaging. One patient had a mild hypertro-
phic cardiomyopathy, while four other patients had minor cardiac abnormalities that 
could be attributed to advanced age, hypertension or preexisting cardiac pathology 
unrelated to Pompe disease.21,22
laboratory parameters
Most patients had moderately increased serum CK; in two patients it was more than 10 
times the upper limit of normal, while 10 had a normal serum CK. Serum CK activity was 
moderately inversely associated with age (ρ -0.71, p<0.001), disease duration (ρ -0.45, 
p<0.001), and the presence of muscle atrophy (ρ -0.53, p<0.001).
Prospective follow-up
General aspects
Prospective follow-up data for a period longer than six months were available for 66 pa-
tients (median 1.6 years, range 0.5–4.2 years), 52 of whom were followed for longer than 
one year, and 22 of whom for longer than two years. Within the follow-up period, one 
patient became wheelchair bound, mechanical ventilation was initiated in four patients, 
and eight patients needed to increase their number of hours of ventilation per day. One 
severely affected patient died due to pneumonia complicated by respiratory failure.
Disease progression and predictors for disease outcome
Muscle strength and muscle function
At baseline, the MRC sumscore ranged from 39.2% to 100% (median 84.7%, one patient 
had the maximum possible score). During follow-up, the MRC sumscore deteriorated 
by 1.3% points per year on average (p<0.001; Figure 3A). Baseline values for hand-held 
dynamometry ranged from 31.6% to 100% (median 77.0%, three patients had the 
maximum score). Within the observed follow-up period, HHD sumscore deteriorated by 
2.6% points per year (p<0.001; Figure 3B). With regard to the individual muscle groups, 
strength declined significantly in the elbow flexors, hip abductors, knee extensors and 
knee flexors, ranging from -6.9 pp/y in elbow flexors to -2.5 pp/y in knee extensors 
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Figure 3 Longitudinal changes in muscle strength
Rate of disease progression measured by manual muscle testing (MRC sumscore) (A) and hand-held 
dynamometry (HHD sumscore) (B) related to follow-up duration measured from time of inclusion in 
the study for 66 adults with Pompe disease. The figure shows the measured values and regression lines 
at group level for the following subgroups: 1) Patients with normal pulmonary function (FVC ≥80% 
predicted) and disease duration <15 years (circles, black line); 2) patients with normal pulmonary function 
(FVC ≥80% predicted) and disease duration ≥15 years (red squares, red line); 3) patients with abnormal 
pulmonary function (FVC <80% predicted) and disease duration <15 years (green triangles, green line); 
and 4) patients with abnormal pulmonary function (FVC <80% predicted) and disease duration ≥15 years 
(blue asterisks, blue line).
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Figure 4 Muscle strength in individual muscle groups measured by hand-held dynamometry
Values for individual patients are shown at baseline (black squares) and during follow-up (last measured 
value) (open squares). Mean and standard error of the mean are given for each muscle group.
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(Figure 4). Subgroup analysis (Table II) revealed that the decline was faster in patients 
with a reduced pulmonary function at baseline (FVC <80%) than in those with normal 
pulmonary function (-2.2 pp/y against -0.6 pp/y for MRC sumscore (p=0.01), and -4.5 
pp/y against -1.4 pp/y for HHD sumscore (p<0.01)), and in patients who had had the 
disease for longer than 15 years compared to those who had been ill less long (-2.1 pp/y 
against -0.7pp/y for MRC sumscore (p=0.04), and -4.2 pp/y against -2.0 pp/y for HHD 
sumscore (p<0.01)). Baseline QMFT scores ranged from 16.7% to 100% (median 63.7%). 
The changes that were found in muscle strength were however not reflected in changes 
in the QMFT (annual change 0.05% points, p=0.9). In no subgroups was a significant 
decline observed.
Pulmonary function
At baseline, FVC measured in sitting position was reduced (<80% of the predicted value) 
in 56 patients (60%). The reduction in FVC was more prominent in males than in females 
(mean FVC 57.5 % predicted against 80.3 % predicted, p<0.001). Patients with scapular 
winging had significantly lower FVC than those without scapular winging (mean FVC 
50.7% predicted against 84.5% predicted, p<0.001). In supine position, 76 patients 
(80%) had a reduced FVC. Changing from a sitting to a supine position, FVC fell in 21 
patients by over 25%, indicating possible diaphragmatic weakness. Neither was testing 
in the supine position attempted in 12 patients whose pulmonary function was already 
severely restricted in sitting position. We have recently reported more detailed data on 
pulmonary function in some of the study cohort.23 The mean yearly change in FVC mea-
sured in supine position was 1.3% points (p=0.02), and for FVC in upright position -1.0% 
points (p=0.06) (Figure 5). The rate at which pulmonary function declined was consistent 
across subgroups.
There was no significant association between the change in muscle strength or pul-
monary function and residual enzyme activity (Spearman’s rho for MRC sumscore -0.21, 
p=0.14; for HHD sumscore -0.51, p=0.74; for FVC in upright position 0.07, p=0.65; and for 
FVC in supine position -0.32, p=0.84).
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Figure 5 Longitudinal changes in pulmonary function
Decline in pulmonary function in the upright seated (A) and supine (B) positions related to follow-up 
duration. Circles represent the measured values, the line represents the mean regression line at a group 
level.
a
b
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Disease course variability
In 59 patients progress of muscle weakness and pulmonary dysfunction could be com-
pared. In nine patients (15%; 4 males, 5 females), pulmonary function and muscle strength 
did not decline during the prospective follow-up period. Relative to the total group, they 
had a shorter disease duration from onset of symptoms (7.3 years against 15.5 years, 
p=0.03). At baseline, the following had all been higher, though not significantly: FVC in 
sitting position (88.1% against 78.6%); FVC in supine position (80.4% against 61.1%); 
MRC sumscore (87.2% against 83.4%); and HHD sumscore (86.2% against 76.3%). In 28 
patients (47%), pulmonary function and skeletal muscle strength declined at a similar 
rate. In 22 patients (37%) the course of pulmonary function and muscle weakness fol-
lowed different courses, one deteriorating while the other remained stable, or one dete-
riorating faster than the other. Of the 50 patients who deteriorated during the follow-up 
period, eight (2 males, 6 females) had a relatively fast decline – more than 5 percentage 
points per year – in muscle strength, while a rapid decline in pulmonary function was 
seen in five patients (1 male, 4 females). There were no significant differences between 
these groups with regard to sex, age, age at onset of symptoms, duration of disease, 
length of prospective follow-up, level of residual enzyme activity, and the severity of 
pulmonary or skeletal muscle involvement at the start of the study.
Discussion
characteristic clinical features and pattern of muscle weakness
Our study in 94 adults with Pompe disease – which included virtually all known adult 
patients in the Netherlands – shows that, generally speaking, muscle weakness typically 
fits a pattern of limb-girdle myopathy. Interestingly, our findings about the distribution 
of muscle weakness, based on clinical examinations, match those of CT and MRI stud-
ies.24-26 We found weakness of the quadriceps muscle in 55% of patients only. This may 
have been due to our method of measuring muscle strength: whereas the advantage 
of the MRC score and HHD lie in the fact that they are easy for the clinician to use, 
quantitative muscle testing using QMT13,27 may be more reliable in patients with only 
minor loss of strength.
Besides limb-girdle weakness, many patients had less familiar features, which are 
sometimes symptomatic of other neuromuscular diseases. Though ptosis has been 
reported in the literature in no more than seven adult patients to date28-31, it was found 
in almost one quarter of our patients. Notably, while one might expect myogenic ptosis 
to be bilateral, it was unilateral in two-thirds of our patients.
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Despite the fact that bulbar muscle weakness is reported only occasionally in adult 
Pompe patients28,32, twenty-eight percent of the patients in our cohort had distinct bul-
bar muscle weakness. These patients are at risk of pulmonary complications.
One third of patients had prominent scapular winging, which is in line with several re-
cent reports.32,33 Many of these patients also had bulbar muscle involvement and severer 
weakness of the shoulder-girdle muscles than patients without scapular winging; these 
features are reminiscent of FSHD. If patients with such a “pseudo-FSHD” phenotype 
are overlooked, diagnosis may be delayed. However, the asymmetrical distribution of 
muscle weakness, the relatively common involvement of the distal muscles of the lower 
limbs, and the absence of severe or relatively severe pulmonary involvement in FSHD will 
generally allow the two diseases to be diagnosed correctly.34
Serum CK activity was normal in 10 patients, confirming that a normal serum CK does 
not rule out Pompe disease.35-37 In early stages of the disease, however, normal serum 
CK is quite uncommon. Although we did not systematically perform electromyography 
or muscle biopsies, it is well known that these may reveal no or only non-specific ab-
normalities in a considerable number of patients.38,39 Therefore, measurement of acid 
α-glucosidase activity and mutation analysis remain essential to confirm the diagnosis.
natural disease course
Although the average follow-up duration of 19 months seems rather short for a chronic 
disorder such as Pompe disease, it is the longest prospective follow-up ever carried out 
in “late-onset” Pompe disease. Moreover, as many patients are now treated with enzyme 
replacement therapy, prospective data on the natural course of the disease over a longer 
period of time are now impossible to obtain.
We found a significant worsening of muscle strength, reflected by declines in MRC 
sumscore (mean decline -1.3 pp/y) and HHD sumscore (mean decline -2.6 pp/y). Although 
we found significant changes in muscle strength and some patients became wheelchair 
or ventilator dependent during follow-up, the QMFT did not indicate a deterioration 
in limb-girdle muscle function. There may be two main reasons for this. First, the de-
cline in muscle strength may have been too small to cause changes in functional daily 
activities within the observed time-span. Second, although the QMFT showed a good 
discriminative ability and good responsiveness to change after start of enzyme replace-
ment therapy, it may not be sensitive enough to reflect minor changes in strength in 
functional changes during the natural course.18
Mechanical ventilation became necessary in four of the 67 hitherto un-ventilated 
patients, eight patients needed to increase their number of hours of ventilation, and one 
patient died due to respiratory complications. Despite this indication that pulmonary 
function clearly worsened during the time-span of the study, our findings regarding the 
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yearly decline seem somewhat lower than those of other studies.13,27 This may have been 
due to our method of patient selection: in the present study participation was open to 
all adult patients with a confirmed diagnosis of Pompe disease, including those with 
very limited pulmonary function to those who were invasively ventilated 24 hours a day. 
Although this reflects the spectrum of disease encountered in daily practice, one would 
expect further deterioration of pulmonary function in these patients to be minimal, 
thereby partly obscuring decline in the total group. Secondly, when enzyme replacement 
therapy became commercially available, we decided first to treat the most severely 
affected patients and patients with a rapid decline in pulmonary function and muscle 
strength, while patients with a slow disease course were started on ERT at a later stage. 
As a result, the length of prospective follow-up for the most severely affected patients 
was somewhat shorter (1.1 years on average) than for the least affected patients (1.7 
years on average, the longest follow-up being 4.2 years). Another factor that could have 
influenced the estimated rate of decline is the fact that data on seven patients who par-
ticipated in the placebo arm of the randomized controlled trial on the safety and efficacy 
of alglucosidase alfa in late-onset Pompe disease were included in the present analyses. 
However, a second analysis, excluding these patients to overcome a possible placebo 
effect, led to similar estimates of the rate at which muscle weakness and pulmonary 
dysfunction progress (not shown).
It should be noted that all patients except one had the c.-32-13T>G (IVS1-13T>G) 
mutation in combination with a null allele. Although this is the most common genotype 
in adult Pompe patients – present in 68-93% of patients27,40,41 – the estimated rate of 
disease progression may not apply to patients with different genotypes.
Predictors for disease outcome and disease course variability
Longer disease duration (>15 years) and pulmonary dysfunction (FVC <80%) were shown 
to be associated with a faster decline in muscle strength. Our results thus support those 
of the only other prospective study in adult Pompe patients, which found baseline sta-
tus and duration of illness to be the most important predictors of disease severity and 
disease progress.27
A subset of patients with shorter average disease duration and better baseline status 
did not deteriorate during follow-up, indicating that there might be a stable phase of sev-
eral years before a gradual decline inevitably occurs. This raises an interesting dilemma 
regarding the best time to start ERT.42 On the one hand, in patients who are only mildly 
affected and whose condition is stable, one might advocate that this – costly – lifelong 
treatment be postponed. On the other hand, studies measuring the effect of ERT show a 
trend toward better outcome in patients who were in a relatively good condition at the 
start of treatment.11,13,14 On the basis of our results, we suggest to start ERT in all patients 
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with pulmonary dysfunction and in patients with progressive muscle weakness, whereas 
in patients with minimal weakness, or in patients with solely elevated laboratory param-
eters treatment may be postponed, provided that they are monitored regularly. At our 
center, all patients undergo evaluation of muscle strength, pulmonary function, cardiac 
function, and hearing at referral, and evaluation of progression of muscle weakness and 
pulmonary dysfunction every three months thereafter.
conclusions
In summary, since the approval of enzyme replacement therapy in Pompe disease, early 
recognition of affected individuals has gained importance. The typical limb-girdle type 
muscle weakness – including prominent involvement of the trunk musculature – com-
bined with early and disproportionate pulmonary involvement relative to the degree 
of skeletal muscle weakness should raise the suspicion of Pompe disease. Although 
these are the most salient characteristics, less familiar features such as ptosis, scapular 
winging and bulbar weakness are far more common than generally thought. If these 
are recognized properly, timely diagnosis will be facilitated. Longer disease duration and 
reduced pulmonary function stand out as the most important factors for a rapid decline 
in muscle strength, which may aid in deciding whom to treat and when.
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abstract 
Background Pompe disease is a rare lysosomal storage disorder characterized by muscle 
weakness and wasting. The majority of adult patients have slowly progressive disease, 
which gradually impairs mobility and respiratory function and may lead to wheelchair 
and ventilator dependency. It is as yet unknown to what extent the disease reduces 
the life span of these patients. Our objective was to determine the survival of adults 
with Pompe disease not receiving ERT and to identify prognostic factors associated with 
survival.
Methods Data of 268 patients were collected in a prospective international observational 
study conducted between 2002 and 2009. Survival analyses from time of diagnosis and 
from time of study entry were performed using Kaplan-Meier curves and Cox-propor-
tional-hazards regression.
Results Median age at study entry was 48 years (range 19-79 years). Median survival after 
diagnosis was 27 years, while median age at diagnosis was 38 years. During follow-up, 
twenty-three patients died prior to ERT, with a median age at death of 55 (range 23-77 
years). Use of wheelchair and/or respiratory support and patients’ score on the Rotterdam 
Handicap Scale (RHS) were identified as prognostic factors for survival. Five-year survival 
for patients without a wheelchair or respiratory support was 95% compared to 74% in 
patients who were wheelchair-bound and used respiratory support. In a Dutch subgroup 
of 99 patients, we compared the observed number of deaths to the expected number of 
deaths in the age- and sex-matched general population. During a median follow-up of 
2.3 years, the number of deaths among the Dutch Pompe patients was higher than the 
expected number of deaths in the general population.
Conclusion Our study shows for the first time that untreated adults with Pompe disease 
have a higher mortality than the general population and that their levels of disability 
and handicap/participation are the most important factors associated with mortality. 
These results may be of relevance when addressing the effect of ERT or other potential 
treatment options on survival.
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backgrounD
Pompe disease, synonymously ‘acid maltase deficiency’ or ‘glycogen storage disease type 
II’, is a metabolic myopathy caused by deficiency of the enzyme acid α-glucosidase and 
resulting in intralysosomal accumulation of glycogen. This autosomal recessive disorder 
is mainly characterized by progressive loss of muscle strength and respiratory function 
due to destruction of muscle tissue.1, 2 Because of its low frequency of approximately 
1 in 40,000 births and the broad ethnic spreading,3-5 Pompe disease is a true orphan 
disease with the associated problem of collecting data in sufficiently large groups. Clini-
cal heterogeneity is an additional complicating factor.5, 6 Classic infantile Pompe disease, 
the most severe form, presents in the first months of life with generalized muscle 
weakness and cardiac hypertrophy. Without treatment these infants die before age one. 
Later-onset forms of Pompe disease comprise childhood, juvenile, and adult cases. The 
majority of these patients present with symptoms in adulthood with limb- girdle weak-
ness and respiratory problems.5  
For a long time, supportive care such as respiratory support was the only way of 
managing Pompe disease, but in the course of 2006 enzyme replacement therapy (ERT) 
with recombinant human α-glucosidase became available. Clinical trials showed that 
ERT can ameliorate motor outcome, improve cardiomyopathy and prolong survival in 
classic infantile Pompe disease.7-11 In children and adults treatment with ERT has been 
shown to stabilize respiratory function and to improve muscle function.12-16 
In contrast to classic infantile Pompe disease, in which survival is a key outcome 
measure to describe the natural course of the disease and to evaluate the effects of 
treatment, information on mortality in adults with Pompe disease has been lacking. 
The present study was performed to fill the gap of knowledge on the impact of Pompe 
disease on survival in untreated adult patients, using data collected prospectively in 
an international patient survey prior to the introduction of ERT. The objective was to 
determine natural course survival in adult patients with Pompe disease, to compare this 
to the general population and to assess differences in survival between subgroups of 
patients. 
methoDs
Data
Data were collected between May 2002 and December 2009 as part of an ongoing 
study on the natural course of Pompe disease (‘Pompe Survey’),6, 17 e.g. in which patients 
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complete a number of self-report questionnaires each year, gathering information on 
medical history, current disease status, use of care and quality of life.
Patients were recruited through patient organizations affiliated with the International 
Pompe Association (IPA) in Australia, Canada, Germany, the Netherlands, the United 
Kingdom and the United States. Inclusion criteria for the Pompe Survey were a diagnosis 
of Pompe disease and an age above 2 years. The present analyses only include patients 
of 18 years and older with late-onset Pompe disease.   
For the Dutch patients, more information was available as Erasmus MC was desig-
nated as the single referral center for treatment and longitudinal follow-up of Pompe 
patients in the Netherlands. 
All research protocols were approved by the medical ethics committee of Erasmus MC 
and/or the Central Committee on Research Involving Human Subjects. Written informed 
consent was obtained from all patients. 
explanation of variables
For the international participants in the Pompe Survey, the date of the last completed 
questionnaire before December 2009 was considered as the date of last follow-up. For 
the Dutch subgroup, the date of last follow-up was the last visit at our hospital in 2009 
or the date of the last completed questionnaire, whichever came last.  
When the date of death for the deceased was not exactly known it was estimated to 
be halfway between the date of the last completed questionnaire and the date at which 
the next questionnaire should have been completed.
The date of diagnosis was estimated as precisely as possible according to the informa-
tion provided in the questionnaires.
To assess the level of participation (defined as a person’s involvement in life situa-
tions; previously called ‘Handicap’),18, 19 the Rotterdam Handicap Scale (RHS) was used. 
The RHS consists of 9 questions on the topics of mobility, kitchen tasks, domestic tasks, 
leisure activities, travelling and work or study. The scores per item range from 1 (‘unable 
to fulfil the task or activity’) to 4 (‘complete fulfilment of the task or activity’).  If an item 
is not applicable to a patient, a score of 0 is given. The total score is calculated as the sum 
of the scores per item * 9/ (9-number of non-applicable or missing items).17, 20 The RHS 
score thus ranges from 9 to 36 and in the present analysis the number of items necessary 
to calculate a score was 5 out of 9 questions. 
To assess disability level at study entry patients were divided into four groups: 1) no 
wheelchair or respiratory support, 2) only wheelchair, 3) only respiratory support and 
4) both wheelchair and respiratory support. No division was made between partial and 
fulltime respiratory support, or whether it was invasive or non-invasive.
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According to their nationality patients were divided into the following groups: Nether-
lands, United Kingdom, United States, Germany, Canada, Australia and other (Denmark, 
Austria, Switzerland, Spain, Italy, New Zealand, Greece, Taiwan and Luxembourg). 
statistical analysis for survival from diagnosis and from study entry 
Survival was calculated from the date of diagnosis or study entry until the date of last 
follow-up, start of ERT or death. The survival times of patients who were alive at study 
end or lost to follow-up were censored. The survival times of the patients were also 
considered censored at the initiation of ERT. 
For survival from diagnosis and from study entry, the influence on survival was tested 
for the following variables: gender, age at diagnosis, and nationality. The variables age at 
entry, disability level and RHS score were only tested for survival from study entry.
For survival from diagnosis, the PROC PHREG method in SAS was used, because most 
of our patients were enrolled months or years after diagnosis. This means that the data 
are ‘left-truncated’, as opposed to usual time-to-event data where all patients are fol-
lowed from diagnosis. Estimates of survival from diagnosis in case not all patients enter 
the cohort study at the time of diagnosis require special calculations as described by 
Kurtzke.21  
Univariate analysis for survival from study entry was estimated by using the Ka-
plan–Meier method. Factors influencing survival were identified with the log-rank test. 
Multivariate analysis was performed with the Cox proportional-hazards method.  
mortality of Dutch patients compared to the general population 
Death probabilities from study entry were compared between the Dutch Pompe patients 
and the general population using death probabilities derived from the Dutch Central Bu-
reau of Statistics (CBS).22 For each case of our study population, the death probability per 
follow-up year of someone of the same age and gender from the general population was 
taken for comparison. Annual death probabilities per person were summed up and the 
sum of these cumulative death probabilities of the matched persons from the general 
population was used as the expected number of deaths. This was then compared to the 
observed number of deaths in our own cohort using the Poisson distribution.
All analyses were performed using SAS (version 9.2) or SPSS (version 15.0). Statistical 
significance was defined as a p-value ≤0.05 for all analyses.
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results
Patient characteristics 
As of December 2009, 303 adult patients were enrolled in the Pompe Survey. Thirty-five 
of them were excluded from the analyses. These were patients who had provided too 
little information about their diagnosis (n=8), patients with only baseline data available 
(n=15), patients already receiving ERT at study entry (n=2) and patients with important 
data missing such as date of birth (n=10). Thus, the current analyses covering the years 
2002 to 2009 comprise a total of 268 adults with Pompe disease from 15 different coun-
tries. Patient characteristics are summarized in Table I. 
Table I Patient characteristics of 268 untreated adult patients with Pompe disease
General characteristics
Female, n (%) 141 (53)
Median age at study entry, years (range)  48 (19-79)
Median age at diagnosis, years (range) 38 (1-68)
Number of patients diagnosed in age categories of 15 years, n (%)
            <15 years 22 (8)
           16-30 years 59 (22)
           31-45 years 115 (43)
           46-60 years 61 (23)
           >61 years 11 (4)
Nationality, n (%)
           Netherlands 99 (37)
           Germany 48 (18)
           US 69 (26)
           UK 20 (8)
           Australia 13 (5)
           Canada 9 (3)
           Other 10 (4)
Median disease duration at entry, years (range) 9 (0-32)
Median follow up time, years (range)   3.5 (0.02-7)
Disability level at study entry, n (%) 
           No wheelchair use or respiratory supportª 127 (47)
           Wheelchair use 34 (13)
           Use of respiratory support 39 (15)
           Both wheelchair use and respiratory support 68 (25)
Median RHS score* at study entry (range) (n=258) 27 (9-36)
Continuous variables are expressed as median (range). Categorical variables are expressed as n (%).
ª ‘Respiratory support’ includes partial and fulltime, invasive and non-invasive respiratory support
* RHS assesses the level of participation/handicap; score varies between 9 (severe participation restrictions) 
and 36 (no participation restrictions). 
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At study entry patients’ age varied between 19 and 79 years with a median age of 48 
years. This did not differ significantly between countries. The median age at diagnosis 
was 38 (range 1-68) years. Median follow-up time from study entry was 3.5 years, with a 
maximum of 7 years. Seventy-eight percent of the patients were followed for 2 years or 
more and 62% of the patients for 3 years or more. Differences in disability level between 
countries were found, with the lowest rates of wheelchair and ventilator use in the 
Dutch patient group (32% and 26%, respectively). Almost all Dutch patients carried the 
most common c.-32-13T >G (IVS1) GAA mutation in combination with a fully deleterious 
mutation on the other allele. The c.-32-13T>G (IVS1) is a splice-site mutation leading to 
10-20% residual activity of acid α-glucosidase and a broad clinical spectrum.23
Table II Characteristics of deceased patients (34 patients died in total, 23 of them prior to ERT)
34 (All deceased patients) 23 (died prior to ERT)
General characteristics
Female, n (%) 16 (47) 12 (52)
Median age at study entry, years (range) 54 (20-75) 51 (20-75)
Median age at death, years (range) 56 (23-78) 55 (23-77)
Median age at diagnosis, years (range) 42 (13-66) 42 (13-59)
Median disease duration, years (range) 14 (2-27) 16 (2-27)
Age at diagnosis in categories of 15 years, n (%)
            0-15 years 3 (9) 3 (13)
           16-30 years 6 (18) 3 (13)
           31-45 years 13 (38) 10 (44)
           46-60 years 10 (29) 7 (30)
           >61 years 2 (6) 0
Nationality, n (%)
           Netherlands 9 (27) 5 (22)
           Germany 4 (12) 4 (17)
           US 13 (38) 8 (35)
           UK 4 (12) 3 (13)
           Australia 1 (3) 0
           Canada 2 (6) 2 (9)
           Other 1 (3) 1 (4)
Disability level at study entry, n (%)
          No wheelchair use or respiratory support ª 4 (12) 4 (17)
          Wheelchair use 6 (18) 4 (17)
          Use of respiratory support 7 (21) 4 (17)
          Both wheelchair and respiratory support 17 (50) 11 (48)
Median RHS score* at study entry (range) 23 (9-36) (n=33) 22 (9-36)
Continuous variables are expressed as median (range). Categorical variables are expressed as n (%).
ª ‘Respiratory support’ includes partial and fulltime, invasive and non-invasive respiratory support.
* RHS assesses the level of participation/handicap; score varies between 9 (severe participation restrictions) 
and 36 (no participation restrictions.
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mortality
For 34 of the 268 patients, a death confirmation was received from the patient organiza-
tion or the family. The median age at death was 56 years and did not differ significantly 
between countries. In 23 of the 34 cases information on cause of death was not available. 
For the Dutch patients (n=9), causes of death were reported as respiratory insufficiency 
(n=3), myocardial infarction (n=2), aortic dissection (n=1) and breast cancer (n=1). For 
two of them, cause of death was not known. Characteristics of the deceased patients 
are listed in Table II. Data from only 23 of the deceased patients (median age at death 
55 years) could be used to estimate survival prior to ERT, since the other 11 received ERT 
prior to their death.
survival from diagnosis
The estimated median survival after diagnosis -without enzyme replacement therapy- 
was 27 years. The estimated 5-year survival after diagnosis was 95%. At 10, 20 and 30 
years this was 83, 65 and 40%, respectively (Figure 1).
Univariate and multivariate analysis showed that none of the tested factors were 
related to survival after diagnosis. 
Because the time between the start of ERT and death was mostly less than one year 
and these patients were already severely affected when they started ERT, we performed 
a second analysis including all patients who died within 18 months after start of  ERT 
(n=9). To be consistent with the deceased patients, the follow-up time for all other pa-
tients on ERT was also extended by 18 months. In this analysis with 32 events, only age 
at diagnosis, accounting for gender and nationality, was related to survival (Hazard Ratio 
1.55 per 10 years of age p<0.01). 
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Figure 1 Survival estimates of 268 untreated adults with Pompe disease from diagnosis until end of study, 
start ERT or death. Twenty-three patients died during follow-up.
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survival from study entry
The Kaplan-Meier survival curve from study entry is shown in Figure 2. After 5 years of 
follow-up, 88% of the patients not yet receiving ERT were still alive.  
Univariate analysis revealed a statistically significant difference in survival between 
groups based on disability level (overall p=0.002 log-rank, Figure 3), RHS score (overall 
p=0.002 log-rank, Figure 4) and age at study entry (overall p=0.03 log-rank). After five 
years 95% of patients without a wheelchair or respiratory support survived, while 
this was only 74% for patients with both wheelchair and respiratory support at study 
entry. Table III shows the 5-year survival with respect to potential prognostic factors. 
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Figure 2 Kaplan Meier survival estimates of 268 untreated adults with Pompe disease from study entry 
until end of study, start of ERT or death. Twenty-three patients died during follow-up.
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Figure 3 Kaplan Meier survival estimates of 268 untreated adults with Pompe disease from study entry 
until end of study, start of ERT or death by disability level. Twenty-three patients died during follow-up. 
‘Respiratory support’ includes partial and fulltime, invasive and non-invasive respiratory support.  P–value 
denotes result from log-rank test for trend.
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Multivariate analysis of the factors age at study entry, gender, nationality and disability 
level showed a significant effect of disability level (p=0.01), i.e. less disability at study 
entry was associated with better survival. Analyzing RHS score instead of disability level 
showed that a higher RHS score at study entry was also associated with better survival 
(p<0.001). In the analysis including 32 deceased patients, the factors age at study entry 
(p=0.01) and disability level (p=0.002) were significantly related to survival. When RHS 
score was analyzed instead of disability level both age (p=0.01) and RHS score (p<0.001) 
were significantly associated with survival.
mortality of Dutch Pompe patients compared to the general Dutch population 
For this part of the analyses 99 Dutch patients, with median age at entry 50 (range 24-
79) years, were included. The Dutch subgroup included 5 deceased patients before start 
and 4 after start of ERT. The median age at death was 55 (range 41-78) years. Two of the 
patients who died after start of ERT had died during the first year of treatment; one other 
had died 18 months after start of ERT and one had started and stopped ERT in the year 
before death. These were all severely affected patients using a wheelchair and/or respira-
tory support before start of ERT. To compare the probability of death in the Dutch Pompe 
patient group with that in the general Dutch population two analyses were performed: 
one taking into account only the 5 deaths before start of ERT (median follow-up time 2.3 
years) and one taking into account 9 deaths, while in the latter analysis extending the 
follow-up time after start of ERT with 1 year for every patient on ERT (median follow-up 
time 3.3 years). Table IV shows the results. 
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Figure 4 Kaplan Meier survival estimates of 268 untreated adults with Pompe disease from study entry 
until end of study, start of ERT or death by RHS score.
RHS score was divided into tertiles for comparison: RHS1= score <23, RHS2= score 23-30, and RHS3= score 
>30. Twenty-three patients died during follow-up.  P–value denotes result from log-rank test for trend.
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Table III Summaries of 5-year survival from study entry according to potential prognostic factors (23 
deceased patients)
Prognostic factors n
5-year survival 
percentages
p-value*
Gender 0.7
         Women 141 86
          Men 127 91
Age at diagnosis 0.4
          0-15 years 22 81
         16-30 years 59 92
         31-45 years 115 89
         46-60 years 61 82
        >61 years 11 100
Age at entry 0.03
        18-30 years 32 91
        31-45 years 85 94
        46-60 years 104 89
        >61 years 47 77
Nationality 0.7
        Netherlands 99 90
        Germany 48 93
        US 69 85
        UK 20 67
        Other º 32 93
Disability level at study entry 0.002
       No wheelchair use or respiratory support ª 127 95
       Wheelchair use 34 91
       Use of respiratory support 39 89
       Both Wheelchair use and respiratory support 68 74
RHS score at study entry* 0.002
       1 85 74
       2 85 95
       3 88 97
* Log rank test for the Kaplan-Meier curves, overall p-values of univariate analyses. º Due to small groups 
Canada and Australia were classified into the category “other”.  ª ‘Respiratory support ‘includes partial and 
fulltime, invasive and non-invasive respiratory support. * RHS score was divided into tertiles for comparison.1) 
< 23, 2) 23-30, 3)>30.
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Using data from the Pompe Survey, a long-term, disease-specific database using patient-
reported outcome measures, we were able to perform the first study on survival and 
prognostic factors in adults with Pompe disease.
 Over a prospective follow-up period of 7 years 34 of 268 patients died, 23 of them 
prior to ERT. Some of these patients died relatively young (23 years) and some reached 
very high ages despite Pompe disease (78 years). By using cumulative death probabilities 
of persons from the general population matched by age and gender, our study shows for 
the first time that mortality in adults with Pompe disease is higher than in the general 
population. 
We also found that in our group of patients, diagnosed at a median age of 38 years, 
17% died ten years after diagnosis. The median (50%) survival was estimated at 27 years 
after diagnosis. In an earlier study on the relation between disease severity and disease 
duration based on Pompe Survey data, we showed that 10-15 years after diagnosis 50% 
of the patients were wheelchair-bound or ventilator dependent.24 Thus, although Pompe 
disease in adults generally manifests as a slowly progressive disorder, it seriously affects 
the lives of patients. 
Several factors in our study had a significant effect on survival. For patients without 
a wheelchair or respiratory support the 5-year survival from entry was 95%, while for 
patients with a wheelchair and respiratory support this was 74%. In practice this means 
that patients with a wheelchair and/or respiratory support have a shorter life expectancy 
at any age compared to patients without wheelchair and respiratory support. RHS score 
at study entry, indicative of the level of handicap or participation, also was significantly 
associated with survival. Whether the RHS score is also useful as a prognostic tool in 
clinical practice is a topic for further investigation. 
The strength of our study is its prospective design, the regular follow-up, the repre-
sentation across countries, and the large sample size, especially for a rare disorder such 
as Pompe disease. In orphan diseases, it is quite unique to be able to gather information 
on a large group of patients over so many years, especially prior to therapeutic inter-
vention. Our prospective data collection was achieved by relying on patient reported 
Table IV Mortality of 99 Dutch Pompe patients compared to general Dutch population
Analysis Median follow-up time (range) Observed no. deaths (O) Expected no. deaths (E) * Ratio (O/E) p–value
1 2.3 (<1 month-7 years) 5 2.3 2.2 0.09
2 3.3 (<2 months-7 years) 9 2.8 3.2 0.002
Analysis 1: 5 deceased patients before start of ERT; Analysis 2: including 4 patients who died after start 
of ERT with follow-up of every patient on ERT extended with 1 year after start of ERT. * According to death 
probabilities derived from Dutch Central Bureau of Statistics.
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outcome measures through a close collaboration with patient organizations. This ap-
proach enabled data collection without the support of a large physician’s network that 
is – in orphan diseases – usually activated only after the introduction of a therapy. Our 
approach may stand model for data collection in other rare diseases. Since almost all 
newly diagnosed Pompe patients currently start with enzyme replacement therapy, 
this study might have been the very last chance to collect data on the natural course of 
Pompe disease. 
Nevertheless, some methodological issues need further attention. Firstly, our patients 
were followed from 2002 onwards, which means that the majority entered the study 
at some cross-sectional point of their illness. The ideal method would have been to fol-
low all patients from the time of disease onset or diagnosis until death. However, if we 
had applied those restrictions our study population would have been too small and the 
follow-up period would have been too short. Therefore, the next best thing was to also 
include the patients diagnosed before entering the study. This led to so-called ‘left-trun-
cated’ data, with a grey area between diagnosis and study entry in which other patients 
may have died without entering our study, and could have caused an overestimation 
of the median survival. Additionally, because all data in the Pompe Survey are provided 
voluntarily, some deaths among enrolled patients who eventually became censored due 
to loss-to-follow-up (n=37) may not have been reported. 
Second, differences in wheelchair and ventilator use were observed between coun-
tries, with the Dutch patients tending to be less severely affected on average. This may 
be explained by the fact that the Dutch group includes almost all patients known in the 
Netherlands, while the inclusion through patient organizations in the other countries 
may have led to a larger proportion of more severely affected patients. This may have 
affected the estimation of median survival time, but does not influence our main conclu-
sions that mortality in adults with Pompe disease is higher compared to the general 
population and is associated with disease severity. 
Furthermore, our patients were followed for up to 7 years, but median follow-up 
time was 3.5 years. Although a longer follow-up of untreated patients would offer more 
insight in their survival, such a study will be difficult to do as most patients currently 
receive ERT.
Because our aim was to investigate the natural course survival, we censored patients 
at the initiation of ERT. This means that 11 patients who died after start of ERT were not 
included as deceased patients in our initial analysis. Most (n=9) of these patients died 
within 1.5 year after start of ERT, or stopped ERT after a few infusions. As this treatment 
period is relatively short, we also performed analyses including these patients. Excluding 
these patients could have led to an underestimation of the number of deaths as these 
patients were already severely affected at the point they started ERT. All of them were 
72   |    Chapter 2.2
Chapter
 2.2
wheelchair-bound and/or used respiratory support and most probably would also have 
died without ERT. For the same reason, in our comparison of death probabilities between 
the Dutch subgroup and the general population we also included the 4 patients who 
died shortly after start of ERT. 
Unfortunately, information on cause of death was lacking for the majority of the de-
ceased patients. However in our study, mortality was compared with the data obtained 
from the Dutch Central Bureau of Statistics, which reports deaths irrespective of the 
cause. This comparison showed that the difference in mortality between the two groups 
was statistically significant. This in itself is important information, which can be used 
to evaluate the severity of disease and may serve as a reference when comparing the 
mortality of patients under treatment. With regard to the reported causes of death, it 
seems likely that death due to respiratory insufficiency is related to Pompe disease.2, 25 
Other causes, such as aortic dissection can also (in)directly be related to Pompe disease, 
as it may be a consequence of glycogen accumulation in vascular smooth muscle.26
Whether timely start of ERT can increase survival of adults with Pompe disease is cur-
rently unknown. In a recently published randomized controlled trial of alglucosidase alfa 
in late-onset Pompe disease, significant differences in walking distance and pulmonary 
function between the alglucosidase alfa and placebo groups were found.16 Considering 
these results, and given the fact that most patients die of respiratory failure, it might 
be expected that ERT will also positively influence life expectancy. The present study, 
in which we show that Pompe disease has a serious negative impact on the life span of 
untreated adult patients, allows for future evaluation of the effect of ERT with respect to 
this important parameter.
conclusion
Our study shows for the first time that mortality of untreated adults with Pompe disease 
is high compared to the general population. Both the need of a wheelchair and ventilator 
and a low RHS score are associated with higher mortality. Our results can serve as refer-
ence for future studies addressing survival of patients treated with ERT or alternative 
interventions. This information will also be valuable for families, genetic counsellors, and 
other health-care professionals when Pompe disease is diagnosed. Future studies should 
focus on identifying other factors – environmental or genetic – that may determine 
survival or disease progression in adults with Pompe disease, with or without treatment.
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abstract
Background Enzyme replacement therapy (ERT) in adults with Pompe disease, a pro-
gressive neuromuscular disorder, is of promising but variable efficacy. We investigated 
whether it alters the course of disease, and also identified potential prognostic factors.
Methods Patients in this open-label single-center study were treated biweekly with 20 
mg/kg alglucosidase alfa. Muscle strength, muscle function, and pulmonary function 
were assessed every 3–6 months and analysed using repeated-measures ANOVA.
Results Sixty-nine patients (median age 52.1 years) were followed for a median of 23 
months. Muscle strength increased after start of ERT (manual muscle testing 1.4 per-
centage points per year (pp/y); hand-held dynamometry 4.0 pp/y; both p<0.001). Forced 
vital capacity (FVC) remained stable when measured in upright, but declined in supine 
position (−1.1 pp/y; p=0.03). Muscle function did not improve in all patients (quick motor 
function test 0.7 pp/y; p=0.14), but increased significantly in wheelchair-independent 
patients and those with mild and moderate muscle weakness.
Relative to the pre-treatment period (49 patients with 14 months pre-ERT and 22 months 
ERT median follow-up), ERT affected muscle strength positively (manual muscle testing 
+3.3 pp/y, p<0.001 and hand-held dynamometry +7.9 pp/y, p<0.001). Its effect on up-
right FVC was +1.8 pp/y (p=0.08) and on supine FVC +0.8 (p=0.38). Favourable prognostic 
factors were female gender for muscle strength, and younger age and better clinical 
status for supine FVC.
Conclusions We conclude that ERT positively alters the natural course of Pompe disease 
in adult patients; muscle strength increased and upright FVC stabilized. Functional out-
come is probably best when ERT intervention is timely.
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backgrounD
Pompe disease (OMIM number 232300) is an autosomal recessive metabolic myopathy 
caused by deficiency of the lysosomal enzyme acid α-glucosidase. This deficiency impairs 
lysosomal glycogen breakdown, leading to glycogen accumulation in several tissues.1-4 
The disease covers a broad clinical spectrum, ranging from a rapidly progressive infantile 
phenotype that results in death within the first year of life, to more slowly progressive 
forms in children and adults.5-11 In adults, the disease generally presents as a limb-girdle 
myopathy. As well as the skeletal muscles, respiratory muscles – including the diaphragm 
– are affected.1,12,13 As the disease progresses, most patients lose ambulation and require 
ventilatory support.5,10,11,14,15
Although Pompe disease used to be untreatable, patients’ prospects changed in 2006 
upon the introduction of enzyme replacement therapy (ERT) with recombinant human 
acid α-glucosidase. Initial studies in infants showed that ERT improved survival and mo-
tor outcome.16-23 Several studies focusing on adult patients have been published since 
registration, but most report data in relatively small numbers of patients, or have a 
short follow-up.24-29 Proof of efficacy was provided by the 18-month randomized-placebo 
controlled trial in 90 patients, 60 of whom received alglucosidase alfa. This showed that 
walking distance improved and pulmonary function in upright position stabilized.29 
As mild and severely affected patients had been excluded, the trial involved a selected 
group of patients.
The aims of the current study were therefore 1) to determine whether ERT alters 
the progressive course of Pompe disease in a broader adult patient population ranging 
from very severely affected to mildly affected; 2) to determine how much ERT alters the 
course of the disease relative to that reflected in pre-treatment data; and 3) to identify 
prognostic factors for response to treatment.
methoDs
Patients and study design
This single-center, prospective, open-label cohort study on the use of ERT was conducted 
from January 2005 to August 2009 at the Center for Lysosomal and Metabolic Diseases, 
Erasmus MC University Medical Center, Rotterdam, which is the Dutch national referral 
center for Pompe patients.
Patients were eligible for inclusion if 1) they were over 18 years of age; 2) their di-
agnosis had been confirmed by enzyme analysis in leukocytes or fibroblasts30-32 and by 
mutation analysis33; 3) they had not previously been treated with recombinant human 
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acid α-glucosidase; 4) they had been treated for a minimum of 5 months; and 5) they 
were symptomatic, i.e. had measurable muscle weakness and/or diminished pulmonary 
function.
Patients received intravenous infusions with 20 mg/kg alglucosidase alfa every two 
weeks. Clinical assessments were performed every three to six months before the start 
of ERT and every three months thereafter.
The study protocol was approved by the Medical Ethical Committee at Erasmus MC 
University Medical Center. All patients provided written informed consent.
Twenty of the 69 patients participated in the randomized-placebo controlled trial 
on the safety and efficacy of alglucosidase alfa in late-onset Pompe disease; 13 in the 
treatment arm and seven in the placebo arm.29 Data on FVC in upright position of these 
patients collected during the 18 months study period were included in the current 
analyses.
Skeletal muscle strength and function
Skeletal muscle strength was measured by manual muscle testing using the Medical 
Research Council (MRC) grading scale (range 0–5) and hand-held dynamometry (HHD) 
(Cytec dynamometer, Groningen, the Netherlands).34,35 The following muscle groups 
were tested: neck extensors, neck flexors, shoulder abductors, elbow flexors, elbow 
extensors, hip flexors, hip abductors, knee flexors, and knee extensors. The MRC grade 
was also assessed for shoulder adductors, exorotators and endorotators, hip extensors, 
and hip adductors. A MRC sumscore was derived by adding the grades for all 26 muscles 
and expressing the sum as a percentage of the maximum possible score. HHD values 
(Newton) of each muscle group were first expressed as a percentage of the median 
strength of healthy males or females35, and then combined into a sumscore by averaging 
these for all 16 muscle groups. If values for three or more muscle groups were missing, 
no sumscores were calculated for either method.
Muscle function was assessed using the Quick Motor Function Test (QMFT)36; this 
consists of 16 motor skills related to daily activities that require the use of muscles of the 
shoulder girdle, trunk, pelvic girdle and/or proximal lower limbs. Each item was scored 
on a 5-point ordinal scale, with 0 representing „cannot perform task” and 4 „can perform 
task with no effort”. Adding all items gives a total score between 0 and 64. The actual 
sumscore was expressed as a percentage of the maximum score.
The use of wheelchair and walking aids was registered at each visit.
Pulmonary function
Forced vital capacity (FVC) in upright and supine positions was measured using spirom-
etry as described earlier.13,37 Results were expressed as a percentage of the predicted 
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normal value.38,39 Values lower than 80% of predicted normal values were considered to 
be abnormal. The use of ventilatory support and hours of use per day was registered at 
each visit.
Safety assessments and laboratory investigations
Vital signs and adverse events were recorded at each visit. Electrocardiograms, a physical 
examination, and haematological, biochemical and urine analyses were made at regular 
intervals.
Statistical analysis
Longitudinal analysis of the outcome parameters (MRC, HHD and QMFT sumscores and 
FVC in upright and supine positions) was performed using repeated-measures ANOVA 
(random coefficient models). This method allows for irregular measurement times and 
different treatment durations. First, we assessed the mean annual change in the out-
come parameters during the treatment period. Mean annual changes were expressed in 
absolute percentage points (pp/y). Analyses were also stratified by subgroups described 
in previous studies: gender, age (<45 years and ≥45 years old), disease duration (<15 
years and ≥15 years), wheelchair use, ventilation use, FVC in upright position (≥80% and 
<80%) and MRC sumscore (in tertiles).12,29
Second, for the patients with pre-treatment and treatment data we established the 
extent to which the course of disease altered after starting ERT. To be included in this 
analysis, patients should have had at least one measurement done a minimum of 4 
months before ERT. We included a linear effect of time before and during ERT in the 
repeated-measures ANOVA. Per individual, the two linear segments connect with each 
other at the time of start of ERT. This method is also known as the “broken-stick method” 
or as “piece-wise linear regression”.
Third, we investigated prognostic factors for treatment response. As well as perform-
ing the subgroup analysis, we assessed the association between patients’ characteristics 
and their individual response to ERT. Patients were classified into three groups: 1) non-
responders, i.e. people in whom the course of disease (measured by one of the outcome 
parameters) was the same or worse during ERT than before; 2) good responders, whose 
disease course improved more than the median improvement of responders; and 3) 
moderate responders. Each patient’s response was represented by the individual change 
in regression lines calculated in the “broken-stick” analysis. In patients without pre-
treatment data, the natural course slope was imputed. Associations were tested using 
the Spearman test for continuous variables and the Chi-square trend test for categorical 
variables.
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Analyses were performed with SPSS for Windows (version 17, SPSS Inc., Chicago, IL) 
or SAS (version 9.2, SAS Institute Inc., Cary, NC). A p-value lower than or equal to 0.05 
(two-sided) was considered significant.
results
Patients
In total, 71 adult Pompe patients started ERT within the study period. Two were excluded 
because they had received ERT for less than five months: one died two months after 
starting ERT due to a dissection of the aortic arch; the second withdrew from the study 
after four months and died six months later due to respiratory insufficiency.
Table I shows the patients’ characteristics at start of ERT. The median age at the start 
of ERT was 52.1 years, 52% were male, 40% used a wheelchair, and 37% used mechanical 
ventilation. The median treatment duration was 23 months (range 5–47 months). Of the 
69 patients, 13 were treated for more than 3 years and six patients for less than 1 year, 
respectively for 5, 6, 7, 10, and two for 11 months.
All but one patient carried the common c.-32-13T>G (IVS1-13T>G) mutation on 
one allele in combination with another pathogenic mutation on the second allele. Of 
the patients carrying the c.-32-13T>G (IVS1-13T>G) mutation, 14 different mutations 
were found on the second allele. Forty-eight percent carried the c.525delT and 16% the 
c.2481+102_2646+31del mutation. The other mutations found were the c.-32-13T>G 
+ c.1076-22T>G, c.1115A>T, c.1396G>T, c.1548G>A, c.172C>T, c.1799G>A, c.2314T>C, 
c.378_379del, c.461_469del, c.701C>A, c.896T>C and c.925G>A mutation. Of those 
mutations, 74% was indicated as very severe and 26% as potentially less severe (www.
pompecenter.nl). For three patients the result of the mutation analysis could not be 
tracked, because these were performed by another center.
For 49 patients, pre-treatment data were available in addition to the treatment follow-
up. These were slightly younger and less severely affected. Their median follow-up was 
14 months before (range 4–33), and 22 months during ERT (range 6–41).
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Skeletal muscle strength
During ERT, the MRC sumscore among all 69 patients rose by an average of 1.4 pp/y, 
and the HHD sumscore by 4.0 pp/y (both p<0.001; Table II). All individual muscle groups 
contributed to the effect (p≤0.02 for all muscle groups). Subgroup analyses showed that 
the mean annual increase in muscle strength during ERT was greater for women than 
for men (2.6 pp/y vs. 0.4 pp/y; difference between groups p<0.001 for MRC; and 6.3 
pp/y vs. 2.0 pp/y, difference between groups p=0.05 for HHD). For the other subgroups 
investigated, there were no significant differences in the increase in muscle strength 
during ERT.
Before the 49 patients with pre-treatment and treatment data started ERT, their 
muscle-strength sumscores declined significantly (−1.2 pp/y for MRC, p=0.006; −2.8 
Table I Patients’ characteristics and baseline values of clinical outcome measures at start of ERT 
Characteristic
Total study 
population 
(n=69)
Patients with pre-ERT 
and ERT follow-up 
(n=49)
p-value a
Age at start of ERT in years, median (range) 52.1 (26.2–76.3) 50.1 (26.2–74.0) 0.83
Age at onset of symptoms in years, median (range) 30.8 (1.4–62.0) 32.0 (1.4–62.0) 0.63
Age at diagnosis in years, median (range) 39.6 (1.4–63.8) 40.9 (1.4–63.0) 0.97
Duration of disease at start of ERT in years, median (range) 9.3 (0.2–31.2) 8.3 (0.5–31.2) 0.74
MRC sumscore at start of ERT in percentage, median (range) 77.7 (48.3–92.3) 79.2 (60.8–92.3) 0.52
HHD sumscore at start of ERT in percentage, median (range)  69.3 (25.9–94.1) 69.3 (25.9–94.1) 0.97
QMFT score at start of ERT in percentage, median (range) 55.6 (10.0–89.1) 59.5 (21.7–89.1) 0.42
Time of mechanical ventilation at start of ERT per day in 
hours, median (range) 
11.5 (0.0–24.0) 10.5 (0.0 –24.0) 0.81
FVC in upright position at start of ERT in percentage, median 
(range) 
68.3 (11.3–106.9) 71.9 (26.5–106.9) 0.43
FVC in supine position at start of ERT in percentage, median 
(range) 
46.8 (23.0–99.0) 52.4 (23.0–99.0) 0.71
Gender, No. of patients (%)
- Male
- Female
36 (52)
33 (48)
21 (43)
28 (57)
0.43
Wheelchair at start of ERT, No. of patients (%)
- No wheelchair use 
- Partial wheelchair use 
- Permanent wheelchair use
42 (61)
8 (12)
19 (28)
33 (67)
8 (16)
8 (16)
0.22
Mechanical ventilation at start of ERT, No. of patients (%)
- No mechanical ventilation 
- Non-invasive mechanical ventilation
- Invasive mechanical ventilation 
44 (64)
19 (28)
6 (9)
36 (74)
10 (20)
3 (6)
0.72
ERT=Enzyme Replacement Therapy, MRC sumscore=Medical Research Council sumscore, HHD 
sumscore=Hand-Held Dynamometry sumscore, QMFT score=Quick Motor Function Test score, FVC=Forced 
Vital Capacity, N/No.=Number of patients.
a Differences between the total group (N=69) and the group with pre-ERT and ERT follow-up (N=49) were 
calculated using Chi-square tests for the categorical variables, and using Mann-Whitney tests for continuous 
variables.
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pp/y for HHD, p<0.001). Treatment data produced a significant improvement, the differ-
ences being +3.3 pp/y for the MRC sumscore and +7.9 pp/y for the HHD sumscore (both 
p<0.001; Table II, Figure 1A and B).
Skeletal muscle function
Although QMFT scores for all 69 patients increased by an average of 0.7 pp/y during ERT, 
this was not significant (p=0.14). Subgroup analyses showed that while muscle function 
improved in patients with mild muscle weakness (2.1 pp/y, p=0.01) and moderate muscle 
weakness (1.6 pp/y, p=0.05), it fell by 1.4 pp/y (p=0.08) in patients with severe muscle 
weakness (difference between groups p=0.004). In line with this, QMFT scores rose in 
wheelchair-independent patients (1.7 pp/y, p=0.008), but did not improve in those who 
were wheelchair-dependent (−0.6 pp/y, p=0.39; difference between groups p=0.02).
The number of patients who were partially or fully wheelchair dependent at the last 
follow-up visit was the same as at the start of ERT. Nevertheless, two of the 27 patients 
A
C D
B
Figure 1 The clinical course of disease before and after the start of enzyme replacement therapy (ERT) in 
the 49 patients with ERT and pre-ERT follow-up data for A) MRC sumscore; B) hand-held dynamometry 
(HHD) sumscore; C) forced vital capacity (FVC) in upright position; and D) FVC in supine position. The 
figure shows all the individual observations for the different outcome measures (shown as dots) and the 
solid lines represent the estimated mean trend in these observations as calculated by the “broken stick” 
repeated-measures ANOVA. The dotted lines represent the extrapolated natural course slopes.
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who used walking aids at the start of ERT regained the ability to walk independently 
during ERT. Two other patients became dependent on walking aids.
Pulmonary function and use of mechanical ventilation
During treatment with ERT, FVC in upright position remained stable (0.1 pp/y, p=0.92), 
while FVC in supine position declined (−1.1, p=0.03) (Table II). Subgroup analyses showed 
that FVC in supine position did remain stable in patients under 45 years old (0.0 pp/y, 
p=1.0), but declined in those 45 years and over (−2.1 pp/y, p=0.002) (difference between 
groups p=0.03). There were no differences between subgroups for FVC in upright posi-
tion.
Before start of ERT, FVC in upright and supine positions both declined significantly 
(−2.0 pp/y, p=0.001 and −1.8 pp/y, p=0.002, respectively). Compared to this, FVC in up-
Table II Clinical outcome measures during enzyme replacement therapy and relative to the natural course 
of disease
Clinical Outcome Measure Natural course Treatment course Differencea
mean pp/y 
(95% CI) p-value
mean pp/y 
(95% CI) p-value
mean pp/y 
(95% CI) p-value
MRC sumscore
Total study population (N=69, 
M=558) 1.4 (0.8 to 2.1) <0.001
Patients with pre-ERT + ERT 
follow-up (N=49, M=523) -1.2 (-2.1 to -0.4) 0.006 2.1 (1.2 to 3.0 ) <0.001 3.3 (1.9 to 4.7) <0.001
HHD sumscore 
Total study population (N=64, 
M=503) 4.0 (2.5 to 5.6) <0.001
Patients with pre-ERT + ERT 
follow-up (N=42, M=435) -2.8 (-4.2 to -1.3) <0.001 5.1 (3.0 to 7.3) <0.001 7.9 (5.0 to 10.7) <0.001
QMFT score
Total study population (N=69, 
M=553) 0.7 (-0.2 to 1.7) 0.14
FVC in upright position 
Total study population (N=62, 
M=475) 0.1 (-1.0 to 1.1) 0.92
Patients with pre-ERT + ERT 
follow-up (N=46, M=480) -2.0 (-3.1 to -0.8) 0.001 -0.2 (-1.6 to 1.2) 0.76 1.8 (-0.2 to 3.7) 0.08
FVC in supine position
Total study population (N=54, 
M=411) -1.1 (-2.1 to -0.1) 0.03
Patients with pre-ERT + ERT 
follow-up (N=42, M=436) -1.8 (-2.9 to -0.7) 0.002 -1.0 (-2.3 to 0.3) 0.12 0.8 (-0.9 to 2.4) 0.38
ERT=Enzyme Replacement Therapy, pp/y=percentage points per year, 95% CI=95% Confidence Interval, 
MRC sumscore=Medical Research Council sumscore, QMFT score=Quick Motor Function Test score, HHD 
sumscore=Hand-Held Dynamometry sumscore, FVC=Forced Vital Capacity, N=Number of patients, 
M=Number of Measurements. Data shown are mean changes in percentage points per year as calculated by 
repeated-measures ANOVA.
a Difference between the course of disease during treatment and the natural course.
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right position improved during ERT, albeit at borderline statistical significance (+1.8 pp/y, 
p=0.08), while FVC in supine position did not (+0.8, p=0.38) (Table II and Figure 1C and D). 
For the whole group there was no change in the median number of hours of ventila-
tion per day between the start of ERT and the last treatment visit (Wilcoxon signed-rank 
test p=0.88). Mechanical ventilation time could be reduced by one or more hours per day 
in nine of the 25 patients who had been using mechanical ventilation at start of ERT. One 
of these was able to discontinue the use of his ventilator. In 14 patients, ventilation times 
remained the same, while ventilation was intensified in two. Nocturnal ventilation was 
initiated in two others.
Individual response with regard to skeletal muscle strength and pulmonary function
With regard to MRC sumscore, 31 patients (45%) were good responders, 32 (46%) moder-
ate, and six (9%) non-responders (Figure 2). More women than men were good respond-
ers (p=0.002, Table III). Twenty-seven of the 62 patients with FVC data in upright position 
(44%) responded well, 26 (42%) moderately, and nine (15%) poorly. The characteristics 
between these FVC responder categories did not differ significantly.
Although FVC in supine position declined in the whole group during ERT, almost two-
thirds of patients improved after starting ERT: 16 of 54 patients (30%) responded well, 
17 (31%) moderately and 21 (39%) did not respond (Figure 2). Better responses were 
associated with younger age (p=0.007), less severe muscle weakness (p=0.02), wheel-
chair independence (p=0.05) and better pulmonary function in upright position (p=0.02) 
(Table III). None of the good responders were dependent on artificial ventilation.
Responses for muscle strength correlated poorly with responses for FVC. The correla-
tion between response categories for FVC in upright and supine was moderate (Spear-
man’s ρ 0.56, p<0.001).
Safety assessments and laboratory investigations
Laboratory safety parameters and ECGs remained unchanged during ERT. In total, 12 
patients (17%) developed one or more infusion-associated reaction (IARs). These were 
similar to the IARs described in the randomized-placebo controlled study; most could be 
controlled by slowing infusion rates and/or giving premedication.29 To prevent further 
IARs, seven patients received antihistamines as pre-medication, and five a combination 
of antihistamines and corticosteroids. At the end of the study three patients still had 
IARs, three patients were using antihistamines as premedication and two a combination 
of corticosteroids and antihistamines. Enzyme replacement therapy was discontinued 
in three patients who experienced IARs. In only one patient this was for safety reasons: 
this patient had a medical history of multiple auto-immune diseases and drug-induced 
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allergies. In one of the other two patients IARs co-occurred with a very high antibody 
titer and a poor response to ERT, as described previously.40
Two severely affected patients died. Their causes of death (sepsis after severe decubi-
tus and chronic respiratory insufficiency) were considered to be unrelated to ERT.
Discussion
This study describes a large cohort of adult Pompe patients receiving treatment with 
alglucosidase alfa. It reflects a unique situation in which most patients were also pro-
spectively followed before starting therapy, thereby extending median follow-up to 3 
years (14 months before starting ERT and 23 months afterwards). We found that ERT sig-
nificantly altered the natural course of disease in adult Pompe patients. Muscle strength 
increased significantly after they started ERT, and FVC in upright position stabilized. Even 
though, at group level, FVC in supine position and muscle function did not improve dur-
ing ERT, there were improvements in certain subgroups of patients.
Like previous studies, we found that muscle strength deteriorated significantly before 
the start of therapy.10,11 However, the improvement in muscle strength after the start 
MRC  s ums core
31 (45%)
32 (46%)
Non-responders
Moderate responders
Good responders
FVC  in s upine pos ition
21 (39%)
17 (31%)
16 (30%)
FVC  in upright pos ition
9 (15%)
27 (44%)
26 (42%)
6 (9%)
Figure 2 Individual response groups for skeletal muscle strength and pulmonary function
The number and percentage of good responders, moderate responders and non-responders are shown for 
MRC sumscore, and forced vital capacity (FVC) in upright and supine positions.
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of ERT was greater than that reported in other studies.25-27,29,41 There may be various 
reasons for this. Our study was restricted to adult patients, but included patients across 
the entire disease spectrum. We tested more muscle groups, included more patients, 
and followed a longer treatment period than other studies, thereby producing over 500 
measurements in total.
One new finding of this study is that women benefit more from ERT with respect to 
muscle strength than males. At the same dosage of 20 mg/kg bodyweight, it is possible 
that the relative dose of alglucosidase alfa received per gram of muscle-fiber tissue is 
higher in women than in men. Men generally have a higher lean body mass than women, 
and thus a somewhat higher muscle mass per kg.42 As women also have smaller muscle 
fibers than men, they have a higher ratio of muscle-fiber surface to muscle-fiber volume. 
Consequently, they may have relatively more mannose 6-phosphate surface receptors, 
which mediate the uptake of alglucosidase alpha.42,43 Other factors that may underlie 
the greater benefit women derive from ERT include muscle-fiber types, activity patterns, 
and hormonal influences.
Our study did not incorporate the six-minute walk test, a measure of functional 
endurance used in other studies24,27,29 Instead, we assessed motor skills related to daily 
activities, using the QMFT, which was recently validated for use in patients with Pompe 
disease.36 Although there was no change in muscle function across the entire group, 
there were significant improvements in wheelchair-independent patients and those 
with less pronounced muscle weakness. This finding indicates that timely intervention 
with ERT may be crucial to improving muscle function. The same is suggested by the 
results of the subgroup analysis in the trial of late-onset patients.29
The stabilization of FVC in upright position in our patients was similar to that recorded 
in the trial and in other studies24,27,29; the decline in FVC before ERT was similar to that 
observed in the placebo arm of the trial and natural course studies.10-12,29
This is the first study to report on the effect of ERT on the FVC in supine position. In 
the whole study population, this measure continued to deteriorate despite ERT, but in-
dividual results showed an improvement in almost two-thirds of patients. Patients were 
more likely to improve if they were younger, were independent of artificial ventilation, 
had a better FVC in upright position, and had less severe muscle weakness at the start 
of treatment. Again, this suggests that starting ERT early in the disease course may be 
beneficial.
Because ERT has been available since 2006, we performed an open-label study rather 
than a clinical trial, assessing the effect of ERT in all adult patients – from mild to severely 
affected – for many of whom we had also collected pre-treatment data prospectively. As 
this is an observational study, we could not correct for residual confounding. The small 
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sample size inherent to rare disorders meant that we could not apply a full multivariate 
model to identify prognostic factors.
conclusions
In summary, by improving muscle strength and stabilizing pulmonary function in up-
right position, treatment with alglucosidase alfa positively altered the natural course of 
Pompe disease in adults. As well as finding that female gender is potentially a favourable 
prognostic factor for the effect of ERT on muscle strength, we found that younger age 
and better clinical status are favourable prognostic factors for pulmonary function. This 
suggests that it is important to start treatment early in the course of disease. Prognostic 
variables may help to identify patients with the best chances of benefiting from treat-
ment.
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abstract
Background Clinical trials have demonstrated beneficial effects of enzyme replacement 
therapy (ERT) with alglucosidase alfa in infants, children and adults with Pompe disease. 
Recent studies have shown that high antibody titers can occur in patients receiving ERT 
and counteract the effect of treatment. This particularly occurs in those patients with 
classic-infantile Pompe disease that do not produce any endogenous acid α-glucosidase 
(CRIM-negative). It is still unclear to what extent antibody formation affects the outcome 
of ERT in adults with residual enzyme activity.
Case We present the case of a patient with adult-onset Pompe disease. He was diag-
nosed at the age of 39 years by enzymatic testing (10.7% residual activity in fibroblasts) 
and DNA analysis (genotype: c.-32-13TNG/p.Trp516X). Infusion-associated reactions 
occurred during ERT and the patient’s disease progressed. Concurrently, the antibody 
titer rose to a similarly high level as reported for some CRIM-negative patients with 
classic-infantile Pompe disease. Using newly developed immunologic-assays we could 
calculate that approximately 40% of the administered alglucosidase alfa was captured 
by circulating antibodies. Further, we could demonstrate that uptake of alglucosidase 
alfa by cultured fibroblasts was inhibited by admixture of the patient’s serum. 
Conclusion This case demonstrates that also patients with an appreciable amount of 
properly folded and catalytically active endogenous acid α-glucosidase can develop 
antibodies against alglucosidase alfa that affect the response to ERT.
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introDuction
Pompe disease (glycogen storage disease type II, acid α-glucosidase deficiency, or acid 
maltase deficiency; OMIM 232300) was the first disease to be identified as a lysosomal 
storage disorder.1 Acid α-glucosidase deficiency results in lysosomal accumulation of gly-
cogen in all tissues, most notable in skeletal muscle.2-4 Patients with a slowly progressive 
form of this disease typically present with skeletal muscle weakness in the limb-girdle 
region and/or respiratory insufficiency. Severely affected infants present as floppy babies 
due to generalized muscle weakness and have hypertrophic cardiomyopathy from birth 
on.5,6
Enzyme replacement therapy (ERT) has become available for the treatment of six 
lysosomal storage disorders; Gaucher disease, Fabry disease, MPS I, MPS II, MPS VI and 
Pompe disease. The registration of alglucosidase alfa (Myozyme®) for the treatment of 
Pompe disease dates from 2006.
Antibody formation against the administered enzyme is a well-known side effect of 
ERT.7-11 In Gaucher disease about 15% of the patients start to produce antibodies within 
the first year of ERT while antibody formation is rarely associated with clinical dete-
rioration.7,8,12 In Fabry disease the majority of patients develop antibodies, but alarming 
effects have not been reported although the lowering of the plasma GL-3 level stalled 
in some sero-positive patients.9 The majority of patients with these conditions become 
tolerant after prolonged treatment.
Compared to Gaucher and Fabry diseases the experience with antibody formation in 
Pompe disease is modest, but the currently available data indicate that the majority of 
Pompe patients on ERT develop antibodies against alglucosidase alfa.13-15 A recent study 
clearly shows that infants who lack endogenous enzyme production (CRIM-negative 
patients) more readily develop high antibody titers than those who are CRIM-positive. 
Long-term studies (up to 3 years follow-up) suggest that sustained high antibody titers 
affect treatment outcome.16
Data on the long term effects of ERT in adults with Pompe disease are still scarce, but 
the first findings are hopeful in that ERT seems to halt disease progression and results in 
gain of muscle strength and pulmonary function in the best responders.15,17-22 Thus far, it 
is unknown whether sustained antibody titers occur in adults with Pompe disease, who 
are all CRIM-positive, and whether high titers affect the response to treatment.
This case report concerns a 50-year-old male with adult-onset Pompe disease who 
started to experience infusion-associated reactions (IARs) during ERT with alglucosidase 
alfa. He had a continuous rise of antibody titer and his disease progressed. The aim of our 
study was to develop methods for measuring and evaluating the height of the immune 
response and its effect on treatment outcome.
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materials anD methoDs
Patient history
The male patient (patient 1 in this report; see Table I) presented at the age of 29 years 
with low back pain and a mild lumbar lordosis. The family history was negative for 
muscular and neurological diseases. Over the following decade his disease progressed. 
Bending over and climbing stairs became difficult due to a slowly progressive limb-
girdle myopathy. He was diagnosed with Pompe disease at the age of 39 years. At the 
age of 49 years the patient was referred to our center (Erasmus MC, the Netherlands) 
and from then on was monitored twice yearly according to a protocol for standardized 
clinical follow-up of patients with Pompe disease not receiving ERT. One year later he 
was included in a randomized double blind placebo controlled clinical trial investigating 
the effects of alglucosidase alfa in late-onset forms of Pompe disease (LOTS; protocol 
number: AGLU02704/03206).15 At the end of that trial it was disclosed that the patient 
had been assigned to the treatment group. He continued to receive ERT and underwent 
regular assessments while participating in a subsequent open-label study to secure 
standardized clinical follow-up.
Table I Baseline characteristics at start of ERT
Patient 1 Patient 2 Patient 3 Patient 4
Sex Male Male Female Female
First symptoms (years) 29 46 36 44
Diagnosis (years) 39 52 62 51
Start ERT (years) 50 54 63 54
Walking aid None None None Walking stick
MRC sumscore (%) 85 92 82 75
Ventilation support None None None None
FVC sitting (%) 48 63 64 100
FVC supine (%) 24 33 NA 75
Creatine kinase U/la 372 747 421 526
α-Glu activity fibroblastsb 9.4 7.6 16 13
α-Glu activity leucocytesc 2.9 8.2 0.1 0.5
GAA genotype
c.-32-13T>G/ 
p.Trp516X
c.-32-13T>G/ 
p.Gly309Arg
c.-32-13T>G/ 
p.Glu176fs
c.-32-13T>G/ 
p.Cys127fs
a Creatine kinase U/l: control range 0–199 U/l; b Activities in fibroblasts are expressed as nmol 4 MU/mg h 
(control range: 40–180 nmol/mg h); c Activities in leucocytes are expressed as nmol glucose/mg h and were 
measured in the presence of 3 μM acarbose (control range: 48–215 nmol/mg h, n = 313).
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reference patients
Three patients (patients 2, 3 and 4) were selected as reference subjects. They were 
matched for age, genotype, acid α-glucosidase activity, MRC sumscore and respiratory 
support at start of treatment (Table I). They also received alglucosidase alfa for more 
than one year, but did not experience infusion-associated reactions and responded well 
to ERT. 
All patients described in this report have given informed consent for all studies they 
participated in.
clinical assessments
Muscle strength was measured by Manual Muscle Testing (MMT) using the Medical 
Research Council (MRC) grading scale (range: 0–5; only full grades were used). A MRC 
sumscore was calculated for the following muscle groups: neck extensors, neck flexors, 
shoulder adductors, shoulder abductors, shoulder exorotators, shoulder endorotators, 
elbow flexors, elbow extensors, hip extensors, hip flexors, hip abductors, hip adductors, 
knee flexors and knee extensors. This sumscore was expressed as percentage of the 
maximum sumscore (range: 0–100%).
Muscle strength was also assessed by quantitative measurement of the maximum 
voluntary isometric contraction using Hand-Held Dynamometry (HHD)23 and computer-
ized quantitative muscle testing (QMT).24,25 Nine muscle groups were assessed to calcu-
late the HHD sumscore, which is expressed as percentage of the maximum sumscore. 
These muscle groups are the neck extensors, neck flexors, shoulder abductors, elbow 
flexors and elbow extensors, hip flexors, hip abductors, knee flexors and knee extensors. 
A composite QMT arm and leg score was calculated as previously described.24
The 6-minute walk test (6MWT) was a primary outcome measure in the LOTS and is 
a measure for the patient’s performance. It measures the distance a patient can walk 
at his or her fastest pace in 6 min. The Forced Vital Capacity (FVC) was measured as 
pulmonary function test in sitting and supine position. Measurements were performed 
according to ATS/ERS standards26 and reference values were derived from published 
data.27-29 The results are expressed in percentage predicted FVC. All infusion-associated 
reactions (IARs), adverse events and serious adverse events were recorded.
biochemical assays
The acid α-glucosidase activity in leucocytes30 and fibroblast31 was measured as previ-
ously described and is expressed in nmol/mg protein per hour. The protein concentration 
of cell homogenates was measured as described by van Diggelen, et al.32
The molecular forms of acid α-glucosidase derived from enzyme synthesis in fibro-
blasts were separated by SDS-PAGE (10% gel) and visualized by Western-blot analysis us-
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ing rabbit polyclonal antiserum raised against recombinant human acid α-glucosidase. 
Equal amounts of protein (40 μg) were applied in each lane. The ECL method (Amersham, 
GE-Healthcare) was used for the final staining.33 The acid α-glucosidase specific protein 
species revealed at the end of this procedure are collectively called CRIM, which stands 
for Cross Reactive Immunologic Material.
Antibody titer
Blood samples for antibody titer determination were drawn just before start of alglu-
cosidase alfa infusion. The serum was stored at −80 °C. Two-fold serial dilutions were 
made starting from 50 to 3200 fold in sodium-phosphate buffered saline (10 mM PBS, 
pH 7.0) containing bovine serum albumin (BSA, Sigma) in a concentration of 1 mg/ml 
(PBS/BSA). A 50 μl solution of alglucosidase alfa (total activity approximately 10 nmol 
4 MU/h) in PBS/BSA was mixed with 10 μl diluted serum and 20 μl of a 1:1 suspension 
of Protein A sepharose CL-4B beads in PBS and incubated under continuous agitation 
for 1 h at room temperature. The beads were then removed by centrifugation (14,000 
g) and the amount of antibody-bound alglucosidase alfa was calculated by measuring 
the enzyme activity in 10 μl of the supernatant using 20 μl 4-methylumbelliferyl-α-d-
glucopyranoside (MUGlc, Sigma) substrate as described previously.
The antibody titer is expressed as the amount of alglucosidase alfa activity that is 
bound by the antibodies present in 1 μl of the patient’s serum. Alternatively, the anti-
body titer was determined using an Enzyme-Linked ImmunoSorbent Assay (ELISA) and 
the results were confirmed by a Radio-Immuno Precipitation Assay (RIP) as described.13.
Inhibition of enzymatic activity by antibody binding
Inhibition of enzymatic activity by antibody binding was studied by incubating 100 μl 
of a dilution of alglucosidase alfa in PBS/BSA (total activity of 20 nmol 4 MU/h) with 20 
μl of two-fold serial dilutions of the patient’s serum overnight at 4 °C. The next day the 
activity in the solution was measured with MUGlc and glycogen as substrates.
Pharmacokinetic analysis
Blood was drawn before the start of alglucosidase alfa infusion, 2 h after the start of 
infusion, 15 min before the end of the infusion, at the end of infusion, and at 15, 30, 
60, and 120 min after the end of enzyme infusion. For patient 1, additional samples 
were drawn 4 h after the start of infusion and 3 h after the end of infusion. Plasma was 
separated and stored at −80 °C. Of a thousand-fold diluted plasma sample, 100 μl was 
incubated with 20 μl of either a suspension of sepharose beads or Protein A sepharose 
CL-4B beads. Further analysis was as described in the paragraph on assay of antibody 
titer.
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Inhibition of alglucosidase alfa uptake
Two methods were used to evaluate whether the patient’s antibodies interfere with up-
take of alglucosidase alfa by human fibroblasts in culture. In the first method fibroblasts 
from a patient with classic-infantile Pompe disease, homozygous for the pathogenic 
sequence variation 525delT and fully deficient in acid α-glucosidase production, were 
seeded in a 6-well tissue-culture plate and maintained in 2 ml Ham’s F10+ medium 
supplemented with heat inactivated fetal calf serum in a final concentration of 10%, at a 
temperature of 37 °C. For the purpose of measuring uptake of alglucosidase alfa overnight 
(16 h), the medium was buffered with 3 mM pipes to keep the pH slightly acidic at 6.8. 
Alglucosidase alfa was added in an amount equivalent to 2 μmol 4 MU/h. Patient’s sera 
were added in a volume of 40 μl (final dilution 50 fold). The acid α-glucosidase activity 
in the medium was measured directly after enzyme addition and just before harvesting 
the fibroblasts. Uptake of enzyme by the fibroblasts was measured in a cell homogenate 
with MUGlc substrate, and the intracellular forms of the enzyme were visualized by SDS-
PAGE followed by immunoblotting as described for the CRIM assay.
The second method involves flow cytometry, whereby human fibroblasts were grown 
in a 24-well tissue-culture plate overnight in Dulbecco’s Modified Eagle’s Medium. A 
known quantity of Oregon Green labelled alglucosidase alfa was pre-incubated with 
2-fold serially diluted patient’s sera and then added to the fibroblasts in HAMA uptake 
media for 3 h. The fibroblasts were harvested and the internalized labelled alglucosidase 
alfa was measured by flow cytometry. Percent inhibition was calculated by obtaining the 
Median Fluorescence Intensity (MFI) of the sample containing potential inhibitory anti-
bodies, the MFI of the background, and the MFI of the sample containing only labelled 
alglucosidase alfa in 10% normal human serum.
% inhibition of enzyme uptake was calculated as follows:
%inhibition = 100−100*
(MFI sample−MFI background)
(MFI total−MFI background)
Percentages of inhibition of enzyme uptake in normal sera and baseline samples of 
Pompe patients supported the use of 20% as cut-off point to define positive inhibitory 
antibody response and further verified the need to require this reactivity in at least two 
sera dilutions. Samples that have enzyme uptake inhibition greater than the assay cut-
off are considered to be positive. The uptake inhibitory antibody titer is defined as the 
reciprocal of the highest serum dilution with a signal above the assay cut-off.
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results
Enzymatic and molecular diagnosis
The baseline characteristics of the patient discussed in this report (patient 1) and 
three reference cases (patients 2, 3 and 4) are presented in Table I. Patient 1 had an 
acid α-glucosidase activity of 9.4 nmol 4 MU/h mg protein in fibroblasts and 2.9 nmol 
4 MU/h mg protein in leucocytes. DNA analysis revealed compound heterozygosity for 
c.-32-13T>G/p.Trp516X (Table I). c.-32-13T>G is the most common mutation among Cau-
casians with attenuated forms of Pompe disease and is characterized by the formation of 
only 10–20% correctly spliced GAA-mRNA and corresponding levels of acid α-glucosidase 
activity.34,35 p.Trp516X (c.1548G>A) does not contribute to acid α-glucosidase production. 
These features stand out in Figure 1 illustrating that patient 1 has much less mature acid 
α-glucosidase of 76 kDa and 70 kDa than a healthy individual, but substantially more 
than a selected case of classic-infantile Pompe disease without any acid α-glucosidase 
production.
Figure 1 Acid α-glucosidase production in fibroblasts 
Immuno-blot analysis of acid α-glucosidase production in fibroblasts of patient 1 compared with acid 
α-glucosidase production in fibroblasts of a patient with classic-infantile Pompe disease and a healthy 
individual. The acid α-glucosidase activities in patient 1 and in the patient with classic-infantile Pompe 
disease are expressed as percentage of the activity in the healthy individual. The activities were measured 
with MUGlc. Equal amounts of protein were applied to each lane (0.04 mg). The blot was stained as 
described in Materials and methods.
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Muscle strength, 6-minute walk test and pulmonary function
In the year before start of treatment the patient’s condition gradually declined. With 
regard to muscle strength, the MRC sumscore was 86% at start of follow-up and the 
HHD sumscore was 70% (Figure 2A). Both sumscores declined with approximately 1% in 
the year before start of ERT. Pulmonary function measured as FVC in sitting and supine 
position declined with 5% during this year (FVCsitting from 53% to 48% and FVCsupine 
from 29% to 24% as shown in Figure 2B). Total follow-up after start of ERT with algluco-
sidase alfa was 33 months. After start of ERT, the disease continued to progress. 
The FVCsitting and FVCsupine both declined with a rate of 1.9% per year (Figure 2B). 
After 21 months of treatment the patient became dependent on non-invasive nocturnal 
ventilation. In parallel, his muscle strength continued to decline during treatment. He 
experienced more difficulties with walking, fell more often, could not bend over, squat 
nor get out of his chair. The MRC sumscore declined with 3.7% and the HHD sumscore 
with 2.2% per year (Figure 2A). The QMT arm score declined with 4.5% and the leg score 
with 8.9% per year (Figure 2C). The distance walked as measured with the 6-minute walk 
Figure 2 Muscle strength, pulmonary function and 6-minute walk test during ERT
A: Muscle strength as expressed in sumscore of nine muscle groups as measured with Hand-held 
dynamometry (□) and sumscore of 14 muscle groups as measured by MMT (■) in % of normal. B: 
Pulmonary function (FVC) as percentage of predicted in sitting (□) and supine (■) position. C: Muscle 
strength as measured with computerized quantitative muscle testing (QMT); for arms (□) and legs (■). D: 
Results of the 6-minute walk test as distance walked in meters (■).
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test (6MWT) initially increased, but started to decline after twelve months of treatment 
from 397 m to 353 m at 32 months of treatment (Figure 2D).
Infusion-associated reactions
Enzyme replacement therapy was initially administered according to the regular 
infusion schedule as shown in Table II with stepwise increase of the infusion rate. 
Infusion-associated reactions started to occur after five months of treatment. They were 
characterized by general malaise, shaking chills, and fever. The IARs could be managed 
with premedication (100 mg hydrocortisone), extending the duration of infusion steps I 
to III and lowering the infusion rate of step IV according to the adjusted infusion sched-
ule shown in Table II. The IARs were endurable for the patient, but not fully controlled. 
Because of ongoing disease progression the treatment was finally stopped after a total 
duration of 33 months.
antibody formation and pharmacokinetic analysis
Since antibodies against recombinant forms of human acid α-glucosidase might elicit 
IARs and affect the therapeutic outcome, three types of tests were performed to evalu-
ate antibody formation. Figure 3 (dotted line) shows a continuous rise of antibody titer 
during the first 18 months of treatment as measured with ELISA.
A second antibody titer test was developed based on binding and precipitation of 
catalytically active alglucosidase alfa by antibodies in serum samples of the patient col-
lected prior to enzyme infusions. Figure 4 shows that alglucosidase alfa is precipitated by 
serially diluted serum of patient 1, whereas all activity remains in the supernatant when 
sera from patients 2, 3 and 4 are mixed in. The calculated titers at different time points 
are inserted in Figure 3 (▲) as numbers to allow comparison with the ELISA assay. With 
both methods the highest titers were measured in month 18.
In month 32 after start of treatment, we measured the binding of circulating anti-
bodies during infusion of alglucosidase alfa. Figure 5 shows the total acid α-glucosidase 
activity in the plasma and the activity remaining after Protein A sepharose mediated 
immuno-precipitation of antibody-bound alglucosidase alfa. Two hours after the start 
of alglucosidase alfa infusion at low infusion rate, almost all acid α-glucosidase activity 
Table II Infusion schedules
Step I Step II Step III Step IV
Regular
5 ml/h 20 ml/h 88 ml/h 250 ml/h
30 min 30 min 30 min Till end infusion
Adjusted
5 ml/h 20 ml/h 88 ml/h 180 ml/h
60 min 60 min 60 min Till end infusion
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is precipitated (Figure 5A). The proportion of antibody-bound enzyme decreases with 
increasing infusion duration and infusion rate and is 42% at the end of the infusion. 
Figure 5B shows the pharmacokinetics of three adult patients without IARs, without 
antibody titer, and with a good clinical response (patients 2, 3 and 4). In these three cases 
none of the infused alglucosidase alfa was antibody-bound.
Figure 3 Antibody titer during ERT
Antibody titer as measured with ELISA (□ dotted line) and by immuno-precipitation (▲; in nmol 4 MU/h per 
1 μl undiluted serum).
Figure 4 Antibody titration curves
Two-fold serially diluted sera of patient 1(♦), patient 2 (●), patient 3 (▲) and patient 4 (■), starting from 
a 50 fold dilution were added to a fixed amount of alglucosidase alfa. The antibody-bound alglucosidase 
alfa was precipitated with the aid of protein A sepharose, and the activity remaining in the supernatant 
measured with MUGlc.
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in vitro uptake of alglucosidase alfa by fibroblasts
To investigate the adverse effect that antibody binding can have on the efficacy of 
ERT we applied two procedures to measure the uptake of alglucosidase alfa by in vitro 
cultured fibroblasts. In the first experiment we directly added alglucosidase alfa to the 
culture media and analyzed uptake in the presence of the sera of patient 1 with antibody 
titer (S1) and patient 2 without antibody titer (S2), and in the absence of human serum 
(S0). After 16 h of incubation, the acid α-glucosidase activity in the medium was in all 
cases less than added (1000 nmol 4 MU/ml), but on average 25% lower in S1 compared 
to S2 and S0 (Figure 6, medium). Figure 6 also shows by Western-blot analysis that the 
enzyme added to the medium has a molecular mass of 110 kDa, which is characteristic 
for alglucosidase alfa. There was no obvious difference in the amount of enzyme-protein 
Figure 5 Antibody binding of alglucosidase alfa during infusion
Pharmacokinetic curves and the binding of infused alglucosidase alfa to circulating antibodies. Blood 
samples were collected just prior to start of infusion (0 h) and at regular time intervals thereafter. The 
closed symbols in panel A and B represent the total acid α-glucosidase activity in the plasma; the open 
symbols the amount of activity that is antibody-bound. The activity in the supernatant was measured 
with MUGlc and is in this figure expressed in nmol 4 MU liberated per 10 μl supernatant per hour. Panel A 
shows the pharmacokinetic curve of patient 1 (♦); panel B shows the pharmacokinetic curves of patient 2 
(●), patient 3 (▲) and patient 4 (■).
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contained in the three media (samples S0–S2) despite the lower acid α-glucosidase activ-
ity in medium S1 (Figure 6, 564 versus 769–742). Thus, it seems that the serum of patient 
1 has a slightly inhibitory effect on the catalytic function or stability of alglucosidase 
alfa. Part of the enzyme added to the fibroblasts was recovered inside the cells as shown 
in Figure 6 (cells) by increased enzyme activity in the cell homogenates and the detection 
of processed forms of alglucosidase alfa (95 kDa and 76 kDa) by Western-blot analysis. 
Notably, in the three experiments that we performed there was repeatedly a clear dif-
ference in the amount of alglucosidase alfa inside the cells depending on the addition of 
serum from either patient 1 (S1) or patient 2 (S2), and no serum addition (S0). The lower 
protein signal in lane S1 compared to S0 and S2 indicates inhibition of enzyme uptake by 
the serum of patient 1 as is also reflected by the lower acid α-glucosidase activity in the 
fibroblasts fed with alglucosidase alfa in the presence of serum from patient 1 (Figure 6, 
cells).
In the second procedure the uptake of alglucosidase alfa by human fibroblasts was 
measured by flow cytometry. Oregon Green labelled alglucosidase alfa was incubated 
with two-fold serially diluted sera from the patient before addition to the cultured nor-
mal human fibroblasts. Percent inhibition was calculated and the end point inhibition 
titer was reported. Figure 7 shows a continuous rise of the uptake inhibitory antibody 
Figure 6 Uptake of alglucosidase alfa by fibroblasts
An amount of alglucosidase alfa equivalent to 978 nmol 4 MU/h was added to a 1 ml culture medium. The 
receiving fibroblasts were derived from a CRIM-negative patient with classic-infantile Pompe disease. The 
activity in the medium was measured the day after enzyme addition and is expressed in nmol 4 MU/h ml. 
The activity in the cells is expressed in nmol 4 MU/h mg cellular protein. The lanes contain 20 μl medium 
(Medium) or 0.04 mg protein (Cells). S0, no serum addition; S1, addition of serum from patient 1; S2, 
addition of serum from patient 2.
108   |    Chapter 3.2
Chapter
 3.2
titer during the first 18 months of ERT followed by a decline. The peak titer was 320 at 
month 18.
 Discussion
Antibody formation is frequently encountered in patients who regularly receive protein 
infusions to combat the manifestations of a genetically determined protein deficiency. 
In Pompe disease, early anecdotal reports have mentioned the finding of high antibody 
titers in 2 of 3 children receiving the very first formulas of recombinant human acid 
α-glucosidase produced in CHO cells and suggested a correlation between antibody for-
mation and CRIM status.36 ‘CRIM-positive’ are the patients who produce a demonstrable 
amount of native enzyme and ‘CRIM-negative’ are those who don’t. Another early study 
included one adult, two adolescents and four infants (one of which CRIM-negative) who 
were treated with recombinant human acid α-glucosidase from rabbit milk. The CRIM-
positive adult patient in that study had the highest titer at the time of reporting.37 A 
recent evaluation of all available data indicates that CRIM-negative patients are more 
prone to develop high antibody titers than CRIM-positive patients and that antibody 
formation negatively affects the treatment outcome in infants with Pompe disease.16
Our present study supports the notion that immune responses to alglucosidase 
alfa are not limited to infants but can also occur in adults despite the fact that they 
Figure 7 Uptake inhibitory antibody titers as measured by flow cytometry during ERT
Oregon Green labelled alglucosidase alfa was pre-incubated with 2-fold serially diluted patient’s sera and 
then added to the fibroblasts. The titer was calculated as described in Materials and methods.
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all are CRIM-positive; a situation comparable to type I Gaucher disease. In our case of 
adult-onset Pompe disease the poor response to treatment and the occurrence of IARs 
coincided with a very high antibody titer. The most alarming clinical finding was the 
ongoing decline of muscle strength of our patient during ERT compared to the positive 
group-wise response of 60 adult patients receiving ERT in a recently published random-
ized study of alglucosidase alfa in late-onset Pompe disease (summarized in Table III).13-15
The combination of sustained IARs and poor response to treatment was the main 
reason to investigate antibody formation as causative factor. The ELISA assay measur-
ing the antibody titer is based on antibody binding to a fixed, but unknown, amount of 
immobilized alglucosidase alfa. The method employing Protein A sepharose beads mea-
sures the amount of catalytically active antibody-bound enzyme via precipitation. It is a 
semi-quantitative test showing how much enzyme is actually bound per serum volume. 
In case of patient 1, all alglucosidase alfa activity is ultimately precipitated at the highest 
serum volume (Figure 4). Inclusion of Protein A sepharose beads in the pharmacokinetic 
analysis provides an estimate of what percentage of administered enzyme is captured 
by the patient’s circulating antibodies. The results obtained with the different methods 
corroborate each other. ELISA shows a gradual rise of antibody titer in patient 1 from 
start of treatment. The antibody titer test employing Protein A sepharose beads shows 
a similar trend (Figure 3) and additionally reveals the potential impact of a high titer on 
ERT as illustrated by the following calculation. The specific activity of alglucosidase alfa 
is approximately 300 μmol 4 MU/h mg protein. A titer of 91 nmol 4 MU/h μl (highest 
titer in Figure 3) implies that 1 μl of the patient’s serum contains enough antibodies to 
bind 3 × 10−4 mg alglucosidase alfa. Thus, the antibodies in 2 liter serum can capture 
600 mg alglucosidase alfa while a patient with a weight of 80 kg receives a total dosage 
of 1600 mg. It is evident that a substantial part of the total infusion dosage is bound by 
antibodies (37.5% in this example). The pharmacokinetic analysis including Protein A 
sepharose beads leads to a similar conclusion (42% at end of infusion; Figure 5A). Figure 3 
shows that an ELISA titer of 400,000 to 800,000 roughly corresponds to a titer of 50 to 
90 nmol 4 MU/h μl. If one translates these figures to the situation in infants receiving 
ERT, the circulating antibodies capture more than half of the alglucosidase alfa dosage 
Table III Response of patient 1 to ERT compared to the group-wise response to ERT
Outcome measure Response of patient 1 Group-wise response (n = 60)
6MWT −8.2a 16.8 (6.7 to 26.8)
QMT arm score −4.5b 3.4 (1.3 to 5.5)
QMT leg score −8.9b 0.8 (−0.7 to 2.3)
FVC sitting −1.9b 0.8 (−0.1 to 1.7)
a The figures represent the change from baseline in meters per year for the 6-minute walk test (6MWT) and 
b percentage points per year for QMT scores and FVC. The 95% confidence interval is given between brackets. 
The group-wise response per year was calculated from Table II of A. van der Ploeg, et al.15
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that is administered to infants with equally high antibody titers. This would provide an 
explanation for their poor response.16
The way antibody binding affects ERT is not totally clear, but from the experiments 
we performed it is evident that admixture of antibodies to alglucosidase alfa inhibits 
the uptake of the enzyme by fibroblasts in a cell culture system. Kishnani et al. and Nico-
lino et al. in their recent publications stated that some of their patients also produced 
antibodies that interfered with the uptake of alglucosidase alfa.14,16 The most likely 
hypothesis for the poor response of our patient is that antibody binding also inhibits 
the in vivo uptake of alglucosidase alfa by the target tissues. The same adverse effect of 
antibody formation on enzyme uptake has previously been demonstrated in relation to 
the treatment of patients with Fabry disease. In that study, the inhibitory effect was not 
only demonstrated in vitro but also in vivo by injecting mice.38
Antibody binding and immune-complex formation can also inactivate the enzyme’s 
catalytic function, but that does not seem to be the case in this patient. This holds for the 
activities towards both glycogen and MUGlc (results not shown). Frequently, patients 
receiving ERT become tolerant after prolonged treatment. If this is not the case immune 
tolerization protocols may help to annihilate the detrimental effects of antibody for-
mation. One report on the successful application of immune tolerization in a case of 
CRIM-negative infantile-onset Pompe disease has recently been published.39
It remains enigmatic why the patient in our study developed exceptionally high 
antibody titers since he is CRIM-positive and has the most common GAA mutation (c.-
32-13T>G). The immune response in this case is apparently also determined by genetic 
background or environmental factors.
Conclusively, we have shown that alglucosidase alfa can occasionally elicit an adverse 
immune response even in CRIM-positive adult patients. A high antibody titer can become 
detrimental to the therapeutic effect of ERT when the number of circulating antibodies 
approaches the number of administered alglucosidase alfa molecules. The antibody titer 
assay and the pharmacokinetic analysis, as described in this report, including precipita-
tion of antibody-bound alglucosidase alfa, give a meaning to the height of the antibody 
titer. If the circulating antibodies inhibit uptake of enzyme by the target tissues, they 
reduce the effective dosage of alglucosidase alfa. Immune-surveillance should be a rou-
tine procedure in the follow-up of patients receiving ERT for Pompe disease independent 
of the patient’s clinical subtype or CRIM status.
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abstract 
Purpose High sustained antibodies against enzyme replacement therapy with algluco-
sidase alfa adversely affect treatment outcome in classic-infantile Pompe disease. The 
long-term effects of antibody formation on therapeutic efficacy in other forms of Pompe 
disease are unknown. 
Methods This prospective study included 73 adult patients treated with 20 mg/kg alglu-
cosidase alfa every other week for 3 years. Antibodies were measured using ELISA before 
start of ERT and during ERT at 6, 12 and 36 months. Their effects on enzyme activity were 
measured in vitro. Clinical parameters included muscle strength, pulmonary function, 
and infusion-associated reactions. 
Results 71 of the 73 (97%) patients developed antibodies. At 6 months of ERT, we found 
the highest titer, as the geometric mean titer was 1:1259 (95% CI 1:696 to 1:2276). 
Thereafter, the titer declined to 1:270 after 36 months of treatment. Individual titers and 
titer courses varied, but in the majority (93%) of patients titers decreased or stabilized 
with continued enzyme replacement therapy. Patients with high maximal titers showed 
moderate to high levels of enzyme inhibition in vitro. The height of the antibody titers 
correlated with the occurrence of infusion-associated reactions. At group-level no poorer 
clinical outcome was found as assessed by MRC sumscore and FVC in upright and supine 
positions. The exception was the patient with the highest antibody titer (1:3,906,250), 
who showed an ongoing clinical decline during ERT.  
Conclusion Antibody formation to alglucosidase alfa in adults with Pompe disease in-
creases the risk of infusion-associated reactions, but is not associated with unfavorable 
clinical outcome at group-level during 3 years of treatment.
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introDuction
Pompe disease, also known as acid maltase deficiency and glycogen storage disease 
type II (OMIM 232300), is an autosomal recessive lysosomal storage disorder due to a 
deficiency of the enzyme acid α-glucosidase (GAA).1, 2 This results in intralysosomal ac-
cumulation of glycogen in all tissues, but most notably in skeletal muscles. 
Since 2006 enzyme replacement therapy (ERT) with alglucosidase alfa (recombinant 
human acid α-glucosidase, rhGAA, Myozyme®) is available for patients with Pompe 
disease. Registration was mainly based on studies performed in classic infantile pa-
tients − the most severely affected patients − suffering from rapidly progressive muscle 
weakness and a hypertrophic cardiomyopathy.3, 4 Treatment with ERT leads to substantial 
improvement in survival, motor outcome and reversal of the hypertrophic cardiomyopa-
thy,5-9 whereas untreated infants succumb to cardiorespiratory failure within the first 
year of life.3, 4
Children, juveniles and adults exhibit a milder phenotype (non-classic Pompe disease) 
and suffer from gradually progressive limb-girdle muscular weakness and respiratory 
insufficiency.10-14 The first symptoms can present at any age, from early infancy to late 
adulthood. The natural course of the disease is more heterogeneous as compared to clas-
sic-infantile Pompe disease, but over time the majority of patients becomes wheelchair 
and ventilator dependent.15, 16 Subsequent studies, including a randomized-clinical trial, 
have also demonstrated positive effects of ERT on muscle strength, pulmonary function 
and survival in non-classic Pompe disease.17-23 While the majority of patients benefits 
from ERT, profound variations in individual treatment responses have been observed in 
all forms of the disease.5-9, 18, 19, 21-24 
Several factors are known to influence the response to ERT in classic-infantile Pompe 
disease. For example, an early start of treatment within the first weeks after birth and a 
relatively good patient’s condition are both associated with a better clinical outcome.8, 9, 
25 However, high sustained anti-rhGAA antibodies can be associated with a less favorable 
response to ERT.26, 27 These high sustained titers occur more frequently in patients with 
a CRIM (cross-reactive immunologic material) negative status, i.e. those patients who 
produce no endogenous GAA at all.27, 28 
In children and adults with Pompe disease predictive factors with regard to treatment 
outcome are less well established. Younger age and better clinical status at start of ERT 
seem to be favorable prognostic factors for the effect of ERT.19, 23, 24 So far, it remains 
unclear whether antibody formation in these patients is of influence on treatment ef-
ficacy. Patients with non-classic Pompe disease synthesize a fair amount of catalytically 
active GAA themselves. Hence, it was anticipated that their immune responses would be 
less vigorous and would not adversely affect treatment outcome. This assumption was 
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endorsed by the only randomized controlled trial for ERT, the Late-Onset Treatment Study 
(LOTS).23 In this study all of the 59 adult patients receiving alglucosidase alfa developed 
anti-rhGAA antibodies during 18 months of treatment, but not to an extend that the 
effect of treatment was impaired. One patient in this trial had a very high and sustained 
antibody titer (maximal titer of 1:819,200). Extended follow-up (up to 33 months ERT) of 
this patient showed declining muscle strength, progressive respiratory insufficiency and 
persisting infusion-associated reactions (IARs).29 Pharmacokinetic studies demonstrated 
that the patient’s anti-rhGAA antibodies captured approximately 40% of administered 
alglucosidase alfa and in vitro studies showed inhibition of enzyme activity and enzyme 
uptake by cultured fibroblasts. A following publication by Patel et al. described three 
cases with adult-onset Pompe disease who all developed high sustained antibodies 
coinciding with a poor clinical response to ERT,30  suggesting that undesirable effects of 
antibodies may also affect the treatment response of patients with non-classic Pompe 
disease. Because the impact of antibody formation on clinical outcome in non-classic 
Pompe disease is not fully understood, and as the disease is characterized by a slow 
disease progression, longer follow-up studies in large patient cohorts are desired to 
further investigate this point.
For these reasons we studied anti-rhGAA antibody formation in a cohort of 73 adult 
Pompe patients over a treatment period of 36 months. Clinical parameters included IARs, 
skeletal muscle strength and pulmonary function in upright and supine positions. This 
study represents the largest cohort with the longest follow-up for the effects of antibody 
formation on therapeutic efficacy of alglucosidase alfa and association with occurrence 
of IARs in adults with Pompe disease to date. 
Patients anD methoDs
Patients and study Design
In 2005 the ongoing single-center, prospective, open-label cohort study on the natural 
disease course and the use of ERT in adults with Pompe disease was initiated at the Cen-
ter for Lysosomal and Metabolic Diseases at the Erasmus MC University Medical Center 
(the designated center of expertise for Pompe disease in the Netherlands).
Patients were eligible for inclusion in the study if 1) they were over 18 years of age; 2) 
their diagnosis had been confirmed by enzyme analysis in leukocytes or fibroblasts31-33; 
3) they had not previously been treated with rhGAA; and 4) they were symptomatic, 
i.e. had measurable muscle weakness and/or diminished pulmonary function. In this 
study on anti-rhGAA antibody formation, patients were included who started treatment 
between January 2005 and July 2010 (to allow a three year treatment period) and for 
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whom blood samples were available just before start of ERT and during ERT at 6, 12 and 
approximately 36 months. Data presented here were collected from January 2005 up to 
February 2013. During the study all patients intravenously received 20 mg/kg algluco-
sidase alfa every other week. The study protocol is described in more detail elsewere.19
The Institutional Review Board approved the study protocol, and all patients provided 
written informed consent.
antibody Detection
Blood samples were either drawn just before the infusions, or, in case patients re-
ceived home treatment, on a day patients did not receive ERT. When a blood sample 
was missing at 36 months ERT, a sample between 24 and 42 months was used closest in 
time to 36 months. Blood samples were stored at -20 0C. Enzyme-linked immunosorbent 
assays (ELISA) were performed as described.34 Experiments were repeated two to four 
times for high antibody titers (≥1:31,250). 
For twelve patients, titers were determined in the 6 and 12 months sera as part of the 
LOTS study using a non-commercial ELISA assay established in the Genzyme Clinical Spe-
cialty Laboratory (Genzyme Corp., Framingham, Massachusetts).23, 35 For four of these,  6 
and 12 months sera were used to validate the Erasmus MC ELISA protocol. Exact titers 
differed due to different dilution ranges (5 x in the Erasmus MC assay, 2 x in the Genzyme 
assay) and due to higher dynamic range of the Erasmus MC assay, but in all cases, the 
patients were placed in identical titer groups (no-low, intermediate, or high). Average 
values were used in these cases. For reasons of graphical representation of Figure 1B, 
titers derived from 2-fold dilutions were rounded to titers derived from 5 fold dilution. 
effects of antibodies on alglucosidase alfa activity
Fibroblasts from a patient homozygous for the 525delT pathogenic mutation and 
therefore fully deficient for endogenous GAA activity were grown in 24-well tissue-culture 
plates and kept overnight at 37 0C 24 hours in Ham’s F10+ medium supplemented with 
10% heat inactivated fetal calf serum (FCS) and antibiotics. The medium was replaced 
with 200 μl HAM’s F10+ medium containing antibiotics, 3 mM PIPES, alglucosidase alfa 
(in an amount equivalent to 200 nmol GAA activity), and  20 μl of the patients’ sera. FCS 
served as control. Fibroblasts and medium were harvested after 24 hours. Alglucosidase 
alfa activity was measured using 4-methylumbelliferyl α-D-glucoside (4MU) as substrate 
as described.34 The experiment was repeated three times for patients with an antibody 
titer and twice for patients without a titer. All measurements were performed in dupli-
cate. Alglucosidase alfa activity was expressed as percentage of the activity present in 
FCS, measured in the medium directly after addition of alglucosidase alfa.
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clinical outcome measures and infusion-associated reactions
Skeletal muscle strength and pulmonary function tests were performed every three to 
six months before the start of ERT and every three months thereafter. Methods are de-
scribed in more detail elsewhere.19 Briefly, skeletal muscle strength was assessed using 
manual muscle testing according to the Medical Research Council (MRC) grading scale. A 
Figure 1 Anti-rhGAA antibody titer course and maximal titers during 36 months of enzyme replacement 
therapy
A Geometric mean and 95% confidence intervals of anti-rhGAA antibody titer course during enzyme 
replacement therapy for the total group and separately for patients with high titers, intermediate 
titers and no-low titers. B Distribution of the maximal anti-rhGAA antibody titers. Based on the highest 
antibody titer measured, patients were divided into the following groups: 1) no or low titer (0 – <1:1250); 
2) intermediate titer (1:1250 – <1:31,250); and 3) high titer (≥1:31,250). 
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sumscore was calculated combining scores of the most affected muscles and the calcu-
lated score was expressed as a percentage of the maximum possible score. Forced vital 
capacity (FVC) was measured in upright and supine positions. Results were expressed as 
a percentage of predicted normal values. All clinical data up to a follow-up of 42 months 
ERT were incorporated in the analysis, as this was the maximal allowed follow-up for 
inclusion of blood samples for antibody testing. 
Vital signs, IARs and medical interventions to treat IARs were recorded every other 
week when patients received their alglucosidase alfa infusions. We defined IARs as 
symptoms or signs with onset during the infusion or within a 48 hour time frame after 
start of infusion. Only IARs that were clinically judged to have a possible, probable, or 
definite relationship with the infusion were included in the analysis. The severity of IARs 
was classified as mild, moderate, or severe.
statistical analysis
Patients were divided into groups according to the highest titer observed: 1) no or 
low titer (0 – <1:1250); 2) intermediate titer (1:1250 – <1:31,250); and 3) high titer 
(≥1:31,250). When differences in demographic and clinical characteristics were calcu-
lated, it concerned the variables as shown in Table I. To calculate differences across the 
three antibody titer groups, we used the chi-square trend test for nominal data and the 
Kruskal-Wallis test for continuous and ordinal data. 
To estimate whether there was an effect of antibody formation on treatment outcome 
as assessed by MRC sumscore and FVC in upright and supine positions, we carried out 
the following statistical analysis. First, in the total group, repeated measures ANOVA 
applying a piecewise regression (‘brokenstick’ method) was used to calculate: 1) the 
mean pre-treatment course; 2) the mean treatment course at 36 months ERT; and 3) 
the response to ERT at 36 months ERT. The latter is defined as the difference in course 
between the pre-treatment and the treatment period. As the mean treatment course in 
MRC sumscore violated the assumptions of linear regression, an exponential regression 
model was fitted. For the reason that the duration of follow-up for the pre-treatment 
course differed among patients, it was expressed in absolute percentage points per year 
(pp/y). The treatment course and response to ERT were expressed in percentage points 
(pp) over a 36 months treatment period.
Lastly, to estimate whether there were differences in pre-treatment course, treatment 
course, and response to ERT across the three antibody titer groups, a subgroup analysis 
was performed applying the same statistical methods as in the total group. 
Analyses were performed with SPSS for Windows (version 21, SPSS Inc., Chicago, IL) 
and (repeated measures analysis using) SAS (version 9.3, SAS Institute Inc., Cary, NC). The 
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p-values for the exponential term were calculated in R-3.0.2. A p-value lower than 0.05 
(two-sided) was considered statistically significant.
results 
Patients
Seventy-three patients met the inclusion criteria as they had started ERT at least three 
years ago and had blood samples available for antibody testing just before start of ERT 
and during ERT at 6, 12 and approximately 36 months. At the last ELISA measurement, the 
median treatment duration was 35 months (range 24 – 41 months). Of the 73 patients, 
72 received ERT during the entire study follow-up. In one patient ERT was discontinued 
after 33 months due to a poor response to ERT, the presence of IARs and co-occurrence 
of a very high antibody titer.29
The general characteristics of these patients at the start of ERT are shown in Table I. 
Male and female gender were evenly represented. Age of onset among the 73 patients 
differed widely between 1.4 and 62 years of age with a median age of 32 years. Enzyme 
replacement therapy was started at a median age of 52 (range 26 and 74 years) after a 
median disease duration of 8 years. One third of the patients was wheelchair dependent 
and 30% used mechanical ventilatory support. All but one carried the common c.-32-
13T>G (IVS1) mutation on one allele in combination with a second pathogenic mutation 
on the second allele. The most common second mutations were c.525delT in 44% of 
cases and c.2481+102_2646+31del (delex18) in 15% of cases. For three patients the 
results of the mutation analysis could not be traced, because these were performed in 
another center. 
anti-rhgaa antibodies
Seventy-one patients (97%) developed antibodies to alglucosidase alfa. The highest titer 
for the whole group was reached after 6 months ERT, as the geometric mean titer was 
1:1259 (95% CI 1:696 to 1:2,276). The geometric mean titer, thereafter, declined to 1:270 
(95% CI 1:123 to 1:595) after 36 months of ERT (Figure 1A, bold line). Individual titers 
varied widely. Three groups could be defined according to the highest titer observed: 16 
patients (22%) developed high titers (≥1:31,250), 27 patients (37%) intermediate titers 
(1:1250 –  <1: 31,250), and 30 patients (41%) no to low titers (0 – <1:1250) (Figure 1B). 
These three groups showed similar mean trends compared to the total group (Figure 1A). 
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Figure 2 Different anti-rhGAA antibody titer courses stratified for the anti-rhGAA antibody titer groups 
during 36 months of enzyme replacement therapy
A – C Geometric mean and 95% confidence intervals of anti-rhGAA antibody titer course during enzyme 
replacement therapy for patients as stratified for the three anti-rhGAA antibody titer groups: A decreasing 
titer course; B stabilized titer course; and C increasing titer course (no 95% confidence intervals could be 
given due to small numbers). The titer course was defined as decreasing/increasing when the 36 months 
ERT titer was at least one dilution lower/higher compared to the 6 or 12 months titer. 
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However, within these groups, the course varied among patients. Three courses could be 
observed: a decreasing course, a stabilizing course, and an increasing course (Figure 2). 
The majority of patients (93%) showed either stabilizing or decreasing titers over time. 
When demographic and clinical characteristics at start of ERT were compared across 
the three antibody titer groups many characteristics were similar (Table I). However, 
some of the clinical characteristics were different between the three groups, such as 
disease duration (shortest in the high titer group), partial or permanent wheelchair use 
(lowest prevalence in the high titer group), FVCsupine and serum creatine kinase (all lowest 
in the no-low titer group). All four invasively ventilated patients belonged to the no-low 
titer group. Although the observed differences did not reach statistical significance, 
when taken together, a trend was observed for a worse clinical status for the no-low titer 
group and a better clinical status for the high titer group. No differences in enzymatic 
activities or prevalence of a specific genotype were observed. 
effects of antibodies on alglucosidase alfa enzymatic activity
Antibodies to alglucosidase alfa have the potential to interfere with the enzymatic activ-
ity or uptake of alglucosidase alfa into cells. To test this, sera from patients were admixed 
with alglucosidase alfa in cell culture medium in which GAA-deficient fibroblasts were 
grown. After 24 hours, enzymatic activity was measured in both the medium and the 
cells. Reduction of activity in the medium is indicative of direct effects on enzymatic ac-
tivity, while disproportional reduced activity in cells indicates reduced uptake. This was 
tested using blood samples from seven patients with high titers, three with intermediate 
titers, and three with no-to low titers. In vitro studies for the one patient with a very high 
titer of whom results were published previously were not repeated.29 
Enzymatic activity was not inhibited by sera of patients with no-low to intermediate 
titers (Figure 3A,B). Blood samples of patients with high titers showed inhibition of 
enzymatic activity in both the medium and the cells, but the degree of inhibition in the 
medium and the cells varied per patient (Figure 3A,B). A very strong correlation (Spear-
man ρ=0.81, p=0.001) was observed between the activities as measured in the medium 
and in the cells, suggesting that the predominant and relevant effect of the antibodies 
was inhibition of enzymatic activity rather than other effects such as inhibition of uptake 
of alglucosidase alfa by the cells (Figure 3C). 
association between anti-rhgaa antibodies and infusion-associated reactions 
Thirteen patients (18%) showed clinically confirmed IARs (Table II), of whom 12 were 
female (p=0.001). A strong relationship between IARs and the highest antibody titer 
was observed. First, the number of patients that experienced IARs was seven out of 16 
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Figure 3 Effects of anti-rhGAA antibody titers on in vitro alglucosidase alfa enzymatic activity
Tests were performed for 13 patients, of whom 7 with a high titer, 3 with an intermediate titer, and 3 
with a low or no titer. A and B show the alglucosidase alfa enzymatic activities in relation to the height 
of the antibody titer in the medium at the (A) and the cells (B; GAA-deficient fibroblasts) after 24 hours 
incubation. C Correlation between the rhGAA activities as measured in the medium and in the cells 
(Spearman ρ 0.81, p=0.001). 
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patients (44%) in the high titer group, five out of 27 (19%) in the intermediate titer group 
and only one out of 30 (3%) in the no-low titer group (p=0.001) (Figure 4A). Second, pa-
tients who had a high antibody titer experienced IARs more frequently (ρ 0.47, p<0.001; 
Figure 4B). 
Most patients (nine) experienced their first IARs within the first year of treatment 
(median onset of IARs was 9 months of ERT, range 6 weeks to 35 months). Infusion-
associated reactions usually commenced during the infusion of alglucosidase alfa or in 
the hours just after completion of the infusion. Only once, a patient suffered from an 
IAR the day after the infusion. Patients experienced various types of IARs (Table II), with 
general malaise, cold chills, and hyperthermia being the most frequently observed com-
bination of symptoms (five patients). Almost all IARs were mild or moderate in nature, 
only one patient developed a severe IAR in the form of a transient hypertension up to 
211/102 mmHg. To prevent further IARs, the infusion rates were slowed down in all but 
one patient. Additionally, pre-medication was given either in the form of antihistamines, 
corticosteroids, or as a combination of the two. At the end of the study IARs had resolved 
Table II Infusion-associated reactions 
Type of IAR
Number of IARs
No. (%)
Patients experiencing the IARa
No. (%)
General malaise 162 (22.7) 4 (31)
Fatigue 5 (0.7) 2 (15)
Cold chills 181 (25.3) 5 (38)
Itching 12 (1.7) 2 (15)
Flushing 2 (0.3) 2 (15)
Localized exanthema 8 (1.1) 4 (31)
Generalized exanthema 11 (1.5) 3 (23)
Local angioedema 1 (0.1) 1 (8)
Dyspnea 4 (0.6) 2 (15)
Chest discomfort 12 (1.7) 4 (31)
Musculoskeletal pain 74 (10.3) 2 (15)
Palpitations 3 (0.4) 1 (8)
Hypertension 20 (2.8) 8 (62)
Tachycardia 78 (10.9) 5 (38)
Hyperthermia 114 (15.9) 7 (54)
Desaturation 1 (0.1) 1 (8)
Headache 16 (2.2) 3 (23)
Dizziness 1 (0.1) 1 (8)
Nausea 9 (1.3) 3 (23)
Vomiting 1 (0.1) 1 (8)
Total 715 (100) 13 (100)
Total infusions with IARs 226
a Patients may have had experienced more than one type of IAR. 
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in 11 of the 13 patients, two of whom continued to receive corticosteroids to prevent 
further IARs. All symptoms related to the infusions were reversible.
association between anti-alglucosidase alfa antibodies and treatment outcome
To evaluate whether antibody formation interfered with clinical outcome, the pre-
treatment course and the treatment course over the 36 months treatment period were 
Figure 4 The association between infusion-associated reactions and the maximal anti-rhGAA antibody 
titer
A shows the number of patients with and without infusion-associated reactions (IARs) for each anti-rhGAA 
antibody titer group. B Correlation between the number of IARs and the maximal anti-rhGAA antibody titer 
(Spearman ρ 0.47, p<0.001).
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calculated for the three clinical outcome measures. Subsequently, the response to ERT 
was estimated by calculating the difference in course between the pre-treatment and 
the treatment period over 36 months of ERT. 
For 58 patients pre-treatment data on disease progression were available with a me-
dian follow-up of 16 months (range 4 to 55 months). For all patients data were available 
during the treatment period. Table III gives the results in the total patient population 
and stratified for the three antibody titer subgroups.
During the pre-treatment period, the clinical outcome measures significantly declined 
at -0.9 pp/y for MRC sumscore, -1.7 pp/y for FVC in upright position, and -2.1 pp/y for FVC 
in supine position in the total patient population. The mean treatment course for MRC 
sumscore was 2.1 pp (p=0.001) during 36 months of ERT, whereas the treatment course 
of FVC in upright and supine position stabilized. The responses to ERT were found to be 
5 to 6 pp for all three outcome measures (MRC sumscore p<0.001; FVC in upright and 
supine positions p<0.01). 
With regard to the subgroup analysis, similar results across the three antibody titer 
groups were obtained for the treatment course of MRC sumscore and FVC in upright 
and supine positions. For MRC sumscore and FVC in upright position, also no significant 
differences between the three titer groups were found with regard to the response to 
treatment. A co-incidental finding was that the pre-treatment course of FVC in supine 
position differed across the antibody titers groups (borderline significant, p=0.06), with 
a more rapid decline in patients with high titers and intermediate titers as compared 
to the patients with no-low titers. This difference in pre-treatment course also explains 
the observed difference in the response to ERT for FVC in supine position (borderline 
significant, p=0.05), because the treatment course did not differ between the subgroups. 
As we wondered whether the individual treatment courses of the seven patients 
with very high titers (≥1:156,250) showed an ongoing decline during ERT, we studied 
these courses separately (Figure 5). The patients with the highest titer of all patients 
(1:3,906,250) was the only patient with a rapid decline with regard to MRC sumscore 
during ERT. His FVC in both upright and supine position continued to decline after start 
of ERT, but less dramatically than his muscle strength (results published previously).29 
There was one other patient, who showed an ongoing decline with regard to pulmonary 
function, which was most pronounced for FVC in supine position. For the other patients 
with titers equal or higher than 1:156,250 muscle strength increased and FVC in upright 
and supine position remained fairly stable during ERT. Of note, among the patients with 
lower anti-rhGAA antibody titers there are also some patients, who continued to decline 
with regard to muscle strength and pulmonary function (data not shown), but not as 
rapid as the decline observed in the patient with the highest titer of all.
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Discussion
This study represents the first systematic study analyzing the relation between the for-
mation of anti-rhGAA antibodies in response to ERT and clinical outcome, as well as the 
occurrence of IARs in adults with Pompe disease. It is the largest group of 73 patients, 
with the longest treatment follow-up (36 months), reported to date. The analyses show 
that the vast majority of adult patients develop antibodies to alglucosidase alfa, but that 
there are various immune response patterns. Although, after an initial rise in antibody 
titer, the titer stabilized or decreased with continued ERT in the majority of patients 
(95%). A strong association was found between the height of the antibody titer and the 
occurrence of IARs. No marked adverse effects on clinical outcome were found in the 
group of patients with high titers (≥1:31,250). An exception was the one patient with the 
Table III Natural course, treatment effect and response at 36 months enzyme replacement therapy for the 
total group and the antibody titer groups
Pre-treatment course
Treatment course
36 months ERT
Response to ERTb
36 months ERT
mean pp/ya p-value mean pp p-value mean pp p-value
MRC sumscore
Total group (n=73) -0.9 <0.01 2.1 0.001 4.8 <0.001
Subgroups anti-rhGAA 
antibody titer
   - No-low titer n=30 -0.8
0.67*
2.8
0.76*
5.1
0.67*
   - Intermediate titer n=27 -1.3 2.2 6.1
   - High titer n=16 -0.5 0.6 2.2
FVC in upright position
Total group (n= 68) -1.7 <0.01 1.2 0.24 6.2 <0.01
Subgroups anti-rhGAA 
antibody titer
   - No-low titer n=26 -0.9 0.34* 1.6 0.77* 4.4 0.54*
   - Intermediate titer n=26 -2.1 1.1 7.4
   - High titer n=16 -2.1 0.8 7.2
FVC in supine position
Total group (n=60) -2.1 <0.001 -0.8 0.43 5.4 <0.01
Subgroups anti-rhGAA 
antibody titer
   - No-low titer n=23 -1.1 0.06* -1.8 0.75* 1.5 0.05*
   - Intermediate titer n=22 -2.0 0.1 6.2
   - High titer n=15 -3.3 -0.8 9.0
a For the reason that duration of follow-up differed for each patient before start of ERT, the pre-treatment 
course is expressed in percentage points per year (pp/y). b The response to ERT is defined as the difference in 
course between the pre-treatment and the treatment period. * P-value for the difference between the three 
anti-rhGAA antibody subgroups, in case there was a linear relation a trend test was used to estimate the 
p-value.
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Figure 5 Individual courses of the MRC sumscore
(A) and FVC in upright (B) and supine positions (C) of patients with very high titers (≥1:156,250) before 
start of ERT and during ERT. 
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highest titer of all patients (1:3,906,250), who continued to decline rapidly with regard 
to muscle strength and moderately with regard to pulmonary function.29 
Immune responses to recombinant human enzymes are a well-known phenomenon 
in lysosomal storage diseases. They are encountered in Pompe disease,8, 23, 26, 27 Gaucher 
disease,36 Fabry disease,37-39 and Mucopolysaccharidosis type I, II and VI.34, 40-43 The pro-
portion of patients that develop antibodies varies from 2% to 100%, with the lowest 
proportions seen in Gaucher disease. 
The biggest concern is that antibodies counteract the efficacy of ERT, but no adverse 
effects of antibody formation on therapeutic efficacy were found in Gaucher disease36 
nor in Mucopolysaccharidosis type I, II and VI.34, 40-43 In Fabry disease, however, the low-
ering of globotriaosylceramide (GL-3) clearance stalled in some seropositive patients, 
although this had no adverse effect on treatment outcome.39  
In this study, we found that 71 out of 73 patients with Pompe disease developed 
antibodies, which is similar to the findings of LOTS where all 59 treated patients sero-
converted.23 We found that patients with high titers showed inhibition of the algluco-
sidase alfa activity although to different extents. No significant effects on uptake of 
alglucosidase alfa were found. This suggests that inhibition of activity was the primary 
effect of the antibodies rather than inhibition of cellular uptake. In LOTS none of the 59 
treated patients tested positive for inhibition of enzyme activity.23 Two of these patients 
were also tested in the present study. For one of these patients, who had a high titer, 
we did found strong inhibition of enzymatic activity in both the medium and the cells. 
This discrepancy may be explained by the use of different assays. For example, the ratio 
alglucosidase alfa/serum and the time of incubation may play a role. The experiment 
performed here shows that similar titers can have different effects on in vitro enzyme 
inhibition, highlighting that our assay can detect antibody specificity and quantitative 
differences.
Although the in vitro studies demonstrated significant inhibition of GAA enzymatic 
activity, no clear adverse effect on clinical outcome in the high titer group (≥1:31,250) 
was observed. As mentioned before, the exception was the patient who developed the 
highest antibody titer.29 Patel et al. also reported three patients who developed high sus-
tained antibodies (range 1:102,400 to 1:819,200) coinciding with a poor clinical response 
to ERT.30  It could be that these individual patients produce high levels of antibodies 
with specific binding affinities for the catalytic site and mannose-6-phosphate moieties 
resulting in impaired therapeutic efficacy of alglucosidase alfa.44 
Our group recently published on the relation between high sustained antibodies 
and clinical outcome in classic-infantile Pompe disease. In this study it was concluded 
that ELISA titers of 1:6250 and lower probably have no clinical significant effect on 
clinical outcome, whereas titer of 1:31,250 and higher may counteract the efficacy of 
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alglucosidase alfa in a dose of 20 mg/kg every other week.28 The results of our study and 
LOTS indicate that antibodies seldom impede the effects of ERT in adults with Pompe 
disease,23 and when they do, the critical threshold of the ELISA titers seems to lay higher 
than the observed threshold in classic-infantile Pompe disease.26, 28, 30 For the reason that 
antibody formation has little impact on clinical outcome in adults with Pompe disease, 
there must be other factors that determine the observed variance in clinical outcome. 
Another concern of anti-rhGAA antibody formation is that it may alter drug safety. 
Indeed, we found that patients with higher antibody titers were more likely to develop 
IARs. For the majority of patients, first onset of IARs was within the first year of treat-
ment. Fortunately, most IARs were tolerated fairly well and through slowing down the 
rate of infusion in combination with the use of pre-medication, these diminished over 
time with continued administration of alglucosidase alfa. 
The LOTS study could not establish a consistent relation between the formation of 
antibodies and the occurrence of IARs. This difference in findings could be explained 
by the fact that LOTS reported all IARs and that in our study symptoms or signs being 
clinically judged to be related to the IARs were defined as IARs. Moreover, it could be 
explained by differences in study population (12 patients receiving ERT participated in 
both studies) and in follow-up duration. This may also explain the differences in preva-
lence of IARs, 18% in our study cohort versus 28% in the LOTS treatment group and 23% 
in the LOTS placebo group).23 A remarkable finding was that all but one of the patients 
who developed IARs were female. This was independent of age or pre/postmenopausal 
status. Interestingly, it has been found that females tend to respond better to ERT as 
compared to males,19, 23 but it is unlikely that this is related to antibody formation, as no 
gender differences were observed for either the level of the maximal antibody titer or 
presence of inhibitory antibodies in the study performed here. 
The current clinical practice in the Netherlands is to receive in-hospital infusions 
during the first year of ERT and thereafter transfer to a home treatment environment. 
Earlier implementation of home treatment would be preferable, as this has a positive 
effect on quality of life and reduces health care costs.45 The finding that patients with 
no or a low titer have a very low risk for IARs may lead to shortening of the period of 
in-hospital infusions for these patients. 
Unexpectedly, we found a trend that less severely affected  patients at start of ERT 
seem to develop higher antibody titers against ERT, as compared to patients who are 
more severely affected. Second, we found that a faster pre-treatment decline of pul-
monary function in supine position was associated with the development of high anti-
rhGAA antibody titers. An  explanation for the latter may lie in the fact that they had a 
higher forced vital capacity to begin with, and therefore had more to lose as compared 
to the group of patients with no-low antibody titers who had overall more advanced 
134   |    Chapter 3.3
Chapter
 3.3
disease. The reason that disease status before start of ERT seems to be correlated with 
susceptibility to antibody formation to alglucosidase alfa might be that a milder disease 
state would allow a better and more reactive immune system. Although the immune 
system is known to function during the initial stages of muscle regeneration through 
the action of macrophages,46 it is unknown if and how this translates to the propensity 
of antibody formation.
To conclude, antibody formation does not substantially attenuate the clinical response 
in adults with Pompe disease at group-level. But in patients who develop exceptional 
high antibody titers, treatment efficacy may be adversely affected. A new finding of this 
study was that the higher the antibody titer, the higher the risk for IARs. Therefore, close 
monitoring of IARs is indicated in patients with substantial antibody titers.
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abstract
Background Enzyme replacement therapy (ERT) with alglucosidase alfa was registered as 
a treatment for Pompe disease in 2006. It is as yet unknown whether ERT can be safely 
applied during pregnancy and lactation. 
Case A primiparous 40-year-old woman diagnosed with Pompe disease continued receiv-
ing ERT during pregnancy and lactation. Before pregnancy, she had moderate limb-girdle 
weakness and used nocturnal ventilation. During pregnancy, her clinical condition re-
mained fairly stable until the 25th gestational week. Thereafter she experienced more 
problems with mobility and respiration. Fetal growth was normal as monitored by regular 
ultrasound investigations. A healthy boy was born at a gestational age of 37 weeks and 
5 days by elective Cesarean section. There were no maternal complications and the child 
developed normally. One year after delivery the mother’s physical condition was similar 
as prior to her pregnancy. Pharmacokinetic studies following enzyme infusion showed 
that alglucosidase alfa was secreted into the breast milk. Activity levels in the milk (245 
nmol/ml.h) peaked at 2.5 hours after the end of the infusion; which was 2 hours later 
than in the plasma (80 μmol/ml.h). Twenty-four hours after start of the infusion, the 
enzyme activity in the breast milk was back to the pre-infusion level.
Conclusions In this case report, the continuation of treatment with alglucosidase alfa 
during pregnancy and lactation has been safe for the mother and the child.
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introDuction
Pompe disease (OMIM 232300) is an autosomal recessive glycogen storage disorder 
caused by acid α-glucosidase deficiency due to mutations in the GAA gene. The clinical 
spectrum ranges from a very severe and rapidly progressive form in infancy to a more 
slowly progressive form later in life. Adults endure limb-girdle muscular weakness and 
respiratory insufficiency.1
In 2006 alglucosidase alfa (Myozyme®) was approved for enzyme replacement therapy 
(ERT) in Pompe disease but so far, no studies have been published about the continuation 
of ERT during pregnancy and lactation. In other lysosomal storage diseases the experi-
ence with continuation of ERT during pregnancy, in much lower dosages compared to 
Pompe disease, did not suggest major problems, and the product information of alglu-
cosidase alfa mentions normal fetal development in mice and rabbits.2-6 Based on this 
information we reasoned that continuation of ERT during pregnancy was not likely to 
pose a substantial risk to the mother or the fetus. 
Here, we report about a 40-year-old woman, who continued to receive ERT during 
pregnancy under close monitoring. Additionally, we investigated the potential transfer 
of alglucosidase alfa into the breast milk.
case 
case history 
A primiparous 40-year-old woman was diagnosed with Pompe disease at the age of 22 
on the basis of acid α-glucosidase deficiency caused by mutations in the GAA gene (c.-32-
13T>G/c.1799G>A). Over the years, her limb-girdle weakness gradually progressed and 
she became dependent on nightly mechanical ventilation at the age of 36. 
Before conception, her partner was tested for mutations in the GAA gene. None were 
found. Just before pregnancy, she had a waddling gait, had to use the banister when 
climbing stairs and had difficulties lifting objects. Her forced vital capacity (FVC) in up-
right position was 44% and in supine position 31% of the predicted normal value. When 
she became pregnant, she had been receiving ERT for 17 months. She participated in a 
prospective observational study on the effects of ERT in Pompe disease, for which she 
provided written informed consent. 
Pregnancy and Delivery 
During pregnancy she was treated with 20 mg/kg alglucosidase alfa every other week. 
Her clinical condition remained fairly stable during the first two trimesters (Figure 1). 
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From the 25th gestational week onwards she experienced more mobility and respiratory 
problems. Nearing the end of her pregnancy, the FVC in upright position decreased to 
42% and the FVC in supine position to 25% (Figure 1). Normoventilation was maintained 
by increasing the ventilatory frequency and pressure during night-time ventilation. The 
fetal growth appeared normal as monitored by regular ultrasound investigations.
Due to the increasing dyspnea, an elective Cesarean section was performed at a 
gestational age of 37 weeks and 5 days. Combined spinal-epidural anesthesia was ap-
plied,7 while the patient used her own non-invasive ventilation. There were no maternal 
complications. A small strip of myometrium was dissected, which showed lysosomal 
glycogen storage in the smooth muscle cells and in the tunica media of blood vessels. 
There was no gross tissue damage (Figure 2). 
A healthy boy was born (Apgar scores of 8, 9 and 10) with normal birth weight, length 
and head circumference, and no congenital anomalies. The pH of the cord blood was 
7.29. Regular physical examinations of the child up to 1 year of age revealed a normal 
development. 
In the early postpartum period the mother suffered from overstrain, which was re-
flected in a temporarily decrease in muscle strength. Her dyspnea diminished fairly soon 
Figure 1 Muscle strength and pulmonary function before and after start of enzyme replacement therapy, 
including the pregnancy period 
Muscle strength was measured with manual muscle testing (□) (the MRC sum score of 26 muscle groups 
is expressed as percentage of normal muscle strength). The muscle strength was also measured with 
hand-held dynamometry (■) (the sum score of 16 muscle groups is expressed as percentage of the 
median strength for healthy women). Pulmonary function; the forced vital capacity (FVC) is expressed as 
percentage of the predicted value in upright (Δ) and supine (▲) position.
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after the delivery, and one year postpartum her pulmonary function was even slightly 
better than before the pregnancy. 
lactation 
Before, during and after the first postpartum infusion, the activity of acid α-glucosidase 
was measured in the plasma (500 fold diluted) and in the breast milk (undiluted) 
(Figure 3A).8 Before infusion, the activity in the milk was 3 nmol/hr.ml, which is approxi-
mately 10% of what we measured in the milk of an unaffected mother. During infusion 
the activities in the milk and the plasma increased. The highest activity in the milk (245 
nmol/hr.ml) was reached at 2.5 hours post-infusion, 2 hours later than in the plasma (80 
μmol/hr.ml), and was only 0.3% of the peak plasma value.
The presence of endogenous acid α-glucosidase in the milk of an unaffected mother 
could be demonstrated by SDS-PAGE immunoblot analysis, but the same method de-
tected hardly any enzyme in the pre-infusion milk of the patient (Figure 3B). The milk 
collected after enzyme infusion contained a substantial amount of alglucosidase alfa as 
demonstrated by the strong fluorescent signal.
since the prescribed dose of alglucosidase alfa is up to 20 fold higher
than the dose of any other recombinant human enzyme administered
to patients with lysosomal storage disorders. The mother is likely to
benefit from continued treatment, but the fetus might be exposed
to alglucosidase alfa or any of its constituents that might cross he
placental barrier. From animal studies, it is known that cross-
placental transfer of alglucosidas alfa hardly oc urs, but IgG can
cross the placental barrier [2]. Therefore we measured the occurrence
of anti-alglucosidase alfa antibodies in the serum of the mother and
the child shortly after birth. We did not measure any substantial im-
mune response as compared to the high antibody titers that may
occur in patients receiving ERT [8,9]. Evidently, one of the best proofs
of safe practice is the uneventful course of the pregnancy and the nor-
mal development of the fetus through all gestational stages.
As opposed to potentially negative effects that continuation of ERT
during pregnancymight have on the fetus, it might have positive effects
on the mother regarding muscle strength and pulmonary function [9].
The latter is excessively compromised during pregnancy due to the
expanding uterus. The pulmonary function of our patient decreased
slightly during pregnancy, but there was fortunately no need for inva-
sive ventilation. Continuation of ERT during pregnancymight also coun-
teract the lysosomal glycogen storage in the myometrium that could
affect the uterine strength and contractility needed for natural child-
birth. To mini ize the risk for mother and child an elective Cesare n
section was performed using combined spinal-epidural anaesthesia [7].
We found low l vels of alglucosidase alfa i brea tmilk at the timeof
infusion. Interestingly, the activity in the milk peaked 2 h later than in
the plasma, which roughly indic tes how long it takes for alglucosidase
alfa to cross the endothelial barrier, diffuse through the interstitium and
pass the epithelial lining of themammary gland.Within 24 h after infu-
sion, the activity in themilkwas back to the pre-infusion level. Our find-
ings parallel the recently reported secretion of imiglucerase in the
breast milk of a woman receiving ERT for Gaucher disease [10].
There seems little rationale to entirely refrain from breastfeeding
while mothers are on ERT, but to be on the safe side we have advised
to discontinue breastfeeding from the start of infusion until 24 h later.
We conclude that the continuation of enzyme replacement thera-
py during pregnancy and lactation has been safe for the mother and
the child described in this case report. But, we underline that our ex-
perience is limited to this single case and that careful monitoring of
each pregnancy is required.
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Figure 2 A) P iodic acid Schiff (PAS) staining of a sect on f the my metrium demo strates glycogen 
accumulation in smooth muscle cells; B) A section of the myometrium stained for acid phosphatase (red 
color) demonstrates lysosomal pathology; C and D) Electron microscopic images demonstrate lysosomal 
glycogen accumulation in a smooth muscle cell of the myometrium. The area indicated with an arrow in C 
is magnifi d i  D showing a single lysosome filled with glycogen particles.
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anti-alglucosidase alfa antibody titers
At day 3 and day 77 after delivery, the mother and child tested negative for anti-algluco-
sidase alfa antibodies using the immuno-precipitation method as previously described.8 
The antibody titer was also determined by using an Enzyme-Linked ImmunoSorbent 
Assay (ELISA). To this end, F96-Maxisorp Nunc-Immuno plates were coated with a 50 μl 
solutions of 5 μg/ml alglucosidase alfa in phosphate buffered saline (PBS). After blocking 
Figure 3 A) Pharmacokinetic analysis of alglucosidase alfa activity in plasma and breast milk during and 
after infusion. The administration of alglucosidase alfa was stepwise increased according to the regular 
infusion schedule.(7) Blood samples (◆) and milk samples (●) were collected just prior to the start of the 
infusion (0 h) and at regular time intervals thereafter as indicated in the figure. The acid α-glucosidase 
activity in the plasma is expressed in mmole/ml.h and in breast milk in νmol/ml.h. B) SDS-PAGE 
immunoblot analysis to demonstrate the presence of endogenous acid α-glucosidase and alglucosidase 
alfa in breast milk. Alglucosidase alfa has the same molecular mass (110 kD) as the endogenously 
produced precursor form of acid α-glucosidase (arrow head). M = molecular marker; C = milk sample from 
an unaffected mother; P- = pre-infusion milk sample from the affected mother; P+ = post-infusion milk 
sample from the affected mother; My = alglucosidase alfa (Myozyme®). 
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with a 250 μl solution of 1% bovine serum albumin in PBS, the serum of the mother and 
the child were added to the wells in two-fold serial dilutions (50 fold up to 3200 fold), and 
the plates were incubated for 1 hr at room temperature. The plates were then washed 
6 times with PBS containing 0.05% Tween-20, and subsequently incubated for 1 hr with 
50 μl of an HRP-conjugate (Acris Antibodies Shop, R1343-HRP). After a second wash, the 
colour (450 nm) was developed by the addition of 100 μl 3,3’,5,5’ – tetramethylbenzidine 
(TMB) for 10 min, and 100 μl of 1M ortho-phosphoric acid to stop the reaction. Sera 
from unaffected individuals were used as negative controls and a mouse serum that 
was raised against alglucosidase alfa was used as a positive control. Readings above two 
times the negative control were taken as titer. 
At day 3 post-partum, this method revealed very low titers of 1:800 in the mother and 
1:400 in the baby.
Discussion
This case report indicates that alglucosidase alfa can be safely administered during 
pregnancy in Pompe disease; the condition of the affected mother remained fairly stable 
and both the prenatal as well as the postnatal development of her child were uneventful.
Continuation of ERT during pregnancy has become common practice in Gaucher disease 
and in Fabry disease.2-6 Nevertheless, we were cautious with our decision to continue ERT 
in Pompe disease since the prescribed dose of alglucosidase alfa is up to 20 fold higher 
than the dose of any other recombinant human enzyme administered to patients with 
lysosomal storage disorders. The mother is likely to benefit from continued treatment, 
but the fetus might be exposed to alglucosidase alfa or any of its constituents that might 
cross the placental barrier. From animal studies, it is known that cross-placental transfer 
of alglucosidase alfa hardly occurs, but IgG can cross the placental barrier.2 Therefore 
we measured the occurrence of anti-alglucosidase alfa antibodies in the serum of the 
mother and the child shortly after birth. We did not measure any substantial immune 
response as compared to the high antibody titers that may occur in patients receiving 
ERT.8,9 Evidently, one of the best proofs of safe practice is the uneventful course of the 
pregnancy and the normal development of the fetus through all gestational stages.
As opposed to potentially negative effects that continuation of ERT during pregnancy 
might have on the fetus, it might have positive effects on the mother regarding muscle 
strength and pulmonary function.9 The latter is excessively compromised during preg-
nancy due to the expanding uterus. The pulmonary function of our patient decreased 
slightly during pregnancy, but there was fortunately no need for invasive ventilation. 
Continuation of ERT during pregnancy might also counteract the lysosomal glycogen 
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storage in the myometrium that could affect the uterine strength and contractility 
needed for natural childbirth. To minimize the risk for mother and child an elective Ce-
sarean section was performed using combined spinal-epidural anaesthesia.7
We found low levels of alglucosidase alfa in breast milk at the time of infusion. Inter-
estingly, the activity in the milk peaked 2 hours later than in the plasma, which roughly 
indicates how long it takes for alglucosidase alfa to cross the endothelial barrier, diffuse 
through the interstitium and pass the epithelial lining of the mammary gland. Within 
24 hours after infusion, the activity in the milk was back to the pre-infusion level. Our 
findings parallel the recently reported secretion of imiglucerase in the breast milk of a 
woman receiving ERT for Gaucher disease.10
There seems little rationale to entirely refrain from breastfeeding while mothers are 
on ERT, but to be on the safe side we have advised to discontinue breastfeeding from the 
start of infusion until 24 hours later. 
We conclude that the continuation of enzyme replacement therapy during pregnancy 
and lactation has been safe for the mother and the child described in this case report. 
But, we underline that our experience is limited to this single case and that careful 
monitoring of each pregnancy is required. 
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abstract
Fatigue accounts for an important part of the burden experienced by patients with 
neuromuscular disorders. Substantial high prevalence rates of fatigue are reported in 
a wide range of neuromuscular disorders, such as Guillain–Barré syndrome and Pompe 
disease. Fatigue can be subdivided into experienced fatigue and physiological fatigue. 
Physiological fatigue in turn can be of central or peripheral origin. Peripheral fatigue is 
an important contributor to fatigue in neuromuscular disorders, but in reaction to neu-
romuscular disease fatigue of central origin can be an important protective mechanism 
to restrict further damage. In most cases, severity of fatigue seems to be related with 
disease severity, possibly with the exception of fatigue occurring in a monophasic disor-
der like Guillain–Barré syndrome. Treatment of fatigue in neuromuscular disease starts 
with symptomatic treatment of the underlying disease. When symptoms of fatigue 
persist, non-pharmacological interventions, such as exercise and cognitive behavioral 
therapy, can be initiated.
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introDuction
Everybody experiences periods of fatigue, but these usually can be mended by taking 
a rest or enjoying a good night’s sleep. In a wide range of diseases, however, fatigue 
is a well-known chronic symptom. In patients without demonstrable somatic disease 
chronic fatigue may occur and may lead to the diagnosis of chronic fatigue syndrome.31 
Severe fatigue as a chronic symptom and its impact on daily living are starting to receive 
more and more attention as patient-reported outcome measures in clinical trials in 
patients with somatic disease. Several studies have demonstrated that fatigue is a dis-
abling symptom in chronic diseases such as cancer, but also in a variety of neurological 
disorders and conditions (Table I).14 Severe fatigue can also occur as a side effect of drugs 
like beta-blockers, proton-pump inhibitors, anxiolytic drugs and antipsychotics.2
The first studies on fatigue in neurological diseases focused on diseases of the central 
nervous system (CNS), such as cerebrovascular disease, multiple sclerosis and Parkin-
son’s disease.29, 30, 44, 54, 88, 106 Nowadays, it is recognized that fatigue is also an important 
and frequently occurring symptom in disorders of the peripheral nervous system (PNS) 
with a high impact on physical abilities and perceived health status in these patients.104
This review focuses on fatigue in neuromuscular disorders, with emphasis on fatigue 
in Guillain–Barré syndrome (GBS), an immune-mediated polyradiculoneuropathy, and 
Pompe disease, a metabolic muscle disorder. Various aspects of fatigue will be discussed, 
including differences between experienced and physiological fatigue and different meth-
ods available for assessment of fatigue. GBS and Pompe disease are taken as examples to 
discuss possible pathological mechanisms of fatigue, treatment strategies and options 
for future research.
Different tyPes of fatigue anD their Definitions
Fatigue covers a broad spectrum of symptoms and complaints, and has no uniform defi-
nition. In clinical research, commonly used definitions of fatigue are an overwhelming 
and persistent feeling of tiredness and diminished ability to sustain voluntary mental 
and physical activities. In addition, weakness, lethargy and lack of energy that interfere 
with daily activities are used as definitions.9, 13, 22, 23, 29, 51, 53, 57, 107 In basic neurosciences, it is 
defined as a time-related force decline.32,102  Considering the different aspects of fatigue it 
is best regarded as a multidimensional concept in which the level of experienced fatigue 
and the ability to perform activities are influenced by the type of disease, the health 
status of the patient and several aspects of patient functioning. A distinction is made 
between experienced fatigue and physiological fatigue, which can both be influenced 
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by psycho-sociological factors.101 The multidimensional concept of fatigue is depicted 
in Figure 1. In this figure fatigue is integrated in the World Health Organization’s Inter-
national Classification of Functioning, Disability and Health (WHO-ICF). The WHO-ICF 
represents the effect of disease on body function and structure and the level of activities 
and participation of the patient.1
Physiology of fatigue
With electrophysiological testing, fatigue can be measured as a loss of voluntary force-
producing capacity of the muscles during exercise.8,72 To understand this reduced capac-
ity of the muscle it is important to know how fatigue arises. The central governor model 
clarifies in a logical way how fatigue arises during mental or physical effort and how 
fatigue is essential for protecting the body against damage due to excessive exercise.69 
During performed effort the CNS is continuously informed about the level of perceived 
Table I Neurological disease or condition associated with fatigue
Cerebral commotion
Cerebral vasculitis and cerebrovascular diseases
Channelopathies
Charcot-Marie-Tooth disease type 1 (CMT type 1)
Chronic inflammatory demyelinating polyneuropathy (CIDP)
Developmental disorders (cerebral palsy, Arnold-Chiari malformations)
Dysautonomic states
Encephalitis 
Facioscapulohumural dystrophy (FSHD)
Granulomatous disorders (neurosarcoidosis, Wegener’s granulomatosis)
Guillain-Barré syndrome (GBS)
Hypothalamic and pituitary diseases
Intracranial infections (meningitis and encephalitis)
Metabolic encephalopathy and mitochondrial diseases
Migraine
Motor neuron disease
Multiple sclerosis
Multiple system atrophy
Myotonic dystrophy
Narcolepsy and related sleep disorders
Paraneoplastic (limbic encephalitis, opsoclonus-myoclonus)
Parkinson’s disease and other parkinsonian disorders
Pompe disease and other metabolic myopathies
Post-infection fatigue states (poliomyelitis, Lyme disease, Q-fever, and viral infections)
Postoperative (posterior fossa) surgery 
Table adapted from Chaudhuri et al., The Lancet, 2004.14
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exertion by feedback from muscles, joints, body temperature, the cardiorespiratory 
system and cognitive domains (afferent pathways). This feedback is processed at the 
primary somatic sensory cortex, subsequently sensory motor integration takes place and 
the activation by the primary motor cortex of the brainstem motor nuclei and anterior 
horn cells in the spinal cord (efferent pathway) is adjusted if needed to maintain body 
homeostasis. This continuous feed forward and feedback control mechanisms regulate 
the work rate and determines when rest is needed.14,69
With this model it is not fully explained how severe fatigue can be present in chronic 
disease or how fatigue can be present in a resting situation. In patients with severe fa-
tigue the sense of normal fatigue is amplified due to pathological changes in the motor 
system, disruption of feedback to the primary somatic sensory cortex and/or change in 
Figure 1 Fatigue as a multidimensional concept implemented in the World Health Organization’s 
Classification of Functioning, Disability, and Health
The multidimensional concept of fatigue is integrated in the World Health Organization’s International 
Classification of Functioning, Disability and Health (WHO-ICF), representing the effect of disease on 
body function and structure, activity and participation of the patient.1 Both experienced fatigue and 
physiological fatigue have an effect on activity and participation and are in most diseases related to 
health status and disease severity. Psychosocial factors have an influence on fatigue and on activity and 
participation. The numbers indicate at which level the different treatment strategies have an effect on 
fatigue: I treatment of underlying disease; II rehabilitation and exercise; III pharmacotherapeutics; IV 
cognitive behavior therapy.
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patients’ motivation.14,69 In a resting situation an estimation is made whether the body 
can cope with an increase in effort. Up-regulation of metabolism occurs during exercise; 
however, in case of disease, the capacity to increase the metabolic rate is limited. This 
is perceived at the level of the CNS as fatigue and the patient will avoid excessive effort 
and requires rest.
In systemic diseases loss of voluntary force-producing capacity is caused by multi-
systemic consequences of the underlying disease. In neurological disease a distinction 
can be made between fatigue caused by disease at the level of the CNS (central fatigue) 
versus fatigue caused by disease at the level of the PNS (peripheral fatigue). Neurological 
diseases can be located at various levels of the nervous system, such as the motor cortex, 
the spinal cord, the peripheral nerve, the neuromuscular junction or the muscle itself.107 
Most of these structures are either important feedback pathways for the perceived ef-
fort or important in voluntary force-producing capacity of the muscle. Presumably for 
that reason, severe fatigue is commonly seen in a variety of neurological diseases.
Central fatigue
Central fatigue is the term generally used when symptoms result from either psychiatric 
disease or pathology in the CNS. This can result in either difficulty with sustaining physi-
cal activities and/or impaired cognitive functioning. For example, patients with struc-
tural lesions in brain areas important for cognitive processing will have limited ability 
to sustain concentration and endure mental tasks (mental fatigue).5, 11, 13, 14 Psychiatric 
diseases may disturb neuronal processing in the CNS, for example, in depression there 
is reduced internal input from the CNS, which results in loss of interest and motivation 
and an exaggerated sense of fatigue.14 Loss of voluntary force-producing capacity of the 
muscles during exercise due to central mechanisms seems to result from suboptimal in-
put from the CNS. This is observed in patients with diseases disrupting the motor cortex 
or the motor pathways of the CNS such as multiple sclerosis.84 Endocrine disturbances 
as seen in hypothalamic-pituitary diseases may give rise to profound chronic fatigue.14 
Temporal hypothalamic-pituitary dysregulation is also responsible for fatigue as seen in 
the over-trained athlete syndrome.3
Peripheral fatigue
Peripheral fatigue, which is similar to muscle fatigability, is likely to occur in a patient 
showing a topographic pattern of muscle weakness or sensory disturbances at neuro-
logical examination based on dysfunction of the lower motor unit or sensory nerves. 
Patients with metabolic myopathies (e.g., Pompe disease), with disorders at the level of 
neuromuscular transmission (e.g., myasthenia gravis), with disorders affecting the pe-
ripheral nerves (e.g., GBS and Charcot Marie Tooth type 1 (CMT type 1)) and the anterior 
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horn cells (e.g., motor neuron disease) can all suffer from peripheral muscle fatigability, 
which is characterized by failure to sustain the force of muscle contraction over time. 
In patients with myopathies, muscle fatigability is enhanced due to structural changes 
or altered muscle metabolism in the muscle, which hampers muscle contraction. When 
motor conduction is impaired, this leads to decreased recruitment of motor units, result-
ing in an earlier occurrence of muscle fatigability.14 Myasthenia gravis is characterized by 
rapid progressive reduction of muscle strength with repeated muscle contraction with 
(partial) recovery after a period of rest. This phenomenon of inability to sustain physical 
activities is caused by anti-acetylcholine (Ach) receptor antibodies and a reduction in the 
number of Ach receptors of the neuromuscular junction.19
Fatigue of central origin in neuromuscular disease
Interesting is the finding that patients with PNS disease also suffer from a generalized 
form of fatigue, which originates at the level of the CNS. This should not be confused 
with muscle weakness or (exercise induced) muscle fatigability. Previously, it was 
thought that generalized fatigue was caused by skeletal muscle hypoxia or anaerobiosis; 
however, these metabolic changes should lead to muscle rigor.69, 73 Furthermore, one 
would expect that the primary motor cortex tries to compensate for the decrease of 
generated force by recruiting the maximum number of motor units; however, this is not 
seen during maximal exercise.87 For example, in muscle disease, if muscle metabolism is 
beforehand affected, this will result in a continuous afferent feedback to the CNS. The 
CNS will minimize activities to protect further damage to the muscles (central governor 
model). In case of muscle weakness an increase in applied effort is needed to perform 
the same activities as a healthy person. This will lead to a higher perceived exertion at 
the level of the primary somatic sensory cortex and an earlier occurrence of fatigue.14, 69 
In neuro-inflammatory diseases, e.g., post-poliomyelitis syndrome or chronic inflamma-
tory demyelinating polyneuropathy (CIDP), fatigue may arise from dysregulation of the 
neuro-endocrine system. The local inflammatory process in the muscle or nerves may 
trigger a systemic inflammatory response, which causes neuro-endocrine dysregulation.
Experienced fatigue
Experienced fatigue is the patient’s perception of his or her level of fatigue in daily life, 
which is alike to feeling or sense of fatigue.14, 107 This reflects to what extent individual 
patients notice the increase in effort needed to complete daily activities and their limita-
tions in endurance during sustained physical and mental activities.107 It is a subjective 
form of fatigue. The way how fatigue is experienced is influenced by psycho-sociological 
factors of the patient, such as attributions towards fatigue, coping mechanisms, overall 
well-being and social circumstances (Figure 1).101 For example, patients who are stress-
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sensitive or encounter a stressful event in life are often in a fight or flight state, char-
acterized by activation of the sympathetic nervous system and initiation of the acute 
stress response via the hypothalamic–pituitary–adrenal axis. These prolonged stress 
responses may result in exhaustion and feelings of fatigue. Certain individual patient 
characteristics, such as emotional state and lack of motivation, may cause a dissociation 
between the level of internal input (motivational and limbic) and that of the perceived 
signal of performed effort.14 This dissociation is responsible for an increased perception 
of fatigue. Experienced fatigue and physiological fatigue can be related to each other, 
but do not necessarily co-occur within individuals. In CMT type 1, facioscapulohumeral 
dystrophy (FSHD) and myotonic dystrophy, central fatigue (not peripheral fatigue) corre-
lates with experienced fatigue; however, in GBS no correlation has been found between 
either peripheral or central fatigue.35, 81
how to assess fatigue
The broad range of mechanisms underlying fatigue, its multi-dimensional character, 
confounding factors and different manifestations of fatigue put high demands on the 
way fatigue is measured. It is often difficult to assess the difference in severity of fatigue 
among individuals. Nevertheless, quantification of fatigue and its impact on the pa-
tient’s life are important for good insight in the overall condition of the patient and may 
be helpful in deciding which supportive measures should be taken to alleviate fatigue.72
Several methods have been developed to assess the level of fatigue. These measure-
ments can be divided into two categories. The first one, generally based on patient-
reported outcome measures, focuses on experienced fatigue. The second category is 
based on objective tests and outcomes, and focuses on physiological fatigue.22, 58 The 
different techniques quantifying the severity of each form of fatigue will be discussed in 
the next paragraphs.
Ways to measure experienced fatigue
Experienced fatigue needs to be quantified via patient-reported outcome measures 
(questionnaires). Most of these questionnaires are designed for use in daily practice, can 
be completed in a limited amount of time and provide the physician with an estimate 
of the severity of fatigue and its impact on the patients’ daily life. To measure treatment 
effects or fluctuations in severity of the underlying disease, a scale should be responsive 
to changes over time.22 A distinction is made between unidimensional and multidimen-
sional scales. A unidimensional scale approaches fatigue as a single construct, while 
multidimensional scales assess several aspects of fatigue, such as physical, cognitive and 
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psychosocial aspects. An elaborate review by Dittner et al.22  gives a systematic overview 
of 10 unidimensional and 20 multidimensional scales for the measurement of fatigue. It 
also provides guidance on choosing the appropriate scale for a particular patient popula-
tion.
An example of a unidimensional fatigue scale frequently used in neuromuscular 
disorders is the Fatigue Severity Scale (FSS). This test is easy to use in clinical practice, 
as the nine items of the test can be answered within less than 5 min. The FSS measures 
fatigue by assessing the consequences of fatigue on daily functioning. The scores of the 
scale can range from 1 (no fatigue) to 7 (extremely fatigued). An average score of 4 and 
higher is indicative for fatigue, and a score of 5 and higher for severe fatigue.27, 40, 45, 56, 
64 The FSS demonstrated good internal consistency (Cronbach’s alpha coefficient=0.88), 
test–retest reliability (Cohen’s kappa value=0.84) and discriminative validity in studies 
among patients with immune-mediated polyneuropathies, multiple sclerosis and Pompe 
disease.22, 38, 40, 56
An example of a multidimensional fatigue scale is the Checklist Individual Strength 
(CIS). This is a 20-item questionnaire that evaluates fatigue severity in general (i.e., not 
related to specific daily activities), concentration, motivation and the level of physical ac-
tivity.81 The CIS was not specifically validated for patients with neuromuscular disorders, 
but has shown good psychometric properties in other populations (internal consistency; 
Cronbach’s alpha coefficient=0.90) and discriminative validity between multiple sclero-
sis and healthy controls).7, 89, 97 The CIS has been used to assess fatigue in patients with 
chronic fatigue syndrome, multiple sclerosis, FSHD, CMT type 1 and myotonic dystro-
phy.81, 83, 89, 97, 101
ways to measure physiological fatigue
There is limited experience with methods that have the potential to objectively 
quantify the level of physiological fatigue. The following methods can be used: electro-
physiological measurement of decline in muscle force after exercise (peripheral fatigue); 
electrophysiological measurement of central activation failure (central fatigue)107 and; 
neuropsychological assessment (central fatigue).14
The most direct method for measuring peripheral fatigue is measuring the generated 
force by electrical stimulation during rest and after muscle contraction and to look at the 
decline in generated force (Figure 2). The decline in force reflects the severity of fatigue. 
It also shows the change in muscle contractibility, such as a fatigue-induced delay of the 
muscle relaxation phase (Figure 2).18 During the contraction a decline over time of the 
maximal voluntary force can be observed (muscle fatigability). The actual force exerted 
is usually expressed as a percentage of the maximal force (e.g., 70% of the maximal 
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voluntary contraction). With a surface electromyogram a decline in fiber conduction 
velocity may be indicative for peripheral fatigue.107
When central fatigue is present, suboptimal input from the CNS to activate the 
muscle results in a decrease in maximal force generating capacity of the muscle. This 
is defined as central activation failure (CAF). When during maximal voluntary contrac-
tion the generated force increases with electrical stimulation, this is indicative for CAF 
(Figure 2). When CAF increases during exercise, this is supportive for the presence of 
central fatigue. CAF can be confirmed with a twitch-interpolation technique, magnetic 
and electrical stimulation of the motor cortex and readiness potential. For a commentary 
on these methods, the review by Zwarts et al. is recommended.107
A method to evaluate mental fatigue is through neuropsychological assessment. 
Via this assessment cognitive domains of memory, learning, attention and information 
processing are evaluated. Patients with mental fatigue perform worse on these tests, 
and their performance will decline during the assessment session.5, 11
Figure 2 Schematic representation of physiological fatigue 
The figure shows the decline over time of the maximal voluntary force (on the Y-axis). The ‘at-rest 
twitches’ are visible before and after the contraction, with the post-contraction twitch being clearly 
lower and slower, indicative of peripheral fatigue. The arrows indicate the moments of superimposed 
electrical endplate stimulation. The twitch interpolation has induced small increments in muscle force 
with examples of a negligible and a large central activation failure (CAF). A (near) absent response 
indicates a full voluntary activation of the muscle. This figure originates from Zwarts, et al., Clininical 
Neurophysiology 2008.107
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fatigue in neuromuscular DisorDers
Neuromuscular disorders include a wide range of disease entities causing abnormalities 
in muscle function and/or sensory function. These may be caused by dysfunction at the 
level of the muscle itself, the neuromuscular junction, the peripheral nerve or at the level 
of the anterior horn cell in the spinal cord or brain stem. Typical features of neuromus-
cular disorders comprise muscular atrophy, muscle weakness and sensory disturbances 
such as pain, tingling-feelings, hyperpathy or hypoesthesia.19
Fatigue has been an under-recognized aspect of neuromuscular disorders over a long 
period of time. As we have mentioned before, fatigue on one hand is caused by a local 
effect on muscle function (peripheral fatigue), and on the other hand fatigue originates 
at the level of the CNS because of feedback about the pathological state of the PNS. This 
fatigue protects the muscles from further damage by down-regulating physical activi-
ties. This is illustrated by the fact that fatigue of central origin was recorded in 36–41% 
of patients with a neuromuscular disorder (FSHD, CMT type 1 and myotonic dystrophy) 
vs. 12% in controls.82 These high percentages, however, were not found in a small study 
in GBS patients.35 In patients with FSHD, CMT type 1 and myotonic dystrophy, fatigue of 
central origin correlated positively with the level of experienced fatigue. In GBS patients, 
this correlation has not been found.35, 81 It should be noted that most individuals with 
severe fatigue, but without demonstrable muscle weakness and/or elevated serum 
creatine kinase (CK) levels do not have a neuromuscular disorder. Thus, fatigue as the 
only complaint excludes in most cases the presence of a neuromuscular disorder.59 An 
exception to this rule are mitochondrial myopathies or other metabolic disorders in 
which clear exercise intolerance can reported by patients where muscle weakness is not 
always present at the time of the neurological examination.14 Furthermore, fatigue can 
persist as a residual symptom after a neurological illness, of which GBS and CIDP are 
good examples.38, 64
Other disorders in which increased levels of fatigue have been reported are myas-
thenia gravis, post-poliomyelitis syndrome, immune-mediated neuropathies, FSHD, 
CMT type I, myotonic dystrophy and Pompe disease.38, 40, 43, 48, 53, 64, 71, 78, 81 The prevalence of 
fatigue in various neuromuscular disorders reported in the literature ranges from 38 to 
86% (Table II). The reported prevalence of fatigue in neuromuscular disorders compares 
with the prevalences of fatigue in multiple sclerosis (range from 53 to 92%),10 where 
fatigue is recognized as an important symptom.54 To be aware of the impact of fatigue in 
neuromuscular disease, it is valuable to compare its high prevalence with the low preva-
lence of severe fatigue in healthy individuals (range 5–18% and mean FSS 2.3–3.3).64, 78, 
92 The ranges seen in the mentioned prevalences are explained by differences in study 
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population, used, assessment method and used definition of severe fatigue (e.g., cutoff 
point).
In the following section of this review we will discuss two different neuromuscular 
disorders for which fatigue has been reported as a important feature. GBS will be taken 
as an example of immune-mediated polyneuropathies and; Pompe disease as an ex-
ample of metabolic myopathies.
fatigue after guillain–barré syndrome (gbs)
GBS is an acute post-infectious immune-mediated polyneuropathy, characterized by 
rapidly progressive, symmetrical limb weakness and areflexia. Sensory disturbances, 
autonomic dysfunction and respiratory insufficiency often occur during its disease 
course. The severity of neurological deficits differs among patients and usually reaches 
a plateau phase within 2 weeks, which is indicative of the start of the recovery phase. 
Final outcome varies greatly among patients and ranges from severe residual weakness 
to complete recovery.4, 99 CIDP may be considered a chronic variety of GBS.98
Patients experience fatigue already at the onset of GBS, and it can surprisingly persist 
for many years, even after total recovery of muscle weakness.38 Fatigue in GBS was spo-
radically reported in the literature until 1999, when a cross-sectional case control study 
showed that fatigue is an essential and incapacitating residual symptom in patients 
with immune-mediated polyneuropathies.64 Eighty percent of patients that recovered 
from GBS or CIDP or had ongoing CIDP suffered from severe fatigue. The patients stated 
that being severely fatigued leads to tremendous impairment in their daily life and social 
activities. As a consequence their quality of life was reported to be negatively affected in 
the long term. Some confounding factors could have affected the outcome of the study 
addressing fatigue in GBS. Sleep disorders, depression and level of physical activity were 
not systematically evaluated in the study. However, other studies confirmed the high 
prevalence of fatigue in GBS, being 38%,78 40%,28 and 86%.64 Part of the differences in 
estimated prevalence can probably be explained by differences in age between study 
Table II Prevalences of severe fatigue in neuromuscular disorders 
Neuromuscular disorder Prevalence of severe fatigue Fatigue scale
Guillain-Barré syndrome28, 38, 64, 78 38-86% FSS, FIS, VAS-F
Pompe disease40 67% FSS
Myasthenia gravis71 82% FIS, MFI
Post-poliomyelitis syndrome53 80% NA
Facioscapulohumural dystrophy48,81 51-61% CIS
Myotonic dystrophy48,81 53-74% CIS
Charcot-Marie-Tooth disease type 1 (CMT type 1)48,81 55-64% CIS
CIS=checklist individual strength; FIS=fatigue impact scale, FSS=fatigue severity scale; MFI=multidimensional 
fatigue inventory; VAS-F=visual analogue scale for fatigue; NA=not applicable.
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populations, as severe fatigue showed a positive correlation with age in GBS.38 Severe 
fatigue does not seem to be related to clinical variables, antecedent infections or the 
severity of the neurological dysfunction in the initial phase of GBS,38, 64 except that severe 
fatigue has a higher prevalence in female GBS patients (74% in females versus 45% in 
males, p=0.003). This difference in sex ratio is also seen in patients with chronic fatigue 
syndrome and can probably best be explained by endocrine differences between males 
and females.77 A conventional nerve conduction study failed to show a relation between 
experienced fatigue and the occurrence of physiological fatigue/residual nerve dysfunc-
tion.37 However, it could well be that newer or more advanced electrophysiological 
methods could be helpful to study this relationship. It has been added that CMAP scans 
potentially could be helpful to study this relationship.24
Another interesting finding was that severely fatigued GBS and CIDP patients showed 
a normal activity level, which was independent of their neurological condition. We pre-
sume that this neglect of patients’ impaired load capacity may even increase symptoms 
of fatigue, as the actual performance of the patient does not match the patient’s physi-
cal load capacity.12 GBS not only affects the peripheral nerves, but also has an impact on 
psychosocial status. This may lead to a disturbed interplay between the structural and/
or functional integrity of sensory, motor and cognitive symptoms, which may increase 
the sense of fatigue.
In general, the occurrence of fatigue in GBS seems independent of the severity of 
(residual) neurological deficits.37, 38, 64 This differs from findings in other neuromuscular 
disorders, where severely affected patients experience higher levels of fatigue.40, 49 The 
fact that GBS is an acute and monophasic disease may explain at least part of the differ-
ences found, as the other mentioned neuromuscular disorders are often chronic diseases 
and progressive in nature. In GBS and in CIDP it could well be that dysregulation of the 
hypothalamic–pituitary–adrenal axis accounts for residual fatigue, which could be linked 
to the antecedent infections seen in GBS and smoldering low-grade infections possibly 
going on in CIDP, because similar immune-mediated fatigue is seen as a residual symp-
tom after an infectious illness.46 Dysautonomia could also be an important contributor to 
fatigue14 and is frequently seen in patients with GBS. At the moment further prospective 
studies in GBS are being executed (as part of the Dutch ‘Graph study’) to investigate the 
relation between fatigue in relation to dysautonomia, preceding infections, severity of 
disease and the occurrence of pain (L. Ruts, personal communication). In conclusion, we 
could state that peripheral fatigue is a more important contributor in the initial phase 
of the GBS. However, because feelings of fatigue persist after resolution of neurological 
symptoms, other factors must be responsible for fatigue in the long run. Post-infectious 
fatigue, dysautonomia and psycho-sociological consequences of the disease may be 
these causative factors.
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fatigue in Pompe disease
Pompe disease (glycogen storage disease type II, acid maltase deficiency) is an autoso-
mal recessive disorder caused by deficiency of lysosomal acid α-glucosidase. As a result, 
glycogen accumulates in lysosomes of several body tissues.52 The disease presents as a 
spectrum of phenotypes. Patients with the classic infantile form are at the severe end 
of the spectrum. They suffer from a rapidly progressive disease course. Presentation is 
shortly after birth with hypotonia, feeding difficulties or respiratory problems. A hyper-
trophic cardiomyopathy is characteristically present. Patients usually die before the first 
year of life because of cardiorespiratory failure.94 On the other end of the spectrum are 
children and adults with Pompe disease in which skeletal muscles are primarily affected. 
In these patients the disease is slowly progressive. The proximal, paraspinal and respira-
tory muscles are most involved. Patients may eventually become wheelchair bound and 
dependent on (nocturnal) ventilation.42, 43
Fatigue is a frequently experienced symptom in adults with Pompe disease and may 
have a disabling impact on the lives of patients.40 Until recently, fatigue in Pompe disease 
did not receive much attention and was not structurally assessed. Incidentally fatigue 
had been reported in case reports and small patient populations of up to 16 subjects.20, 
62, 65, 85, 105 In a study on the natural course of Pompe disease in 54 patients, fatigue was 
rather unexpectedly reported to be the presenting symptom in 25% of the patients.43 
Seventy-six percent of the study population indicated that fatigue had an important im-
pact on their daily life. Subsequently, fatigue was studied by using the FSS in more detail 
in an international group of 225 patients.40 It was demonstrated that fatigue occurs in 
the majority (78%) of Pompe patients (FSS score ≥4) and severe fatigue (FSS score ≥5) in 
two-third of the patients.40 The mean FSS scores differed significantly from healthy con-
trols (mean FSS score of 5.2 versus 2.9, p<0.001). Patients who did not use a wheelchair 
and respiratory support were significantly less fatigued when compared with patients 
using either or both (p=0.01).40 It is of interest that Pompe patients reported only slightly 
lower levels of cognitive well-being in comparison with the general population.41 This 
indicates that depression probably does not contribute to the observed prevalence of 
experienced fatigue, in contrast to, for example, multiple sclerosis, for which depression 
was found to have a substantial influence on the severity of fatigue.74
In Pompe disease the accumulation of glycogen in muscle fibres leads to structural 
changes of the muscle, which impairs muscle contraction, and in a more advanced 
state even destructs muscle fibers. This results in muscle weakness, muscle atrophy and 
muscle fatigability (peripheral fatigue). When patients are performing physical activities, 
they experience burning sensations of the proximal muscles and a heavy-legged feel-
ing, which limits their force-producing capacity. In Pompe disease and other metabolic 
myopathies, such as McArdle’s disease, muscle metabolism is altered, and certain me-
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tabolites could impair skeletal muscle contraction through a direct action. This would be 
perceived as an increase in effort by the CNS, which then responds with down-regulating 
of activities to preserve homeostasis in the muscle.69
Respiratory dysfunction, due to diaphragmatic weakness and weakness of the respira-
tory muscles, is often present in Pompe patients and can also account for an increase 
in fatigue of central origin. Patients have to increase their respiratory effort to sustain 
adequate ventilation during exercise, or even already at rest. By feedback from the respi-
ratory system (hypercapnia and hypoxia), fatigue is perceived at the CNS, and adequate 
ventilation is restored by decreasing the performed physical effort.14, 69 Second, nocturnal 
hypoventilation leads to a decreased oxygenation of the brain and respiratory acidosis. 
Due to altered respiratory function the normal sleep pattern is disrupted;63 as a conse-
quence patients are not well rested, feel fatigued and suffer from day-time sleepiness 
during the day.
The pathophysiology of fatigue in Pompe disease still remains to be established, as 
this topic has not yet been investigated. Muscle fatigability of the proximal muscles 
plays an important role in Pompe patients, as they have difficulties in sustaining physical 
activities. Besides this localized form of fatigue, the occurrence of generalized fatigue is 
explained by the central governor model.14, 69 Respiratory dysfunction also contributes to 
the level of fatigue perceived at the CNS.
imPlications for treatment
Fatigue is a complex and multifaceted entity. In order to determine the treatment strat-
egy for an individual patient, it is important to define the type of fatigue and the under-
lying factors that contribute. First, the implications of fatigue for the patient need to be 
investigated. This can be done by assessing the level of fatigue and its impact on daily 
activities and general wellbeing. Second, potential behavioral and psycho-sociological 
factors need to be identified that contribute to the experienced level of fatigue. Currently 
one or more of the following optional treatment strategies for fatigue in neuromuscu-
lar disorders can be used: (1) (symptomatic) treatment of the underlying disease, (2) 
rehabilitation and exercise, (3) pharmacotherapeutics directed to treat fatigue and (4) 
cognitive therapy. Figure 1 shows how the different treatment strategies act on fatigue 
and the different domains of the WHO-ICF model.
Treatment of underlying disease and symptoms
When a patient complains of symptoms of fatigue, a diagnostic workup should be done 
to identify potential causes of fatigue. As mentioned, fatigue can be a symptom of vari-
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ous (neurological) diseases, but also other underlying diseases may cause fatigue.14 When 
the patient has already been diagnosed with a disorder that may explain fatigue, other 
causes like co-morbidity need to be ruled out. When possible, start or optimize treat-
ment of the underlying disease, and eliminate other causal factors that may contribute 
to fatigue. For example, treatment of myasthenia gravis patients with adequate dosages 
of pyridostigmine can improve the clinical well-being and reduce feelings of fatigue.39, 47 
In a pilot study of late-onset Pompe patients treated with enzyme replacement therapy, 
the patients experienced a reduction in fatigue over a period of 8 years of treatment.93 
The experienced increase in energy level made them more independent in daily life and 
improved their participation in social activities.
Furthermore, in patients with neuromuscular disorders it is of utmost importance 
to rule out sleep-disordered breathing as a cause of sleepiness and fatigue during the 
day.76 Nocturnal hypoventilation is frequently seen in neuromuscular patients with 
diaphragmatic weakness or in patients with obstructive apnoea or hypopnea. Besides 
hypoventilation, obstructive sleep apnea causes a disrupted sleep pattern, which results 
in a lowered quality of sleep.86 Symptoms explained by nocturnal hypoventilation often 
herald complete respiratory failure by months or even years. Diaphragmatic weakness 
is often seen in Pompe disease and is present when there is a significant decline in pul-
monary function when pulmonary function is measured in the sitting and the supine 
position.96 A decline of 25% or more is called postural drop. Sleep-disordered breathing 
can be measured with sleep studies. When mechanical ventilation is implemented in 
patients suffering from nocturnal hypoventilation or sleep disordered breathing, symp-
toms of fatigue can be tremendously reduced.76
rehabilitation and exercise
A well-fitted rehabilitation program can help patients to use their energy more efficiently. 
For example, implementation of ergo-therapeutic devices aimed at improving the ease 
of performing daily activities may increase the level of energy and thereby lessen symp-
toms of fatigue. Also training in developing coping strategies aimed at balancing mental 
and physical activities and rest may improve the patient’s well-being. The potential effect 
of exercise programs on the level of fatigue was investigated in several studies.12, 25, 34, 79 
In patients recovered from GBS and in patients with ongoing but well-treated CIDP who 
suffer from severe fatigue, implementation of tailor-made exercise programs resulted 
in a reduction of 20% of self-reported fatigue. This improvement had been maintained 
at 2-year follow-up.33, 34 These findings are consistent with results reported for healthy 
sedentary individuals (15%) and patients with multiple sclerosis (22%) after completion 
of an exercise program.75, 80 However, the decrease in experienced fatigue in GBS after 
exercise therapy could not be explained by an increase in physical fitness.12 Hypotheti-
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cally, it could be that training also has a beneficial effect on the neuro-endocrine system 
and levels of neurotransmitters, which may reduce perception of fatigue. Additionally, 
recognition of the patients’ complaints of fatigue and the beneficial effect of support 
from fellow patients within the training group are also potential factors that can reduce 
experienced fatigue.12, 34 Figure 3A,B visualizes the relationships among training, physical 
fitness, activity and psychosocial factors in a model. Figure 3A shows the relationships 
as was hypothesized before the start of the training study and Figure 3B the remodeling 
after analysis of the results of the study.12, 34
Although strong evidence for a beneficial effect of exercise on experienced fatigue in 
neuromuscular disorder presently is relatively scarce, a low-intensity training schedule 
is likely to have a positive effect on fatigue and the general condition of patients with a 
neuromuscular disorder. Regular activity prevents physical deconditioning and muscle 
wasting. This was also shown in a rat model for post-poliomyelitis where physical activ-
ity reduced the size of the chronically enlarged motor units in denervated muscles.91
Pharmacotherapeutics
The efficacy of pharmacotherapeutic drugs such as amantadine, modafinil, albuterol 
and aminopyridine has not yet been convincingly proven for the treatment of fatigue in 
Figure 3 Model of fatigue in immune-mediated polyneuropathies
A Represents the hypothetical model of the mechanisms between the different domains in relation 
to physical training. B Is the model resulting from the correlations between the change scores of the 
different domains as a result of the training intervention. Thickness of lines between domains represents 
the strength of the relationship. Figures adapted from Bussmann, et al., Journal of Rehabilitation Medicine 
2007.12
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patients with neuromuscular disorders. Amantadine was shown to be effective in one-
third to half of all treated multiple sclerosis patients.15, 55, 67 Amantadine, however, did 
not show a beneficial effect in a well-powered randomized controlled trial on residual 
fatigue in patients who were in a good clinical condition after recovery from GBS.36 In 
FSHD the effects of albuterol had no effect on experienced fatigue.95 Modafinil has shown 
some beneficial effect in myotonic dystrophy; however, these were studies with small 
populations and a relatively short follow-up.17, 61, 90, 103 Clinical trials studying the efficacy 
of pharmacotherapeutics as treatment for fatigue in other neuromuscular disorders are 
still lacking.
cognitive behavior therapy
Patients’ attitudes towards fatigue, coping mechanisms and psychosocial circumstances 
attribute to the level of experienced fatigue.101 Patients may experience stress, depression 
and anxiety caused by disease-related social consequences, such as loss of employment, 
failure to fulfill family responsibilities and limitations in their social life. If necessary, pa-
tients can be supported with occupational rehabilitation. Cognitive behavioral therapy 
and psychological support have been shown to have a positive effect on experienced 
fatigue in cancer patients.68 Whether the same results can be obtained in patients with 
neuromuscular disorders needs further investigation.
conclusion anD future lines of investigation
The impact of fatigue on the lives of patients suffering from neuromuscular disorders 
has remained long unnoticed and has only recently been recognized as an important 
subject to be addressed in both clinical practice and research.6, 14, 38, 40, 64, 104, 107 A high 
prevalence of fatigue was found in Pompe disease, GBS, post-poliomyelitis, hereditary 
polyneuropathy, myasthenia gravis and myotonic dystrophy.38, 40, 48, 53, 64, 70 The prevalence 
of severe fatigue in these disorders was estimated to be similar to that in patients with 
multiple sclerosis.50
Fatigue can be subdivided into experienced fatigue and physiological fatigue. The se-
verity of both experienced fatigue and physiological fatigue is influenced by psycho- so-
ciological factors. In most neuromuscular disorders, but not in GBS as far as we know now, 
it also depends on disease severity.38, 40, 49, 64, 100 The pathophysiologic mechanisms causing 
fatigue in neuromuscular disorders are not completely understood. Most likely there are 
two main pathways that lead to physiological fatigue: first, the pathology located in the 
PNS causes muscle fatigability by hampering muscle contraction, disturbance of muscle 
metabolism and inability to activate enough motor units (peripheral fatigue). Because 
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patients with neuromuscular diseases have to compensate for their loss of function by 
increasing their motor input to accomplish the same activities as a healthy person, the 
perceived level of effort at the CNS is higher, and patients become more easily fatigued. 
Additionally, the disease state of the muscles is continuously sensed at the level of the 
CNS, which will result in a constant feeling of fatigue of central origin, because body 
homeostasis needs to be maintained. Besides this flexible interactive feedback and feed 
forward system as described in the central governor model, other causes of central fa-
tigue are proposed in patients with neuromuscular disorders.81 Pathology of the PNS can 
eventually induce functional changes in the motor cortex, which may be a consequence 
of deconditioning and/or the relatively large demands put on the affected neuromus-
cular system.16, 21, 60 This indirectly results in central fatigue due to CAF. Second, there is 
some evidence that pathology in neuromuscular disorders is not always restricted to the 
PNS and can affect the CNS as well. In FSHD and myotonic dystrophy, this was revealed 
using magnetic resonance imaging and somatosensory-evoked potentials.26, 66 Although 
central fatigue usually correlates positively with the level of experienced fatigue, this 
correlation was not clearly found in ‘neurologically well-recovered’ GBS patients.35, 81
The differences of several aspects of fatigue found in GBS, as compared to other neu-
romuscular disorders, may lie in the fact that GBS is an acute and monophasic disease, 
often preceded by an infection. In contrast, the others neuromuscular diseases are often 
chronic and mostly progressive diseases.
For the management of fatigue in neuromuscular disorders, it is advised to start with 
optimizing treatment of the underlying disease and of possible co-existing causes of fa-
tigue. When symptoms of fatigue persist, non-pharmacological interventions are prefer-
able to pharmacotherapeutics, as pharmacotherapeutics have not yet been proven to be 
effective for the treatment of fatigue in neuromuscular disorders.36 Further elucidation 
of the pathophysiology of fatigue, with special interest in the central governor model, 
may help to guide the development and proper targeting of new and hopefully effective 
pharmacotherapeutics. Meanwhile, the benefit of non-pharmacological treatments, 
such as low-intensity physical training, rehabilitation and cognitive behavioral therapy, 
as treatment options for fatigue in neuromuscular disorders needs further evaluation. 
The increasing awareness of fatigue as an important part of the burden of disease in 
neuromuscular disorders is not only important for the development of new treatment 
strategies, but also for improvement of current patient care.
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abstract
We present a case of adult Pompe disease (acid maltase deficiency) with an uncommon 
clinical presentation characterized by severe fatigue and myalgia prior to the onset of 
limb-girdle weakness. Remarkably, the muscle biopsy demonstrated selective involve-
ment of type 1 muscle fibers. The cause and clinical effects of fiber type specific involve-
ment are currently unknown, but the phenomenon might contribute to the clinical het-
erogeneity in Pompe disease and the variable response to enzyme replacement therapy.
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introDuction
Limb-girdle weakness is the most common and prominent presenting sign in adults 
with Pompe disease, an autosomal recessive metabolic disorder often referred to as acid 
maltase deficiency or glycogen storage disease type II (OMIM #232300). Pompe disease 
is a lysosomal storage disorder caused by the deficiency of acid α-glucosidase.1-4 Expan-
sion and malfunction of the lysosomal system followed by autophagosomal build-up 
leads to loss of muscle architecture and muscle function.5-9 
The clinical spectrum of Pompe disease is very heterogeneous with regard to the age 
of onset, disease manifestations and rate of disease progression.3,10 Light-microscopic 
examination of skeletal muscle from Pompe disease patients usually reveals a vacuolar 
myopathy and glycogen storage with nonselective involvement of the different muscle 
fiber types.4 However, a limited number of cases have been reported showing preferen-
tial involvement of either type 111-13 or type 2 muscle fibers14. In all seven cases reported, 
the selective fiber type involvement was just reported as an unusual observation and it 
was not questioned whether patients with preferential glycogen storage in one specific 
fiber type might exhibit a different clinical phenotype.
We present a case of adult-onset Pompe disease with an uncommon clinical presenta-
tion characterized by severe fatigue and myalgia prior to the onset of limb girdle weak-
ness. Remarkably, the muscle biopsy demonstrated involvement of only type 1 muscle 
fibers. This unusual observation is relevant in the context of recent publications suggest-
ing that type 1 muscle fibers might respond better to enzyme replacement therapy than 
type 2 fibers.15-17
case report
In January 2007, a 35-year-old Caucasian woman was referred to our hospital. Since Au-
gust 2006 she suffered from severe fatigue and myalgia of the muscles of the shoulder 
girdle and the upper arms and limbs, especially notable when she walked the stairs and 
combed her hair. A few months later, she had noted minor weakness of the upper arms 
and legs. Because of these complaints she had abandoned her job as a children day-care 
worker. There were no clinical signs, such as feeling listless, being without energy, or a 
lack of  motivation, suggesting a vital depression. Physical examination revealed no ab-
normalities. Neurological examination revealed no muscular atrophy or fasciculations. 
The muscles were not abnormally tender. Examination of the cranial nerves, sensory 
functions of the limbs and tendon reflexes were normal. There was symmetrical weak-
ness of the shoulder girdle (m.deltoideus, m.infraspinatus),  the gluteal muscles and 
the proximal muscles of the legs (m. iliopsoas, hamstrings), Medical Research Council 
(MRC) grade 4. The patient was able to squat, but used her hands to rise from the floor. 
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Pulmonary function tests were normal. She had a mean score of 6.75 (range 0-7) on the 
fatigue severity scale (FSS), indicating severe fatigue.
Serum creatine kinase (CK) was elevated (1755 U/l; normal value <169 U/l). Aspartate 
aminotransferase (AST), alanine aminotransferase (ALT) and lactate dehydrogenase (LDH) 
were slightly elevated. Erythrocyte sedimentation rate (ESR) and thyroid-stimulating 
hormone (TSH) were normal. Antinuclear antibodies (ANA), anti-SSA, anti-SSB and anti-
Jo1, were negative (normal).
Based on the relatively short duration of her complaints, the presence of fatigue, myal-
gia, and the elevated CK, we considered it most likely that she would have an inflamma-
tory myopathy. A muscle biopsy taken from the quadriceps muscle, however, revealed 
no signs of inflammation, but rather surprisingly showed a vacuolar myopathy solely 
affecting type 1 muscle fibers. The vacuoles stained positive for acid phosphatase. Rep-
A
B
Figure 1 Biopsy from the m. quadriceps femoralis showing selective involvement of type I muscle fibers 
ATPase staining at pH 9.4: Type 1 muscle fibers are lightly stained and are vacuolated (panel A). Acid 
phosphatase staining (red) of a serial section demonstrates lysosomal pathology in the type I muscle 
fibers (panel B).
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resentative pictures are shown in Figure 1. Glycogen accumulation in some muscle fibers 
was detected by PAS staining and electron microscopy showed glycogen-filled vacuoles. 
No abnormalities were found in the NADH (nicotinamide adenine dinucleotide), SDH 
(succinate dehydrogenase), COX (cytochrome oxidase) and ORO (oil red O) staining. 
Based on these findings Pompe disease was suspected and subsequently confirmed by 
demonstrating acid α-glucosidase deficiency in leucocytes and cultured skin fibroblasts. 
In addition, DNA analysis revealed the presence of two pathogenic mutations in the acid 
α-glucosidase gene, c.-32-13 T>G and 525delT.
Discussion
The case of Pompe disease described here is peculiar in that the patient presented with 
severe fatigue and myalgia prior to the development of limb-girdle weakness, and be-
cause fiber type involvement was restricted to the type 1 muscle fibers. Whether rapid 
progression, fatigue or pain is related to oxidative type 1 muscle fiber abnormalities in 
this patient is uncertain and has not been proven.
Although fatigue is prevalent in adults with Pompe disease, it is rarely reported as first 
symptom.18 Fatigue can have many different causes.19 In case of Pompe disease, expan-
sion and dysfunction of the lysosomal system due to glycogen accumulation followed 
and accompanied by autophagic build-up destroys the muscle architecture and hampers 
the contraction.20 Thus, it takes more energy to achieve the same power of contraction 
resulting in more rapid fatigue.19,21 Decreased pulmonary function may also contribute 
to the level of fatigue, but our patient had a normal pulmonary function in both sitting 
and supine position. Muscle fiber type distribution varies widely within and between 
muscles depending on their function.22 Therefore the selective involvement of type 1 
muscle fibers in this case can be a chance finding and theoretically can be related to 
sampling differences, but might be related to the prominent fatigue, rapid progression 
or pain. Normally, type 1 muscle fibers are fatigue-resistant and well suited for prolonged 
aerobic exercise.22 If type 1 fibers are selectively affected in the disease process, type 2 
muscle fibers might be challenged to partially compensate for the loss of function while 
they are not suited for endurance. Whether these mechanisms explain the fatigue in 
our patient is as yet unknown. Perception of fatigue may also be related to non-physical 
causes.23
Selective type 1 muscle fiber involvement with vacuolization has previously been 
described in a limited number of cases of Pompe disease, but no discussion was devoted 
to its cause or clinical effects. Three of these five patients suffered from respiratory 
dysfunction, which is likely to cause fatigue, but pulmonary dysfunction was not found 
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in the case we present. The muscle fiber type specific involvement however could be 
relevant in clinical practice because possibly it could be related to the effect of enzyme 
replacement therapy. 
Research in mice showed that slow-twitch type 1 fibers respond well to ERT in con-
trast type 2 fibers. In particular, type 2b fibers seemed much more resistant to therapy. 
In knockout mice it was shown that the accumulation of autophagic vacuoles in skeletal 
muscle is limited to type 2 fibers. The combination of increased autophagic activity and 
inefficient endocytic trafficking in type 2 fibers may contribute to an incomplete thera-
peutic response.15,24 However in a single patient with classic infantile Pompe disease it 
was shown that enzyme replacement therapy can reverse the pathological changes in 
both type 1 and type 2a muscle fibers.17
With this case report we want to draw attention to the occurrence of fiber type spe-
cific pathology in Pompe disease. It may be relevant for the clinical presentation and for 
the responsiveness to enzyme therapy, since it has been suggested, that type 1 fibers 
respond better to enzyme therapy than type 2 fibers.17,24 Further research is required 
in adults with Pompe disease to draw further conclusions about the effect of fiber type 
specific involvement. 
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abstract 
Background Pompe disease is a hereditary metabolic myopathy, for which enzyme re-
placement therapy (ERT) has been available since 2006. We investigated whether ERT 
reduces fatigue in adult patients with Pompe disease. 
Methods In this prospective international observational survey, we used the Fatigue 
Severity Scale (FSS) to measure fatigue. Repeated measures ANOVA was used to analyze 
the data over time. In a subgroup of patients, we also evaluated muscle strength using 
the Medical Research Council scale, measured pulmonary function as Forced Vital Capac-
ity, and assessed depression using the Hospital Anxiety and Depression scale
Results We followed 163 patients for a median period of 4 years before ERT and for 3 
years during ERT. Before ERT, the mean FSS score remained stable at around 5.3 score 
points; during ERT, scores improved significantly by 0.13 score points per year (p<0.001). 
Fatigue decreased mainly in women, in older patients and in those with shorter disease 
duration. Patients’ improvements in fatigue were moderately correlated with the effect 
of ERT on depression (ρ 0.55; CI 95% 0.07 to 0.70) but not with the effect of ERT on 
muscle strength or pulmonary function.
Conclusions Fatigue is a common and disabling problem in patients with early and ad-
vanced stages of Pompe disease. Our finding that ERT helps to reduce fatigue is therefore 
important for this patient population, irrespective of the mechanisms underlying this 
effect. 
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introDuction
Fatigue accompanies many chronic neuromuscular and neurological disorders,1, 2 and 
is often reported by patients with Pompe disease,3-5 an inherited metabolic myopathy 
caused by deficiency of acid alpha-glucosidase, a lysosomal enzyme. Pompe disease 
presents as a wide clinical spectrum, the most prominent symptoms in adults being 
muscle weakness and respiratory distress.6, 7 As well as these main symptoms, many 
adults - however badly affected - complain of fatigue.5
The pathophysiology of fatigue in neurological disorders is not fully understood. As 
well as physiological changes in the muscle or the Central Nervous System (CNS), it 
may involve respiratory dysfunction and/or inadequate energy expenditure or energy 
production. Psychological fatigue (‘weariness’) may also be involved.1, 2, 8 
At present there are no proven therapeutic strategies to combat fatigue. Its general 
management involves identifying and treating contributory factors such as psycho-soci-
ological factors, sleep disturbances, and comorbidities.1 
Since 2006, enzyme replacement therapy (ERT) has become available for Pompe 
disease. Though this has been shown to positively affect respiratory and muscle func-
tions in adults,9-13 very little is known about its effect on fatigue. While three studies 
suggested that ERT reduces fatigue in adult patients,14-16 we do not know of any study 
that has investigated this subject in detail.
To establish whether ERT reduces fatigue, we therefore investigated a large interna-
tional cohort of adult Pompe patients. We also investigated whether the potential effect 
of ERT on fatigue differed between subgroups of patients, and whether it was related to 
improvements or changes in muscle strength, pulmonary function, and/or depression.
material anD methoDs
Patients and settings
Data were collected between May 2002 and February 2011 as part of an ongoing obser-
vational follow-up study on the clinical course of Pompe disease in patients in Australia, 
Canada, Germany, the Netherlands, United States, United Kingdom, and in a small num-
ber of patients from other countries. Patients were recruited through national patient 
organizations or directly through our expertise center, the Center for Lysosomal and 
Metabolic Diseases at Erasmus MC University Medical Center, as described previously.3, 
5 The study was approved by the Erasmus MC Ethical Committee, and all participants 
provided written informed consent.
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Beyond a diagnosis of Pompe disease, there were no strict inclusion or exclusion cri-
teria for participation in the study. For the analyses described in this paper, we included 
only patients aged 18 years and older who were receiving ERT, and who had had at least 
6 months of follow-up before and after ERT. 
measurements
Each year, participants were asked to complete several questionnaires, including one on 
fatigue. Demographic and clinical data were collected on country of residence, age, year 
of diagnosis, gender, disease duration, and use of wheelchair and/or ventilator. 
For patients seen at the Dutch center, more frequent measurements and additional 
data were available from clinical assessments and further questionnaires. As well as 
fatigue, these included pulmonary function and muscle strength (assessed between 
January 2005 and August 2009) and depression (assessed between January 2005 and 
February 2011) measured as described below. 
Fatigue assessment
The severity and impact of fatigue were assessed using the Fatigue Severity Scale 
(FSS).17 This self-report questionnaire focuses on the physical symptoms of fatigue, and 
measures the severity of fatigue and its impact on an individual’s daily functioning. A 
mean score is calculated from the nine items, which range from 1 (‘no signs of fatigue’) 
to 7 (‘most disabling fatigue’). Scores ≥4 indicate the presence of fatigue, and scores 
≥5 severe fatigue.17, 18 As described previously,5 we used the English, Dutch and German 
translations. The FSS has demonstrated good internal consistency, reliability and validity 
in studies involving patients with several neurological disorders.5, 17, 19, 20 When individual 
item scores were missing, the mean FSS score was calculated from the remaining items.5 
The maximum number of missing items per questionnaire was 2, and missing items 
were found in only 2% of the 1199 questionnaires completed.
Pulmonary function (Dutch patients)
Forced Vital Capacity (FVC) in sitting and supine positions was measured using spirom-
etry as described previously.21 Results were expressed as a percentage of the predicted 
normal value.
Muscle strength (Dutch patients)
Skeletal muscle strength was measured manually in scores from 0 to 5 using the Medical 
Research Council (MRC) grading scale.22 A sumscore was calculated by adding the grades 
of 26 muscle groups as described earlier.23 This sumscore could range from 0 (total pa-
ralysis) to 130 (normal strength), and was expressed as a percentage of the maximum 
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possible score of 130. When 3 or more muscle groups were missing the score was not 
calculated.23
Depression (Dutch patients)
Symptoms of depression were assessed using the depression subscale of the Hospital 
Anxiety and Depression Scale (HADS-D),24 which ranges from 0 to 21. The HADS has been 
widely used in different disorders (including neuromuscular disorders), and has demon-
strated good reliability and validity.25 
statistical analysis
Analyses of the longitudinally assessed fatigue scores were performed using repeated 
measures ANOVA (random coefficient models), which allows for irregular measurement 
times. To assess the effect of ERT on the mean FSS scores, the model included linear 
effects of time before ERT and time after ERT. Per individual, the two segments connect 
at the time ERT started, a method generally known as the “broken-stick” method or 
“piece-wise linear regression”. The two regression coefficients provide estimates of the 
mean annual change (slope) of the scores before and after the start of ERT. The difference 
between these two provides an estimate of the effect of ERT on the outcome measure.
For subgroup analyses, patients were divided into strata based on gender, age, disease 
duration, wheelchair use, and use of respiratory support, all at start of ERT. 
For the Dutch patients we also analyzed the correlation between the effect of ERT 
on the FSS and its effect on the MRC sumscore, on FVC in upright and supine positions, 
and on the HADS depression score. After performing univariate analysis by using linear 
mixed-effects models with broken-stick evolutions for the FSS and the three other out-
comes, we estimated random effects for each model using Empirical Bayes estimates 
(EB). Afterwards the correlation between the EB estimates for FSS and the other out-
comes was calculated. The significance of the correlation coefficients was tested using 
95% confidence intervals obtained from 1000 bootstrap samples.
Data were analyzed using SPSS for Windows (version 17, SPSS Inc., Chicago, IL) and 
SAS (version 9.2, SAS Institute Inc., Cary, NC). Bootstrap sampling was implemented in R 
(version 2.14). A p-value of ≤0.05 was considered statistically significant. 
results
general characteristics
The eligibility criteria were met by 163 adults (55% female) out of a total of 383 patients 
participating in the survey. Thirty patients were excluded as they were younger than 18 
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years of age, 67 were excluded for not receiving ERT, 85 had no follow-up measurements 
(yet), and 38 had less than 6 months follow-up before and/or after the start of ERT. 
The 163 patients in our study (see Table I) had a median disease duration of 13 years. 
The patients’ median age at start of ERT was 50 years (range 24–76 years); 52% used 
a wheelchair and 50% respiratory support. The median follow-up time before ERT was 
4 years (range 0.5–8); after start of ERT, this was 3 years (range 0.5–8). Per patient, a 
median of seven questionnaires were completed (range 2–18).
At start of ERT, 85% of the patients with an available FSS score were fatigued (FSS ≥4) 
and 68% severely fatigued (FSS ≥5); at the last measurement, 79% were fatigued and 
55% severely fatigued. 
change in fatigue scores before and during ert
Before ERT, the mean FSS score remained stable (annual change of 0.01 score points; 
CI 95% -0.05 to 0.06; p=0.84). In contrast, the mean fatigue score declined significantly 
during ERT by 0.13 score points per year (CI 95% -0.19 to -0.07; p<0.001). Comparison of 
the trends in fatigue over time in the periods before and after the start of ERT showed 
that fatigue significantly improved during ERT (mean difference in slopes 0.14 FSS score 
points per year, 95% CI -0.23 to -0.04; p<0.01, Figure 1). 
Relative to fatigue in the pre-treatment period, fatigue during ERT improved signifi-
cantly in women, in older patients and in those whose disease duration was <15 years. 
This improvement was not statistically significant in men, younger patients, and those 
Table I Patient Characteristics at start of ERT  
Characteristic All (n=163)
Median age at start of ERT, years (range) 50 (24–76)
Median age at diagnosis, years (range) 37 (1–66)
Median disease duration, years (range) 13 (1–33)
Gender, no. (%)
         Female 90 (55)
Country of residence, no. (%)
          Netherlands 59 (36)
          Germany 36 (22)
          US 37 (23)
          Other * 31 (19)
Use of wheelchair at start of ERT, no. (%)
        Yes 85 (52)
Respiratory support at start of ERT **, no. (%)
        Yes        81 (50)
Continuous variables are expressed as median (range). Categorical variables are expressed as numbers (%). 
* Includes patients from Australia, Canada, United Kingdom and a small number of patients from other 
countries. ** Respiratory support includes partial and fulltime, invasive and non-invasive support.
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with longer disease duration (Table II). Fatigue improved significantly in patients who 
used a wheelchair and in those who were not on respiratory support. It also tended 
to improve in wheelchair-independent patients (p=0.06) and in those who received any 
kind of respiratory support (p=0.08). Statistical testing of the differences between these 
subgroups showed that these differences were not significant for any of the aforemen-
tioned subgroups.
correlation between the effect of ert on fatigue and its effect on muscle strength, 
pulmonary function and depression
For this part of the analysis, only the 59 Dutch patients were included. At start of ERT, 
their median age was 52 years (range 26–76), 59% were women and 46% used a wheel-
chair. Relative to the total study population, fewer patients used respiratory support 
(32% versus 50%) and more were fatigued at start of ERT (92% versus 85% of the total 
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Figure 1 The figure shows the change in Fatigue severity-scale scores (FSS) before and after the start of 
enzyme replacement therapy (ERT) 
The dots represent individual measurements and the lines represent the mean slopes calculated by the 
‘broken stick’ repeated measures ANOVA for the group of 163 patients. The median follow-up during the 
natural course of Pompe disease was 4 years and the median follow-up during treatment was 3 years. The 
mean FSS score did not change significantly in the period before ERT, but declined significantly during ERT. 
The difference between the period before and during ERT was 0.14 FSS score points per year (p<0.01).
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patient population). Median MRC sumscore (in percentage) at start of ERT was 78% 
(range 48–92). Median FVC percentages were 70% in sitting position (range 11–107) and 
49% in supine position (range 23–99). Only 13 patients (22%) scored ≥8 on the HADS 
depression subscale, indicating clinical signs of (borderline) depression. Median HADS 
depression score was 4 (range 0–15).
As in the total study population, FSS scores significantly decreased during ERT. The 
difference with the pre-treatment period was borderline significant (Table III), and was 
moderately correlated with a decrease in the level of depression (ρ 0.55; CI 95% 0.07 to 
0.70). No significant correlations were found between the improvement in fatigue and 
muscle strength in response to ERT and in pulmonary function in upright and supine 
positions.
Discussion
This is the first prospective follow-up study to assess the effect of ERT on fatigue in a large 
number of adult Pompe patients. We found that ERT significantly reduces self-reported 
Table II Subgroup analyses for the effect of ERT on the fatigue severity-scale scores
Subgroups
Difference in FSS score before and during ERT * 
Score points/year (95% CI) p-value **
All -0.14 (-0.23 to -0.04) <0.01
Gender
         Female (n=90) -0.18 (-0.31 to -0.05) <0.01
         Male (n=73) -0.08 (-0.23 to 0.07) 0.30
Age at ERT, years
          < 45 (n=66) -0.10 (-0.27 to  0.07) 0.26
          ≥ 45 (n=97) - 0.15 (-0.27 to -0.03) 0.01
Disease duration, years
          < 15 (n=94) -0.19 (-0.32 to -0.05) <0.01
          ≥ 15 (n=68) -0.07 (-0.22 to 0.07) 0.33
Wheelchair use
          Yes (n=85) -0.13 (-0.24 to -0.01) 0.04
          No (n=78) -0.15 (-0.32 to 0.01) 0.06
Respiratory support ***
         Yes (n=81) -0.13 (-0.27 to 0.02) 0.08
          No (n=82) -0.14 (-0.27 to -0.004) 0.04
Data show the mean changes in score points per year (sp/y) as calculated by stratified analysis using 
repeated measures ANOVA; CI = Confidence Interval; FSS = Fatigue Severity Scale. * Comparison between 
change over time in FSS before and during ERT. ** P-value for the difference in FSS score before and during ERT 
per subgroup. Statistical testing of the differences between these subgroups showed that these differences 
were not significant. *** Respiratory support includes partial and fulltime, invasive and non-invasive support.
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fatigue, the mean decrease in FSS score being 0.14 per year relative to the pre-treatment 
period. The decrease in fatigue during ERT was correlated with improvements in depres-
sion, but not significantly with changes in muscle strength or pulmonary function. The 
effect of ERT on fatigue was not consistent across patient subgroups: fatigue decreased 
mainly in women, older patients and those with shorter disease duration. 
Our study mirrors previous findings in this cohort, providing a reminder that fatigue 
is a highly prevalent symptom among adults with Pompe disease. Therapies that can 
reduce fatigue in this population are therefore of great importance, and our finding that 
ERT positively affects fatigue is a significant finding. While the annual improvement 
might seem small (0.14 points per year), it resulted in a substantial drop in the propor-
tion of patients who were fatigued or severely fatigued at the end of our follow-up. 
Subgroup analyses suggest that fatigue may be more responsive to ERT in women, 
older patients and those with shorter disease duration. A better response in women 
might be explained by the more pronounced effect of ERT on muscle strength in females 
that was identified recently by our group.23 It is unknown whether hormonal influences 
are involved in this. The better effect in patients with shorter disease duration might 
be due to less severe muscle damage. The absence of an effect in younger patients may 
seem at odds with this, but it is possible that younger patients have more demanding 
lifestyles, resulting in more fatigue. Since glycogen degradation occurs mainly in the cy-
Table III Change in fatigue as a result of ERT and its correlation with the change over time in muscle 
strength, pulmonary function and level of depression. 
Change over time
Difference before and 
after ERT (95% CI)
Correlation to FSS *
ρ (95% CI)
Before ERT
(95% CI)
During ERT
(95% CI)
Main outcome measure
FSS (n=59) -0.04 (-0.13 to 0.04) -0.21 (-0.33 to -0.09) **  -0.17 (-0.35 to 0.01) Reference
Covariates
MRC sumscore
(n=55 ***)
-1.28 (-1.80 to -0.49) ** 2.01 (1.20 to 2.81) ** 3.29 (2.04 to 4.53) ** -0.36 (-0.61 to 0.08)
FVC upright position 
(n=52 ***)
-1.95 (-3.09 to -0.83) ** 0.06 (-1.09 to 1.21) 2.02 (0.26 to 3.77) ** -0.26 (-0.49 to 0.08)
FVC supine position 
(n=45 ***)
-1.71  (-2.76 to -0.67) ** -0.67 (-1.79 to 0.45) 1.04 (-0.50 to 2.57) -0.31 (-0.56 to 0.17)
HADS depression    
(n=59 ***)
0.08 (-0.40 to 0.48) -0.48 (-0.85 to -0.11) ** -0.57 (-1.23 to 0.09) 0.55 (0.07 to 0.70) **
Data show the mean changes in score points per year (sp/y) as calculated by univariate analysis using linear 
mixed-effects models CI = Confidence Interval; FSS = Fatigue Severity Scale; MRC = Medical Research Council; 
FVC = Forced Vital Capacity; HADS = Hospital Anxiety Depression Scale. * Correlation between the differences 
in FSS scores and the difference in the other outcome measures following ERT. ** Represents statistical 
significance. *** Only patients with sufficient data were included
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toplasm, we doubt that lower levels of fatigue can be attributed to the increased release 
of glucose from the lysosome (by ERT mediated lysosomal glycogen degradation).26
Muscle strength, pulmonary function and depression, have been shown to be related 
to fatigue in other neurological disorders.1, 2, 8 Against our expectations, we found no 
significant correlation between the improvement in fatigue and in muscle strength or 
pulmonary function. This might be due to the smaller sample size available for this sub-
analysis. Alternatively, it may be that the level of fatigue is determined by the degree 
of muscle endurance rather than of muscle strength.27 Because patients with impaired 
pulmonary function often use mechanical ventilation, their oxygen levels will be normal, 
which could explain the absence of a correlation between the response to ERT in fatigue 
and pulmonary function. 
We found that as fatigue decreased during ERT, the scores on the depression scale 
also decreased. Several studies have described a relationship between depression and 
fatigue in neurological disorders.2, 28-31 Depression may predispose for fatigue,2, 28 but fa-
tigue secondary to an underlying illness can also cause depression, with one sometimes 
influencing the other.29 Since the majority of patients (78%) were not depressed, ERT has 
presumably contributed to a decrease in fatigue by affecting the underlying pathophysi-
ology
 As fatigue is a multifactorial entity, it is likely that other factors – including chang-
ing patient’s perspectives and perceptions, intensified medical care and altered muscle 
metabolism – contribute to its improvement after ERT. Although, as a treatment of 
the underlying disease, ERT seemed to reduce fatigue, it is hard to define the extent 
to which it acts directly (by reversing disease-related pathophysiology) or indirectly 
(through psycho-sociological factors). Further research is needed to unravel the underly-
ing mechanisms.
 This study benefits from the relatively large number of patients who participated, 
and from the fact that patients were included irrespective of their disease severity; the 
study thereby represents the entire spectrum of adult Pompe disease. Despite the large 
sample, it was not possible to build multivariate models, and multiple testing might 
limit the results of the subgroup analysis. Our correlation analysis was based on a subset 
of patients and was limited by a smaller sample size. 
Fatigue is a subjective and complex concept that is difficult to define and measure. 
The FSS is a uni-dimensional scale that measures fatigue as a single construct. Because 
of its brevity and simplicity, we preferred the FSS to a multi-dimensional scale in which 
different forms of fatigue – such as physical, cognitive and psychosocial fatigue – are 
assessed separately. Uni-dimensional and multi-dimensional scales have been found to 
produce similar measurements of fatigue.32  
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conclusions
Fatigue is a common problem in patients with Pompe disease. Our finding that ERT helps 
to reduce it is therefore important for this patient population, irrespective of the mecha-
nisms underlying this effect. Fatigue decreased mainly in women, in older patients and 
in patients with short disease duration. 
To manage fatigue successfully, treatment options such as rehabilitation and exercise 
33 should be considered in addition to ERT. Further investigations should be devoted to 
the roles of pharmacotherapeutics and cognitive therapy in treating fatigue, and to the 
exact role of muscle cell changes, pulmonary function, and psychological and other fac-
tors that may be associated with it.
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Through the advent of Enzyme Replacement Therapy (ERT) using alglucosidase alfa 
(Myozyme®), Pompe disease has become the first treatable hereditary neuromuscular 
disorder. This has changed the perspectives for patients affected by Pompe disease for 
the better. In 2006, at the time alglucosidase alfa was registered as a treatment for all 
forms of Pompe disease, data on treatment efficacy in children and adults were still 
limited. In anticipation of the  registration, we started to systematically collect informa-
tion on the clinical manifestations and the natural course across the clinical spectrum; 
from 2004 onwards, in a nationwide prospective study [Appendix A]. The same set of 
standardized measurements was used before and after the patients started to receive 
ERT enabling us to evaluate the change in the course of disease caused by ERT for each 
individual patient.  
With the implementation of this new treatment, a number of questions arose, such as 
‘which factors are predictive of a good response?; ‘what is the clinical impact of antibod-
ies on therapeutic efficacy?’; ‘are there any risks for the mother and her (unborn) child to 
continue treatment with alglucosidase alfa during pregnancy and lactation?; and ‘does 
treatment with ERT decreases the burden of fatigue in adults with Pompe disease?’. The 
studies described in this thesis aimed at answering these questions.
This general discussion summarizes the most important findings and compares these 
with what is known from the literature. The results are translated into recommenda-
tions that can be used in clinical practice. At the end of this chapter some methods 
are addressed that might improve the effect of ERT and potential new treatments are 
discussed.
the clinical sPectrum anD natural Disease course in aDult PomPe 
Disease
The clinical spectrum
The Dutch patient cohort of 94 patients (including three patients from Belgium) described 
in this thesis [Chapter 2.1], reflects the remarkable broadness of the clinical spectrum 
with regard to the wide range in age at first clinical presentation, heterogeneity in 
disease manifestations, and differences in the rate of disease progression as described 
in the medical literature.1-9 In this cohort, all but one patient carried the c.-32-13T>G 
(IVS-1) mutation in the one allele in combination with a ‘null’ mutation in the other 
allele. In these patients, age of symptom onset ranged from 1 to 62 years and age at 
diagnosis from 1 to 63 years. Our findings were thereby very similar to those of a retro-
spective study. This retrospective study reviewed 225 cases published in the literature. 
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Among these cases the maximum age for onset of symptoms was 68 years and for age 
at diagnosis 71 years.8
The advantage of our study approach over clinical studies that either included small 
numbers of patients or used strict eligibility criteria, is that the nation-wide Dutch co-
hort is unbiased in the sense that it included almost all Dutch patients with a confirmed 
diagnosis of Pompe disease, from asymptomatic to very severely affected. However, 
there is also a draw-back in that almost all our patients carried the c.-32-13T>G (IVS1) 
mutation so that the extrapolation of our findings to patients not carrying this mutation 
must be done with caution. 
Diagnostic delay
The rarity of Pompe disease, its heterogeneous clinical presentation, and the overlap of 
signs and symptoms with other neuromuscular disorders may initially result in a low 
clinical suspicion causing diagnostic delay.5 8 10-13 In our cohort, there was on average a 
seven-year delay between the time that the first Pompe related-symptoms were noted 
and the actual time of diagnosis. The diagnostic delay was no different than reported 
in the literature review of 225 cases published in 2005.8 When we examined the length 
of the diagnostic delay before and after the registration of ERT, surprisingly the median 
delay in the Netherlands had doubled from a median of 5 years before 2006 to a median 
of 10 years thereafter. It is also interesting to note that the number of diagnoses made 
in the Netherlands doubled, from three per year between 1990 and 2006 to 6-7 per 
year after the introduction of ERT in 2006. These trends may well be explained by two 
factors. First, when ERT became available, neurologists probably screened for Pompe 
disease among all their patients with limb-girdle weakness who did not have a sufficient 
diagnosis. Second, since the introduction of ERT ongoing efforts are made to increase 
the awareness for Pompe disease. Through this, neurologists are better able to recognize 
patients across the entire clinical spectrum and also test for Pompe disease in patients 
presenting with less familiar features, such as ptosis or scapular winging, now associ-
ated with the disease. 
Since the majority of patients experience substantial disability at the time of diag-
nosis, there is potentially much to be gained by shortening the gap between onset of 
symptoms and diagnosis followed by a timely start of ERT.14 For shortening the diag-
nostic delay, it is important to identify the responsible factors first. One such factor, as 
shown by data from the (industry driven) international Pompe registry, is that patients 
presenting with less familiar manifestations of Pompe disease are diagnosed later than 
patients presenting with typical signs or symptoms like respiratory or musculoskeletal 
problems.15 Our finding that some of the less well-known features of Pompe disease are 
far more common than initially thought, might contribute to the timely diagnosis of 
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patients presenting with these symptoms [Chapter 2.1].16 For instance, we found that 
ptosis (mainly asymmetrical) occurred in 23% of the patients, scapular winging in 33%, 
bulbar muscle weakness in 27%, and scoliosis in 23%. 
Limb-girdle and respiratory muscle weakness
The first presenting symptoms of children and adults with Pompe disease are most fre-
quently related to limb-girdle weakness. The pattern of muscular weakness, as evaluated 
by manual muscle testing using the Medical Research Council (MRC) grading scale and 
quantitative muscle testing using Hand-Held Dynamometry (HHD), is symmetrical and 
reflects the typical limb-girdle distribution. The distal muscles of the upper and lower 
extremities are relatively spared, and if they are affected at all, this occurs only late in the 
disease course [Chapter 2.1].16 Our findings on clinical examination are in accordance 
with the pattern of muscle involvement as revealed by Computed Tomography (CT) and 
Magnetic Resonance Imaging (MRI) scanning.17-19   
The majority of Pompe patients have also respiratory insufficiency with diaphragmatic 
weakness, as 60% of the patients have an abnormally low Forced Vital Capacity (FVC) in 
upright seated position and 80% of the patients have an abnormal FVC in supine posi-
tion [Chapter 2.1].16 It was striking that two of the patients we have seen had a normal 
pulmonary function in upright seated position, but required night-time mechanical 
ventilation due to disproportional diaphragmatic weakness. This stresses the need for 
also performing spirometry also in the supine position as a standard screening measure-
ment in all patients diagnosed with Pompe disease, as otherwise the development of 
respiratory failure may be discovered too late.20  
Unexpectedly and remarkably, the extent of pulmonary dysfunction was more pro-
nounced in males than in females.20 At study entry 38% of the males against 17% of 
the females used mechanical ventilatory support, while 13% of the males and none of 
the females used invasive ventilation.16 20 These findings are consistent with a German 
study in 38 patients, in which 54% of the males and 20% of the females used mechanical 
ventilatory support at study entry 5 In our study, there were no differences in severity of 
limb-girdle weakness, disease duration or age  between males and females that could 
clarify this gender difference. It was also found that males have a higher susceptibility to 
sleep-disordered breathing than females. With regard to this finding, it was speculated 
that it could be explained by the higher upper airway resistance in males compared to 
females caused by a different body-fat distribution and differences in sex hormones in-
duced central ventilator control.21 22 However, this has not been proven as yet for Pompe 
disease.
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Main findings on the clinical features of adults with Pompe disease 
- The broadness of the clinical spectrum of Pompe disease is reflected in the Dutch patient cohort.
- The pattern of muscle weakness generally has a typical limb-girdle distribution.
- Respiratory insufficiency with diaphragmatic weakness is present in 60% of the patients while 
seated and in 80% while supine.
- Males have more severe pulmonary dysfunction than females.
- Less familiar features of Pompe disease, such as ptosis (23%), scapular winging (33%), bulbar 
muscle weakness (27%), and scoliosis (23%) are more common than formerly apprehended.
Recommendations for clinical practice
- It is important to increase the awareness for Pompe disease by spreading the knowledge of the 
wide clinical spectrum and clinical manifestations. This helps to shorten the diagnostic delay, and 
is likely to decrease the burden of Pompe disease. 
- Patients should be screened for respiratory insufficiency by performing pulmonary function 
testing in both upright as well as in supine position to warrant a timely initiation of respiratory 
support measures.
Natural course 
When the prospective observational study started, we opted for a follow-up period of 
at least two years for each patient before the start of ERT. This however was no longer 
feasible with the introduction of alglucosidase alfa (ERT) in 2006. Especially for patients 
who were severely affected, had pronounced pulmonary involvement, and/ or deterio-
rated rapidly, ERT was started as soon as possible. As a consequence, the length of pre-
treatment follow-up for these more severely affected patients was shorter than originally 
planned, whereas the less severely affected patients had a longer pre-treatment follow-
up. At the end, the final median follow-up became 1.6 (0.5 – 4.2) years, which is rather 
short for a slowly progressive disease, although it is the longest follow-up among the 
published prospective natural course studies in untreated adult Pompe disease (Table I).
During follow-up, muscle strength and pulmonary function declined gradually [Chap-
ter 2.1].16 These findings compare to rates of decline reported by other studies (Table I). 
It seems that the patients in the study by Wokke et al. showed a faster decline during 
the 12 month follow-up period, however this is largely explained by reporting relative 
instead of absolute percentages as change from baseline.9 Although the average yearly 
decline appears rather small, the impact on disability over the years is substantial: 15 
years or more after disease onset, 70% of the patients are wheelchair dependent and 
60% require some form of mechanical ventilation.2 Thus, the severity of disease is clearly 
related to disease duration.2 23
About 15% of the patients remained fairly stable during follow-up, relative to the total 
group these patients had a shorter disease duration (7.3 versus 15.5 years, P = 0.03) and 
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were less severely affected at baseline, although differences for the latter did not reach 
statistical significance. In about 10% a more rapid deterioration was observed for either 
muscle strength or pulmonary function. Factors that predicted a faster decline in muscle 
strength included a longer disease duration (>15 years) and more distinct pulmonary 
involvement (FVC in seated position ≤80% of the predicted normal value). Wokke et al. 
also found that patients who had more advanced limb-girdle weakness and pulmonary 
dysfunction at study entry declined more rapidly over the 12-month study period.9
Van der Beek et al. showed that in the cross-sectional study on respiratory status in 
the Dutch patient cohort longer disease duration, male gender and patients with ad-
vanced disease had a worse pulmonary status. However, during prospective follow-up 
we could not detect prognostic factors related to decline in pulmonary function. Not 
finding these prognostic factors can probably be explained by the aforementioned 
differences in length of the pre-treatment follow-up between the more and the less 
severely affected patients. As a result, the average yearly decline in pulmonary function 
was less pronounced, and prognostic factors for respiratory outcome were more difficult 
to establish. 
From the patients’ perspective it is most important how Pompe disease interferes with 
their daily life and how treatment improves their physical functioning. The Quick Motor 
Function Test (QMFT; see also the paragraph on outcome measures) measures several 
domains of physical functioning.24  The test correlates very well with scores of proximal 
muscle strength (MRC and HHD), but unfortunately did not measure changes during 
prospective follow-up. This could be due to: I) the limited duration of follow-up (in a 
slowly progressive disorder), II) the unbalanced difference in the length of pre-treatment 
follow-up between severely and less severely affected patients, and III) a learning effect 
(improvement of performance on repetitive testing) during the first period of follow-up. 
We estimated the natural disease course in a cohort of patients diagnosed with Pompe 
disease, who were referred to our center. When interpreting these natural course data, 
one should realize that we have to do with the ‘iceberg phenomenon’ (John M. Last, The 
Lancet 1963). This selection bias can be overcome by carrying out a population-based 
study.  
Survival
With respect to long-term disease outcome, our group was the first to study survival in 
adults with Pompe disease [Chapter 2.2].25 Survival is a frequently used outcome measure 
in classic-infantile Pompe disease, since the majority of untreated patients succumbs in 
the first year of life. This is quite different in non-classic forms of Pompe disease wherein 
some diagnoses are made beyond the sixth decade of life. The exceptionally long follow-
up of patients (since 2002) participating in the IPA/Erasmus MC Pompe Survey has cre-
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ated the opportunity to compare the life expectancy of adults with Pompe disease and 
adults in the general population. The mortality rate of the patients turned out to be 2-3 
times higher.  Predictors of the higher mortality rate were wheelchair use, mechanical 
ventilation and a high level of disability as measured with the Rotterdam-Handicap Scale. 
Considerations regarding outcome measures in adult Pompe disease
The clinical studies summarized in Table I and Table III show the wide variety of outcome 
measures that were used in Pompe disease, particularly with regard to muscle strength 
and muscle function. For international comparison of data, it is important that outcome 
is measured in a standardized way using the same set of outcome measures. At the 
ENMC workshop of 2010 consensus was reached about a minimal set of assessments 
for adult Pompe patients. The set must include at least the six-minute walk test (6MWT), 
manual muscle strength testing, pulmonary function tests (FVC), and functional tests 
(Walter Gardner scale (WGM)) and timed tests).26
For measuring the muscle strength our group has chosen for the MRC grading scale 
and HHD scores. Both methods have their limitations when used for measuring changes 
in muscle strength in mildly affected patients, as in the higher regions the score is more 
dependent on the strength of the examiner. For HHD the maximal muscle strength was 
defined as the median strength of the general population, meaning that obtained results 
above the median were rounded to the median muscle strength of respectively healthy 
women or men. We defined maximal muscle strength in this way, for the reason that the 
average examiner cannot reliably measure forces beyond 250 Newton.27 The advantage 
of HHD over the MRC grading scale is that it measures muscle strength in a quantitative 
and linear way. 
To overcome the non-linearity of the MRC sumscore, a revised MRC scoring system was 
recently developed on the basis of Rasch methodology.28 This methodology transforms 
an ordinal score into a linear measure and is based on the assumption that patients who 
are less affected should have a greater chance of getting a better score. However, it still 
needs to be determined in clinical practice whether this Rasch-build MRC sumscore is a 
better way of measuring the course of muscle strength in patients with Pompe disease. 
A better method for measuring muscle strength in mildly affected patients might be 
Quantitative Muscle strength Testing (QMT) as applied by Wokke et al.9 and in the Late-
Onset Treatment Study (LOTS).29 As compared to MRC and HHD, this method measures 
more precisely differences in muscle strength in milder affected patients and is not 
dependent on the strength of the examiner. However, QMT has several disadvantages: I) 
it is a time consuming test, II) the test is limited to certain skeletal muscle groups, and 
III) requires the installation of specialized equipment, making QMT unattractive for use 
in daily clinical practice.
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To all methods of assessment described here, it applies that these are not well suit-
able for measuring the strength of the trunk muscles, which are the first to be affected 
in the disease process.16 17 19 Early detection of trunk musculature weakness is of clinical 
importance as this signals that the patient is becoming symptomatic. 
With regard to physical function testing, a frequently used outcome measure is the 
Walter Gardner scale (WGM). This is a crude measure ranging from 0 (the patient has a 
normal activity pattern) to 10 (the patient is bedriddenn). Table I and Table III show that 
the average WGM score did not change over time in most studies, indicating that this 
scale has limited responsiveness. Another commonly used test is the six-minute walk 
test, which is considered to be a reliable outcome measure. The six-minute walk test 
is also used in other neuromuscular disorders, for example in Duchenne muscular dys-
trophy.30 31 However, because the test was originally designed for patients with chronic 
bronchitis,32 it does not specifically measure the limitations of patients with limb-girdle 
weakness. Moreover, this does not particularly mean that minor changes on this assess-
ment scale imply important changes for the patients in daily life.
As none of the tests was truly ideal, we developed the Quick Motor Function Test 
(QMFT) [Appendix C] for evaluating the impairment in physical functioning for patients 
with limb-girdle weakness.24 This test was constructed on the basis of: I) the Gross Motor 
Function Measure (GMFM); 33 34 II) expertise of clinicians involved in the care of patients 
with Pompe disease; and III) on patient-reported information gathered via the IPA/
Erasmus MC Pompe Survey.3 35 As mentioned before, we could not demonstrate a change 
during the pre-treatment period, but after start of ERT the average QMFT increased for 
the total group (0.7 pp/y, P = 0.14), with significant increases observed in the milder 
affected patients (2.1 pp/y, P = 0.01) [Chapter 3.1].36
Main findings on the natural course in adults with Pompe disease
- For most patients the disease evolves gradually and slowly. Some patients remain fairly stable for 
a long time, others suffer from more rapid deterioration.
- Longer disease duration and distinct pulmonary involvement are usually associated with a fast 
decline in muscle strength.
- The average life expectancy of untreated adult patients is shorter than that of the general 
population.
Recommendations for clinical practice
- The advised minimal set of assessments for adults with Pompe disease should preferably include 
the six-minute walk test, manual muscle strength testing, pulmonary function tests ((F)VC) in 
upright seated and supine position, and functional tests.26
- Assessment scales preferentially should have good clinimetric properties, such as those based 
upon Rasch analysis.
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Fatigue
In recent years, the burden of fatigue in patients with Pompe disease and other neu-
romuscular diseases has gained more attention. In Pompe disease 24% of the patients 
reported fatigue as an initial symptom and 76% indicated that fatigue had an important 
impact on their daily life.3 In two subsequent publications of the IPA/Erasmus MC Pompe 
Survey 78-85% of Pompe patients reported to be fatigued (Fatigue Severity Scale (FSS) 
≥4) and 67-68% severely fatigued (FSS ≥5) [Chapter 4.3; Appendix B].37 38 The reported 
prevalence rates in Pompe disease and other neuromuscular diseases resemble those 
reported for multiple sclerosis (Table II) [Chapter 4.1].39-49
In many neurological disorders46 50-53 such as Pompe disease,38 the prevalence as well 
as the severity of fatigue partly depends on disease severity. An exception is formed by 
fatigue in Guillain-Barré syndrome (GBS), which may be due to the fact that this is an 
acute and monophasic disease, often preceded by an infection.45 46 Most patients with 
GBS experience long-lasting severe fatigue, which in part seems to be caused by axonal 
degeneration of the peripheral nerves.54 
In Pompe disease the pathophysiological mechanisms causing fatigue are not fully 
understood, although it seems plausible that the muscle pathology leads to an increase 
in muscle fatigability (peripheral fatigue) [Chapter 4.1].48 In McArdle disease, another 
metabolic myopathy, alterations in muscle metabolism impair skeletal muscle contrac-
tion.55 However, in Pompe disease the skeletal muscle glycogenolytic capacity is not im-
paired, as shown in a recent publication, and the reduced exercise capacity is more likely 
the result of muscle weakness and wasting.56 Moreover, as the limitations in muscle 
performance are perceived by the central nervous system (CNS), it is hypothesized that 
the CNS generates a constant feeling of fatigue (central fatigue) that initiates down-
regulation of activities. This may also protect the body from damage due to excessive 
exercise (central governor model).57
Table II Severe fatigue in neuromuscular disorders 
Neuromuscular disorder Prevalence of severe fatigue Fatigue scales
Pompe disease [Chapter 4.3] 37 38 67-68% FSS
Guillain-Barré syndrome (GBS) 43-46 49 38-86% FSS, FIS, VAS-F, R-FSS
Myasthenia gravis 42 82% FIS, MFI
Post-poliomyelitis syndrome 41 80% NA
Facioscapulohumural dystrophy (FSHD) 39 40 51-61% CIS
Myotonic dystrophy (DM) 39 40 53-74% CIS
Charcot-Marie-Tooth disease type 1 (CMT type 1) 39 40 55-64% CIS
CIS=Checklist Individual Strength; FIS=Fatigue Impact Scale; FSS=Fatigue Severity Scale; R-FSS=Rasch-build 
Fatigue Severity Scale; MFI=Multidimensional Fatigue Inventory; VAS-F=Visual Analogue Scale for fatigue; 
NA=not applicable.
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Respiratory dysfunction can also contribute to the perceived fatigue. This results from 
the decreased physical endurance on the one hand and on the other hand from noctur-
nal hypoventilation causing sleep disturbances.58 
In multiple sclerosis, cerebrovascular disease, and in spinocerebellar ataxia, depres-
sion has a substantial influence on the severity of fatigue.46 50 51 53 59 This seems not to be 
a major factor in Pompe disease given the only slightly lower perceived cognitive well-
being and low prevalence of depression.37 38 
Fatigue in Pompe disease can be managed in the following way: I) rule out other 
possible causes of fatigue; II) evaluate the pulmonary function both in sitting and su-
pine position and if necessary start mechanical ventilator support; III) screen for sleep 
disorders, including sleep-disordered breathing and install treatment when needed; and 
IV) optimize supportive care [Chapter 4.1]. The provided care involves several medical 
specialties, which emphasizes the importance of a multidisciplinary care program. The 
effect of ERT on fatigue is discussed in the subsequent paragraph. The recently con-
ducted training study evaluated the effect of physical exercise on experienced fatigue by 
adult patients with Pompe disease receiving ERT. The results are shortly awaited. In case 
training does have a positive effect on fatigue, just as observed in GBS patients,45 60 this 
should be incorporated into the care program for fatigued patients with Pompe disease. 
enzyme rePlacement theraPy
Effects of enzyme replacement therapy
The timely initiatives taken to start a prospective study in children and adults with 
Pompe disease and to initiate the IPA/Erasmus MC Pompe Survey have led to the unique 
situation that most treated patients were prospectively followed before they received 
ERT. It gave us the opportunity to compare the course of disease before and after the 
start of ERT. In this way we could demonstrate that ERT positively alters the natural 
course of Pompe disease in adults reflected by improved muscle strength and stabilized 
pulmonary function in upright position [Chapter 3.1]. Other studies also found great-
Main findings on fatigue in adults with Pompe disease
- Two-thirds of Pompe patients suffer from severe fatigue, which is comparable to the prevalence of 
severe fatigue in other neuromuscular disorders and in multiple sclerosis.
Recommendations for clinical practice
- It is important to realize that fatigue contributes to the perceived disability in patients with 
Pompe disease. Complaints of fatigue should be taken seriously and managed adequately by a 
multidisciplinary team.
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est effects on muscle strength and function (Table III),10 29 61-69 with the highest level of 
evidence coming from the only performed randomized-controlled trial on the effects of 
ERT (LOTS).29
Improvements in muscle strength reported by our group are more substantial than 
those reported by others,29 61 63 66-69 as over 45% of our patients were good responders, 
46% moderate responders, and only 9% did not benefit from ERT (Figure 1). The better re-
sponse in our study could have several reasons. One is that we were able to compare the 
disease progression before and after treatment and rated not only improvement but also 
slowdown of progression as a positive response. Another reason is that we could not cor-
rect for the placebo effect as was done in the randomized controlled clinical trial (LOTS). 
Other reasons for the difference could be that we included patients across the clinical 
spectrum, that we tested more muscle groups than others, and that we systematically 
followed a large group of patients for a long period (>500 measurements) as compared 
to other studies.29 63 66 68 69 In adult patients, the effect of ERT on muscle strength levels off 
with longer treatment duration.10 29 66 69 This trend was seen in LOTS, as patients obtained 
the largest improvement in walking distance within the first 6 months of treatment. Also 
our finding that the MRC sumscore did not develop linearly over a 36 months treatment 
period [Chapter 3.3] indicates that the muscle strength tends to stabilize after an initial 
increase following ERT. This all might indicate that the maximal regenerative capacity of 
the muscles is reached after a certain time of treatment. With respect to this matter, the 
awaited long-term treatment data are of great interest.
It was surprising that women would benefit more from ERT than men with respect 
to muscle strength. In retrospect, the subgroup analysis in LOTS also suggested a better 
response in women than in men.29 There is no real clue as to what factors might cause 
the difference; a difference in lean body mass, muscle fiber size and type (females have 
smaller muscle fibers, and therefore a higher ratio of muscle-fibre surface to muscle-fibre 
volume, favoring the mannose 6-phosphate-receptor mediated uptake of ERT), activity 
patterns, and sex hormone status are amongst the possibilities.
We were the first to report on the course of pulmonary function in supine position 
during ERT. Though we found an ongoing decline in FVCsupine at group level, it is hopeful 
that the rate of decline after start of ERT was about twice as slow as in the period prior 
to start of ERT. Moreover, in 61% of the patients the decline in FVCsupine was slowed down 
or halted by ERT (Figure 1). The group of non-responders for FVCsupine was characterized 
by older age and more advanced disease status at start of ERT. These findings likely imply 
that loss of diaphragmatic function is more difficult to restore than the loss of skeletal 
muscle function, especially in the older and more severely affected patients. A similar 
observation was made in GAA knock-out mice: ERT restored skeletal muscle better than 
the diaphragm.70 The difference might be related to an effect of age on diaphragmatic 
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function. For instance, it was published that diaphragms of old rats compared to young 
rats have a slower contraction and relaxation speed due to changes in the Ca2+-ATPase 
activity of the sarcoplasmic reticulum and changes in the major myosin heavy-chain 
isoform composition.71 Whatever the reason, timely start of ERT seems especially impor-
tant for the preservation of pulmonary function. A currently conducted pilot-study uses 
cine MRI for investigating respiratory muscle movement in adult patients. The method 
provides insight in the extent of diaphragm dysfunction and may be a useful tool for 
monitoring treatment response in Pompe disease (S.C.A. Wens et al, submitted).
As postulated before, fatigue clearly impairs Pompe patients in their everyday lives. 
Thus, it is an encouraging finding that ERT reduces the level of experienced fatigue on a 
group level [Chapter 4.3]. Also here, women and patients with a shorter disease duration 
may experience a more distinctive improvement (results did not reach statistical signifi-
cance). The recently conducted training study performed in our center also assessed the 
additional effect of exercise on self-experienced fatigue in adult patients receiving ERT. 
The results are shortly awaited.
On the basis of the current clinical experience with ERT, it seems that all patients with 
a confirmed diagnosis of Pompe disease, who are clearly symptomatic should best start 
with ERT unless there are counter indications such as co-morbidities. It seems justified 
to postpone ERT, if patients have only a raised serum creatine-kinase or very limited 
limb-girdle muscular weakness without pulmonary involvement. In those cases the 
best strategy for determining the start of ERT is regular monitoring using standardized 
protocols. In this way, the best guarantee is obtained that any change in the patients’ 
clinical condition will be noticed. Treatment with alglucosidase alfa every other week can 
be experienced by the patient as a burden and is very expensive. Thus, the decision to 
Main findings on enzyme replacement therapy (ERT) in adults with Pompe disease
- ERT positively alters the natural course of Pompe disease in affected adults.
- ERT improves muscle strength and halts further decline in pulmonary function (upright position) 
in the majority of patients.
- Despite ERT, progression of pulmonary dysfunction in supine position continues in 39% of the 
patients.
- ERT reduces the burden of fatigue.
- Female gender, younger age, and better clinical status seem to be predictive factors for favorable 
disease outcome. 
Recommendations for clinical practice
- The expert opinion is to start ERT in clearly symptomatic patients with a confirmed diagnosis 
of Pompe disease, especially when pulmonary function is affected. In asymptomatic patients or 
patients with very mild limb-girdle weakness and a stable disease course, it seems justified to 
apply a watch and wait policy.  
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start treatment should be made carefully and should be made by a group of specialists 
in the field (indication committee). 
Anti-alglucosidase alfa antibody response
Our findings and those of others show that ERT improves the patient’s prospects and 
slows or halts disease progression in 60-90% of patients (Table III). However, with 
growing experience it is also recognized that not all patients benefit equally from ERT, 
and that there are marked variations in treatment response. In classic-infantile Pompe 
disease, part of this variation is clarified by the development of high sustained antibod-
ies titers attenuating treatment efficacy.72 73 Also in other lysosomal storage diseases, 
immune responses to recombinant enzymes are a well-known phenomenon, since these 
are encountered in treated patients with Gaucher disease,74 Fabry disease,75-78 and Muco-
polysaccharidosis type I, II and VI (Table IV).79-83 The proportion of patients that develop 
antibodies varies from 2% to 100%, with the lowest proportions seen in Gaucher disease. 
The biggest concern is that antibodies may impair the efficacy of the infused protein, but 
no adverse effects of antibody formation on therapeutic efficacy could be demonstrated 
in these other lysosomal storage diseases. 
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MRC  s ums core
31 (45%)
32 (46%)
Non-responders
Moderate responders
Good responders
FVC  in s upine pos ition
21 (39%)
17 (31%)
16 (30%)
FVC  in upright pos ition
9 (15%)
27 (44%)
26 (42%)
6 (9%)
Figure 1 Individual response groups for skeletal muscle strength and pulmonary function
The number and percentage of good responders, moderate responders and non-responders are shown for 
MRC sumscore, and forced vital capacity (FVC) in upright and supine positions.
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In adults with Pompe disease, it was anticipated that antibody formation would not 
play a substantial role in treatment outcome since most of these patients produce a 
fair amount of acid α-glucosidase themselves. This was corroborated by the findings of 
LOTS, wherein all 59 treated patients did develop antibodies, but not to such extend 
that the effect of treatment was annihilated. In one of our adult patients and in three 
patients reported by Patel et al.,84 high sustained antibody titers however coincided with 
progressive disease and persisting IARs during ERT [Chapter 3.2].85 By performing phar-
macokinetic studies in our patient with a very high antibody titer it was demonstrated 
that the patient’s anti-rhGAA antibodies captured 40% of the administered alglucosi-
dase alfa and inhibited in vitro uptake of enzyme and enzyme activity. In a subsequent 
study, we investigated the potential impact of antibodies on the treatment safety and 
efficacy in a large group of adult patients [Chapter 3.3]. Of the 73 patients, 71 (97%) 
developed any titer of antibodies against alglucosidase alfa. The mean titer peaked at 6 
months after start of ERT to 1:1259 and declined to 1:270 at 36 months of ERT. In vitro, 
high titers of anti-alglucosidase alfa antibodies had neutralizing effects on the activity 
of alglucosidase alfa in the medium and in the target cells to a similar extent, indicating 
that the predominant and relevant effect of the antibodies was inhibition of enzymatic 
activity rather than inhibition of uptake of alglucosidase alfa by the cells (cultured fully 
GAA deficient fibroblasts).
The findings obtained by in vitro studies did not correspond fully with the clinical 
findings since no statistical significant differences were found in treatment outcome 
across patients with high (≥1:31,250), intermediate (1:1250 -<1:31,250) and low or no 
(0 - 1:1250) antibody titers towards alglucosidase alfa. We did find an increased risk for 
IARs in patients with higher antibody peak titers: 44% of the patients with high titers 
experienced IARs, 19% of the patients with intermediate titers, and a mere 3% of the 
patients with a low or no titer. An explanation for the clinical deterioration in the few re-
ported cases with very high antibody titer,29 84 85 could be that there are some particularly 
destructive epitope-binding sites (Figure 2).86   
Based on our findings and those of others,29 84 85 the immune response to alglucosidase 
alfa  has a far lower impact on treatment outcome in adults than in infants with regard 
to muscle strength and pulmonary function. Thus, in adults there seems no need for 
the implementation of tolerance inducing therapies such as rituximab combined with 
methotrexate and intravenous immunoglobulins or omalizumab as has been practiced 
in classic infantile Pompe disease.87 88 Patients, who develop low or no antibody titers 
(<1:1250) within the first 6 months of ERT, have a very low risk of IARs. Thus they can 
be transferred earlier to home treatment. On the other hand close monitoring of IARs 
remains important in patients with substantial antibody titers (≥1:1250). 
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Figure 2 Impact of neutralizing antibody on enzyme uptake and activity in ERT
A There are several steps by which therapeutic enzymes for Pompe disease and other lysosomal storage 
diseases can influence effectiveness. First, uptake of the enzyme (E) is mannose-6-phosphate (M6P) 
receptor-mediated, endocytosed by clathrin-coated vesicles (CCV) and fused with endosomes and then 
with lysosomes, where enzymatic activity breaks down the accumulated substrate. There are several 
possible outcomes of the binding of lysosomal enzyme–specific antibodies (yellow ‘Y’): blockade of 
enzyme uptake through M6P-receptor by binding to the receptor binding or uptake domain(s) (UD; 
domains containing exposed M6P); blockade of enzyme uptake by M6P-receptor and suppression of 
enzymatic activity by binding to epitopes near the receptor binding domain and the enzymatic activity 
domain (AD; theoretical); blockade of both uptake and activity domains by separate antibodies specific 
for each site; degradation of the enzyme by catalytic antibody (red ‘Y’); reduction of enzymatic activity 
by targeting the enzymatic domain; prevention of enzyme maturation by targeting the enzyme protease 
processing sites (PS); and targeting of other sites (OS) of the enzyme, resulting in conformational or 
trafficking changes. B Binding of antibodies to enzyme may redirect the enzyme to FcR-expressing cells, 
such as macrophages and B cells. Enzyme–antibody complexes internalized through FcRs may prevent 
proper translocation of functional enzymes to the lysosome. Binding of antibody to other domains of 
the enzyme may change pharmacokinetics or redirect the enzyme to FcR-expressing cells. IC, immune 
complex. This figure originates from Wang et. al. Neutralizing antibodies to therapeutic enzymes: 
considerations for testing, prevention and treatment. Nature Biotechnology 2008, by permission of the 
Nature Publishing Group. 
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Enzyme replacement therapy during pregnancy and lactation
In other lysosomal storage diseases the experience with continuation of ERT during 
pregnancy, though in much lower dosages than in Pompe disease, did not suggest major 
problems for the unborn child of the treated mother. Based on this experience together 
with the reporting of normal fetal development in mice and rabbits treated with alglu-
cosidase alfa, 89-93 we assumed that the continuation of ERT during pregnancy would 
not pose a substantial risk for the mother and her child. Our first patient, a 40-year old 
woman, had been receiving ERT for 17 months before she became pregnant. She had 
moderate limb-girdle weakness and used non-invasive nightly ventilation. Her FVC in 
seated position was 44% of predicted and dropped to 31% predicted in the supine posi-
tion. Close monitoring of the pregnancy showed that there were no maternal complica-
tions and the child developed normally [Chapter 3.4].94 Very low levels of alglucosidase 
alfa were detected in the breast milk on the day of infusion. Within 24 hours, the activity 
level in the breast milk was back to the pre-infusion level. Therefore, there seems little 
rationale to entirely refrain from breastfeeding while mothers are on ERT. To be on the 
safe site, we advise our patients to discontinue breastfeeding on the day of the infusion. 
Our experience with a second pregnancy case (unpublished results) and a pregnancy 
case reported by Zagnoli et al. 95 also indicated that ERT can be safely administered 
during pregnancy. Since it concerns only single case-reports, we underline that careful 
monitoring of each pregnancy remains important.
Main findings on antibodies and continuation of ERT during pregnancy and lactation
- The majority of ERT treated adult Pompe patients develop antibodies against alglucosidase alfa.
- Antibodies against alglucosidase alfa are associated with an increased risk for infusion-associated 
reactions
- In the majority of patients with high titer antibodies, no adverse effects on clinical outcome could 
be demonstrated. 
- Continuation of ERT during pregnancy and lactation seems safe for mother and child.
Recommendations for clinical practice
- Immune surveillance in ERT treated children and adults with Pompe disease remains important 
for investigating whether anti-alglucosidsae alfa antibodies have adverse effects on long-term 
treatment outcome.
- Early implementation of home treatment is justified in patients who do not develop a substantial 
antibody response (≤1:1250) in the first 6 months of treatment.
- There seems no need for the discontinuation of ERT in pregnant and breastfeeding women with 
Pompe disease. 
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future PersPectives
The findings described in this thesis demonstrate that the introduction of ERT has 
altered the lives of Pompe patients in a positive way. They also demonstrate that the 
implementation of a new treatment involves new challenges, such as the fact that we 
are still poorly able to explain the observed variability in response. By deciphering the 
mechanisms that hamper treatment efficacy we might be able to improve the thera-
peutic efficacy of ERT. At the same time, scientific efforts are ongoing to develop the 
ultimate curative treatment for this disease.
Improving the efficacy of enzyme replacement therapy
The following approaches can or may increase the therapeutic efficacy of ERT: I) shorten-
ing the delay in diagnosis; II) establishing predictive factors for treatment outcome; III) 
glycoengineering of rhGAA; IV) peptide modification of rhGAA; V) dose augmentation; 
and VI) chaperone therapy as an add-on to ERT.
As mentioned earlier, there is much to be gained by shortening the diagnostic delay, 
because of the presence of substantial disability in the majority of the patients at time 
of diagnosis that could have been prevented by a timely diagnosis and subsequent start 
of ERT.14 Shortening of the diagnostic delay can be accomplished by further increasing 
the disease awareness. In essence the best way to prevent a diagnostic delay is newborn 
screening. However, since the majority of patients become symptomatic later in life, a 
drawback to making a diagnosis just after birth is that it creates a lot of ‘patients-in-
waiting’.96 The feasibility of newborn screening is currently subject of study. 97-100 The pros 
and cons are being carefully considered, before a final decision will be made whether to 
add Pompe disease to the newborn screening program. 
Studying predictive factors for treatment outcome is a challenge in Pompe disease, 
as statistical power is often limited by the small sample sizes inherent to rare disorders. 
For this reason, it is essential to collect reliable data in the context of large international 
collaborative studies or international patient registries. In this way enough power is 
generated for applying a full multivariate model and developing a prognostic model for 
individual treatment outcome. Such a model could assist in clinical decision making for 
the individual patient and in developing treatment guidelines. Real progress is awaited 
this year, as the topic of the upcoming ENMC meeting this September is about the for-
mation of a European network to develop treatment guidelines and prognostic models 
for non-classic Pompe disease. 
Approach III, IV and V are methods for enhancing the uptake of alglucosidase alfa in 
the most affected tissues. As shown in a GAA knock-out mice model, most of the recom-
binant enzyme is captured by the liver and the spleen, and only a minor fraction is taken 
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up by the heart and the skeletal muscle tissue.101 By enhancing the uptake by skeletal 
muscle tissue, the therapeutic efficacy could be improved.
Dose augmentation is the easiest way to ameliorate the therapeutic effect of ERT. In 
classic infantile Pompe disease there is increasing evidence that a weekly dose of 40 mg/
week improves ventilator-free survival and motor outcome compared to the currently 
recommended dose of 20 mg/kg every other week (eow).102 103 Based on theoretical phar-
macokinetic modeling based, it is supposed that weekly dosing, and not per se higher 
dosing contributes most to the better clinical outcome.102 This is supported by the find-
ings of the only conducted (open) study in classic-infantile Pompe disease comparing 
a dosing schedule of 20 mg/kg eow to 40 mg/kg eow.104 No differences with regard to 
safety and therapeutic efficacy over a 3 years of treatment were observed. In children 
and adults there is only one single case report about the improvement of ptosis in a 
17-year old adolescent with Pompe disease after increasing the dose from 20 mg/kg 
to 40 mg/kg, every other week.105 It would be of interest to systematically study the 
effect of dose augmentations in childhood and adult Pompe disease. With higher dosing 
one should realize that the costs of treatment increase as well as the risk for antibody 
response and IARs.106  
Glycoengineering, explained below is an alternative way to enhance the uptake of 
recombinant human acid α-glucosidase by muscle tissue. The uptake of alglucosidase 
alfa is mannose 6-phosphate (M6P)-receptor mediated, however the currently produced 
recombinant human alglucosidase alfa has low numbers of M6P groups. In vitro studies 
have shown that the uptake of acid α-glucosidase by cultured fibroblasts and muscle 
cells improves when the number of M6P-moieties increases. Enrichment of the enzyme 
with M6P-moieties can either be accomplished by genetic plus enzymatic engineering 
(hypermannose-6-phosphorylated enzyme (HP-GAA)) or by the chemical conjugation of 
synthetic oligosaccharides bearing M6P residues (neo-rhGAA/oxime-neo-rhGAA).107-110 
The intended gain would be that the treatment efficacy per milligram infused recom-
binant enzyme increases. The method of carbohydrate modification bears the risk of 
increasing the immunogenicy of the recombinant enzyme and it is therefore important 
to compare the safety profile of glycoengineered forms of recombinant human acid 
α-glucosidase with the currently used alglucosidase alfa. Moreover, as the production 
process of alglucosidase is already quite costly, the question is whether additional 
manufacturing steps will not lead to even higher costs. 
The development of the peptide modified alternative form of ERT, BMN 701 (BioMarin) 
is ongoing. The start of the phase 2/3 study (ClinicalTrials.gov: NCT01924845) is planned 
for this year. BMN 701 is a fusion of insulin growth factor 2 (IGF-2) and GAA, and takes 
advantage of the fact that the peptide IGF-2 also binds to the M6P receptor. Therefore, 
BMN 701 can be taken up into the muscle cells via the M6P receptor. The results of the 
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phase 1/2 study with a follow-up of 24 months in 16 patients showed improvements in 
the distance walked during the 6MWT and in FVC in upright seated position comparable 
to the findings of LOTS. Effects on MIP and MEP were more pronounced. 
Another recent development is the application of chaperone therapy as an add-on to 
ERT. Chaperone therapy is based on the principle that missense mutations can lead to 
improperly folded or unstable proteins. Chaperones are small molecules that selectively 
bind to the enzyme thereby stabilizing its structure and improving intracellular traffick-
ing to the lysosomes.111 A disadvantage of this therapy is that it only fits certain missense 
mutations and will certainly not have an effect on null-mutations, frameshift mutations, 
and splice site effects.112  
The first clinical application of chaperone therapy as a monotherapy for Pompe dis-
ease has been unsuccessful, because of the occurrence of severe side effects in two adult 
Pompe patients in a phase 2 study. The patients developed progressive muscle weakness 
and a marked rise in serum creatinine-kinases. This adverse effect is best explained by 
inadequate dosing, whereby persistent binding of the chaperone to endogenous acid 
α-glucosidase might block the catalytic site permanently and increase the enzyme defi-
ciency. The inhibitory effect of the administered chaperone on intestinal maltase activity 
was not mentioned to play a role, but might have contributed to the general malaise of 
the patients receiving chaperone therapy as monotherapy in Pompe disease. To overcome 
this problem, new chaperones have recently been identified (e.g. N-acetylcysteine) that 
do not bind to the active-site of the enzyme and therefore do not counteract enzyme 
function.113 114 
Subsequent research has focused on whether chaperones might have a synergistic 
effect as adjuvant to ERT with alglucosidase alfa. In vitro studies as well as studies car-
ried out in GAA knock-out mice have shown that chaperone therapy combined with ERT 
increases the lysosomal α-glucosidase activity and the lysosomal glycogen clearance.115 
116 The results of clinical studies performed in patients with Pompe disease are awaited. 
Future therapies 
Since the effectiveness of ERT depends on life-long intravenous enzyme administrations, 
imposing a burden to the patients, there remains a demand for curative, even more ef-
fective, or less invasive intervention. 
Gene therapy uses the principle of transferring an intact copy of acid α-glucosidase 
cDNA to the cells of a Pompe patient, thereby generating a constant production of the 
enzyme. Previous in vitro and in vivo studies are supportive for the practicability of 
gene therapy in Pompe disease. For delivery of the GAA gene construct, retroviral and 
adenoviral vectors expressing human acid α-glucosidase were studied in in vitro experi-
ments. This resulted in the production of catalytically active acid α-glucosidase with ac-
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tual reduction of the lysosomal glycogen content.117-121 In vivo studies performed in GAA 
knockout mice showed that intramuscular or intramyocardial injections of the vectors 
led to acid α-glucosidase expression in only the directly adjacent areas, but not in distant 
muscle groups118 122 123 Transduction of hepatic cells with adeno-associated viral vectors 
carrying the GAA cDNA construct was successful and resulted in sufficient production 
of acid α-glucosidase and secretion in the circulation with subsequent uptake in the 
skeletal muscles. Unfortunately, the previously used strategies induced fierce immune 
responses hampering the long-term efficacy of this treatment.124-126
The fact that the diaphragm is rather unresponsive to ERT has led to the initiation of 
a Phase I/II trial wherein an acid α-glucosidase expression construct based on adeno-
associated virus technology (rAAV1-CMV-GAA) is directly injected into the diaphragm. 
The results of this study are awaited in 2016 (ClinicalTrials.gov: NTC00976352).
Hematopoietic stem-cell transplantation (HSCT) replaces lineages of blood stem-cell 
derived enzyme deficient cells by proficient cells with a chance that the enzyme produced 
by the donor cells spreads to other cells and tissues. Theoretically, the transplanted cells 
can serve as permanent source of newly synthesized acid α-glucosidase, which can be 
taken up by the enzyme deficient skeletal muscle cells.127 So far, the clinical applica-
tion of HSCT for the treatment of lysososmal storage disorders is limited to a subset 
of patients with mucopolysaccharidosis type 1 (Hurler syndrome), Krabbe disease, and 
metachromatic leukodystrophy. HSCT has been unsuccessful in the few patients with 
Pompe disease that underwent this treatment.128 129 Several recent studies indicate that 
HSCT using Lentiviral vectors may become a promising approach in the future.130-132 The 
first results of a clinical trial in another lysosomal storage disorder than Pompe disease 
have been published. 
final remarks
Important steps forward have been made, and further steps can be made by combining 
specialized multidisciplinary care with clinical and fundamental research as has materi-
alized in our Center of Lysosomal and Metabolic Diseases at Erasmus MC. As explicated 
in this thesis, the introduction of enzyme replacement therapy has had a great impact 
Future directions
- Nationwide and international collaboration is needed to estimate the long-term effects of ERT 
and to develop prognostic models by which the treatment for individual patients can be optimized 
and define start and stop criteria further. 
- Improvement of the efficacy of ERT starts with timely diagnosis and timely treatment with an 
optimal dosing regimen. New products and new approaches can be of further help.
- The development of gene therapy based strategies has to be pursued with great energy in order 
to obtain curative intervention in the near future.
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on the prospects for patients with Pompe disease. But, there is undoubtedly room for 
further improvement. Currently, European collaboration is ongoing aiming at identifying 
predictive factors for treatment response and developing uniform treatment guidelines. 
Clinical studies on the efficacy of ERT with new products will start soon, and the results 
are eagerly awaited. Meanwhile, the development of gene  therapy is actively pursued. 
These combined efforts will hopefully gradually change the life of Pompe patients for 
the better.
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Pompe disease is an autosomal recessive metabolic myopathy caused by a deficiency of 
the lysosomal enzyme acid α-glucosidase due to mutations in the GAA gene. Infants with 
a total deficiency accumulate glycogen in almost all their tissues, but primarily manifest 
skeletal and cardiac muscle pathology. Children and adults with a partial deficiency pres-
ent the first symptoms later in life, and the pathologic changes emerge mainly in skeletal 
muscle tissue. Without enzyme replacement therapy (ERT), affected infants have a life 
expectancy of maximally 2 years. The majority of diagnosed adults eventually becomes 
wheelchair-bound and dependent on mechanical ventilation when they are not treated. 
This thesis focuses on adults with Pompe disease.
Enzyme replacement therapy (ERT) using alglucosidase alfa (Myozyme®) is the first 
disease-specific treatment for an inherited neuromuscular disorder, which makes the 
situation for Pompe disease rather unique. Registration of ERT in 2006 was predomi-
nantly based on the positive results obtained from clinical trials performed in infants 
with classic infantile Pompe disease. Information on the effects and safety of the use of 
alglucosidase alfa in children and adults with Pompe disease was limited at start of the 
research described in this thesis.
For that reason, the Dutch nationwide prospective observational study on the natural 
course and the effects of ERT in children and adults with Pompe disease started in 2004 
at Erasmus MC. In addition, patient-reported information on handicap, quality of life 
and fatigue was gathered via the international IPA(International Pompe Association)/
Erasmus MC Pompe Survey. 
The scientific work presented in this thesis is focused on the clinical manifestations, 
natural history, and the effects and safety of treatment with alglucosidase alfa in adult 
Pompe disease. The aims were to investigate: 1) the clinical features and natural course; 
2) the effects of ERT and prognostic factors for treatment response; 3) the impact of 
anti-alglucosidase alfa antibody formation on clinical outcome in patients treated with 
ERT; and 4) whether the continuation of ERT was safe during pregnancy and lactation. 
The final aim was to describe the burden of fatigue in neuromuscular diseases, with a 
focus on Pompe disease and Guillain-Barré syndrome, and to evaluate the effect of ERT 
on fatigue in adults with Pompe disease.
Chapter 1 – the General Introduction – provides information on the clinical spectrum 
and manifestations, diagnosis, pathogenesis and treatment of Pompe disease. The end 
of this chapter accounts for the scope and the aims of the thesis.   
In Chapter 2.1 the clinical manifestations, natural course and predictors for disease 
progression are described in a cohort of 94 patients with a median age of 51 years (range 
25 to 75 years). Data were prospectively collected at Erasmus MC between October 2004 
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and August 2009 in the context of the previously mentioned Dutch nationwide study. 
Skeletal muscle weakness was characteristically distributed in the limb-girdle pattern. 
Less well-known features of the disease were far more common than previously thought, 
as illustrated by the finding that ptosis occurred in 23%, bulbar weakness in 28%, and 
scapular winging in 33% of the patients. During the study, skeletal muscle strength 
declined significantly with a mean of -1.3 percentage points per year (pp/y) for manual 
muscle testing and -2.6 pp/y for hand-held dynamometry (both P <0.001). On average, 
forced vital capacity in supine position deteriorated by -1.3 pp/y (P =0.02). Ten percent 
of patients declined unexpectedly fast. Longer disease duration and reduced pulmonary 
function were predictors of a more rapidly decline of skeletal muscle strength. Chapter 
2.2 encompasses the first international study reporting on survival in adult Pompe dis-
ease. Results were calculated based on follow-up data with a mean of 3.5 years in a total 
of 268 untreated adult patients participating in the IPA/Erasmus MC Pompe Survey. By 
comparing the number of deaths to the expected number of deaths in the Dutch general 
population, it was shown that the mortality rate was higher in patients with Pompe dis-
ease. The estimated 5-year survival rate from diagnosis was 95%. The 10, 20, and 30 year 
survival rates were appraised at 83, 65, and 40%. Predictors of a higher mortality rate 
were wheelchair use, mechanical ventilation and a higher level of disability as measured 
with the Rotterdam-Handicap Scale. 
Chapter 3 focusses on the effects and safety of ERT in adult patients with Pompe dis-
ease. In Chapter 3.1 the effects of ERT as observed in the Dutch nationwide prospective 
study are described and contrasted to the natural disease course. In 69 patients with a 
median age of 52 years (range 26 to 76 years) muscle strength increased on average with 
1.4 pp/y for manual muscle testing and with 4.0 pp/y for hand-held dynamometry over a 
median treatment duration of 23 months (both P <0.001). Pulmonary function remained 
stable when measured in upright position, but declined in supine position (-1.1 pp/y; P 
=0.03). As compared to the natural course, ERT had a beneficial effect on muscle strength 
(manual muscle testing 3.3 pp/y; hand-held dynamometry 7.9 pp/y; both P <0.001). A fa-
vorable prognostic factor for treatment related outcome with regard to muscle strength 
was female gender. Favorable prognostic factors for a better treatment outcome with 
regard to pulmonary function (supine) were younger age, less severe limb-girdle muscle 
weakness and better pulmonary status at start of ERT. Chapter 3.2 reports on an adult 
patient with Pompe disease, suffering from ongoing disease progression and continued 
infusion-associated reactions during treatment with alglucosidase alfa, who developed 
a high sustained antibody response towards the administered enzyme. It was calculated 
that the concentration of antibodies in the patient’s blood was so high that they would 
capture approximately 40% of the administered alglucosidase alfa. When tested in vitro, 
the antibodies substantially inhibited the uptake of alglucosidase alfa by cultured fibro-
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blasts. These findings are indicative of neutralizing effects of antibodies on therapeutic 
efficacy. In Chapter 3.3 it is demonstrated that 71 of the 73 (97%) adult patients develop 
antibodies to alglucosidase alfa. The mean titer peaked at 6 months to 1:1259 declining 
to 1:270 after 36 months of ERT. Individual titers and titer courses varied, but in the 
majority (93%) of patients titers decreased or stabilized with continued enzyme replace-
ment therapy. In vitro studies demonstrated that the higher the antibody titer, the more 
the activity of alglucosidase alfa was inhibited. The proved adverse in vitro effect was not 
reflected in the in vivo findings, as no clear adverse effect of high antibody titers could 
be demonstrated on clinical outcome. We did find that the risk for infusion-associated 
reactions increased with higher peak titers (P =0.001). In Chapter 3.4 we describe our 
experience with a 40-year-old woman with Pompe disease, who continued receiving ERT 
during pregnancy and lactation. A healthy boy was born at a gestational age of 37 weeks 
and 5 days by elective Cesarean section. There were no maternal complications and the 
child developed normally. Alglucosidase alfa was secreted into the breast milk at very 
low levels during the infusion, but 24 hours after start of the infusion the enzyme activ-
ity in the breast milk was back to the pre-infusion level. Based upon these findings, the 
continuation of treatment with alglucosidase alfa during pregnancy and lactation seems 
safe for both mother and child.
Chapter 4 addresses excessive fatigue, which is a frequently encountered complaint 
in patients with a neuromuscular disease. In Chapter 4.1 the pathophysiological 
mechanisms of fatigue and its burden are reviewed with a focus on Pompe disease and 
Guillain-Barré syndrome. Prevalence rates of fatigue in neuromuscular disorders com-
pare to the high levels of experienced fatigue reported in multiple sclerosis. Fatigue can 
be subdivided into experienced fatigue and physiological fatigue, physiological fatigue 
subsequently in central and peripheral fatigue. In neuromuscular disorders, peripheral 
fatigue is an important contributor. Nevertheless, in reaction to the pathology in the 
peripheral nervous system, fatigue of central origin can also be an important protective 
mechanism restricting further damage (central governor model). Severity of fatigue 
seems to be related to disease severity, possibly with the exception of fatigue occurring 
after a monophasic disorder like Guillain–Barré syndrome. Fatigue in neuromuscular dis-
ease can be managed by symptomatic treatment of the underlying disease, exercise and 
cognitive behavioral therapy. In Chapter 4.2 we present a case of Pompe disease with an 
uncommon clinical presentation characterized by severe fatigue and myalgia prior to the 
onset of limb-girdle weakness. Remarkably, the muscle biopsy demonstrated selective 
involvement of type 1 muscle fibers. It is hypothesized that this finding might contribute 
to the uncommon clinical presentation of this patient. In Chapter 4.3 the effects of ERT 
on experienced fatigue in 163 patients participating in the IPA/Erasmus MC Pompe Sur-
vey are reported. The follow-up included a median period of 4 years before start of ERT 
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and of 3 years during ERT. Fatigue severity levels measured with the fatigue severity scale 
(FSS) remained stable at around 5.3 points before start of ERT. During ERT, a reduction in 
the average experienced fatigue was measured, as scores improved significantly by 0.13 
per year (P <0.001). 
Chapter 5 – the General Discussion – outlines the most important findings, compares 
them to relevant medical literature, and translates them into recommendations for 
clinical practice. Also potential methods to innovate ERT, new treatment strategies and 
future research are discussed.
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De ziekte van Pompe is een autosomaal recessieve metabole spierziekte, die ontstaat 
door een deficiëntie van het lysosomale enzym zure α-glucosidase, welke wordt 
veroorzaakt door mutaties in het GAA gen. Patiënten met de klassiek-infantiele vorm 
van de ziekte zijn volledig deficiënt voor het enzym. Dit leidt tot snelle stapeling van 
glycogeen in vrijwel alle lichaamsweefsels, met de meest uitgesproken pathologische 
veranderingen in dwarsgestreept spierweefsel en in het hart. Bij kinderen en volwas-
senen met een gedeeltelijke deficiëntie openbaart de ziekte zich op latere leeftijd, en de 
pathologische veranderingen treden met name op in de skeletspieren. Voordat behande-
ling beschikbaar kwam, hadden baby’s met de klassiek-infantiele vorm een maximale 
levensverwachting van twee jaar. De meerderheid van de volwassen patiënten wordt 
uiteindelijk rolstoel- en beademingsafhankelijk. Dit proefschrift richt zich op volwassen 
patiënten met de ziekte van Pompe.
Enzymvervangingstherapie (ERT) met alglucosidase alfa (Myozyme®) is de eerste 
ziekte-specifieke behandeling voor een erfelijke neuromusculaire ziekte. De registratie 
van het medicijn is tot stand gekomen in 2006 op basis van de positieve ervaringen met 
de behandeling met ERT van klassiek-infantiele patiënten. Gegevens over de behandelef-
fecten en de veiligheid van ERT bij kinderen en volwassenen met de ziekte van Pompe 
waren op het moment van registratie en ten tijde van de start van het onderzoek be-
schreven in dit proefschrift nog beperkt voorhanden.
Om hier meer gegevens over te verkrijgen is in 2004 de Nederlandse prospectieve 
observationele studie naar het natuurlijke ziektebeloop en de behandeleffecten van ERT 
in kinderen en volwassenen met de ziekte van Pompe van start gegaan in het Erasmus 
MC. Daarnaast werden patiënt-gerapporteerde uitkomsten met betrekking tot handi-
cap, kwaliteit van leven en vermoeidheid verzameld in het kader van het internationale 
IPA (International Pompe Association)/Erasmus MC Pompe vragenlijst onderzoek.
Het onderzoek in dit proefschrift heeft betrekking op de klinische presentatie, het 
ziektebeloop, en de effecten en veiligheid van ERT bij volwassenen met de ziekte van 
Pompe. De doelstellingen van het onderzoek waren: 1) het uitgebreid beschrijven van 
het klinisch beeld en het ziektebeloop van de ziekte van Pompe; 2) het bepalen van de 
effecten van ERT en prognostische factoren voor het behandeleffect; 3) het effect van 
antilichaamvorming op het behandeleffect van ERT onderzoeken; en 4) de veiligheid 
van ERT onderzoeken tijdens zwangerschap en lactatie. Als laatste hebben we ernstige 
vermoeidheid bij patiënten met neuromusculaire ziekten beschreven, geïllustreerd aan 
de hand van vermoeidheid bij de ziekte van Pompe en het Guillain-Barré syndroom. 
Daarnaast hebben we gekeken naar het effect van ERT op vermoeidheid bij volwassenen 
met de ziekte van Pompe.  
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In Hoofdstuk 1 – de algemene inleiding – wordt achtergrondinformatie gegeven over 
het klinisch beeld, ziektebeloop, diagnose, pathogenese en behandeling van de ziekte 
van Pompe. Op het einde worden de doelstellingen van het onderzoek uiteengezet.
Hoofdstuk 2.1 geeft een uitgebreide beschrijving van het klinisch spectrum en het 
natuurlijke ziektebeloop van 94 patiënten met een mediane leeftijd van 51 jaar (range 
25 tot 75 jaar). Tussen oktober 2004 en augustus 2009 zijn de gegevens verzameld in het 
kader van de eerder genoemde nationale prospectieve studie uitgevoerd door het Eras-
mus MC. We vonden dat de spierzwakte volgens het limb-girdle patroon was verdeeld. 
Minder bekende uitingen van de ziekte kwamen veel vaker voor dan op voorhand gedacht. 
Ptosis werd in 23%, bulbaire zwakte in 28%, en scalpula alata in 33% van de patiënten 
gezien. Gedurende de studie verslechterde de spierkracht met -1.3 percentagepunten 
per jaar (pp/jaar) voor de handmatige geteste spierkracht en met -2.6 pp/jaar voor 
spierkracht gemeten middels hand-held dynamometrie (beide P <0.001). De gemiddelde 
achteruitgang van de longfunctie in liggende houding was -1.3 pp/jaar (P =0.02). Tien 
procent van de patiënten vertoonde een onverwacht snelle achteruitgang. Een langere 
ziekteduur en een slechtere longfunctie bij aanvang van de studie waren voorspellers 
van een snellere achteruitgang in spierkracht. Hoofdstuk 2.2 betreft de eerste studie 
naar de levensverwachting van volwassenen met de ziekte van Pompe. De resultaten zijn 
berekend over een gemiddelde follow-up van drieënhalf jaar van in totaal 268 patiënten 
die deelnamen aan het IPA/Erasmus MC onderzoek. Door het aantal overleden patiënten 
te vergelijken met de verwachte sterfte in de Nederlandse bevolking kwam naar voren 
dat volwassenen met de ziekte van Pompe een hogere sterftekans hebben. De verwachte 
vijfjaarsoverleving is 95%. De 10, 20 en 30-jaarsoverleving zijn respectievelijk 83, 65, en 
40%. Patiënten met een ernstigere mate van handicap (Rotterdam-Handicap Scale) en 
die een rolstoel en/ of beademing gebruikten hebben een hoger overlijdensrisico.  
Hoofdstuk 3 beschrijft de effecten en de veiligheid van het gebruik van ERT bij vol-
wassenen met de ziekte van Pompe. In hoofdstuk 3.1 worden de effecten van ERT zoals 
onderzocht in de nationale prospectieve studie beschreven, vergeleken met het ziekte-
beloop voor start van de behandeling. In 69 patiënten met een gemiddelde leeftijd van 
52 jaar (range 26 tot 76 jaar) nam op groepsniveau de spierkracht toe met 1.4 pp/jaar 
zoals gemeten met gebruikmaking van de handmatige spierkrachtmeting (MRC) en met 
4.0 pp/jaar voor de kwantitatieve spierkrachtmeting (HHD; hand held dynamometrie) 
gedurende een gemiddelde behandelduur van 23 maanden. De longfunctie in zittende 
houding stabiliseerde op groepsniveau, maar de longfunctie gemeten in liggende hou-
ding ging ondanks behandeling met ERT verder achteruit met -1.1 pp/jaar; (P =0.03). In 
vergelijking met het natuurlijke ziektebeloop werd gezien dat behandeling met ERT het 
beloop gunstig beïnvloedt. Het effect van behandeling met ERT op de spierkracht was 
groter bij vrouwen dan bij mannen. De longfunctie van jongere patiënten en van patiën-
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ten met een betere longfunctie hadden bij aanvang van de behandeling respondeerde 
beter op ERT. In hoofdstuk 3.2 beschrijven we een volwassen patiënt met de ziekte van 
Pompe die tijdens behandeling met ERT verder achteruit ging en infusie-geassocieerde 
reacties ontwikkelde. Daarnaast maakte hij ook hoge antilichaamtiters tegen het toe-
gediende enzym aan. We toonden aan dat er zoveel antilichamen in het bloed van de 
betreffende patiënt aanwezig waren dat ongeveer 40% van het toegediende algluco-
sidase alfa gebonden werd. Bovendien toonden in vitro testen aan dat de opname van 
alglucosidase alfa negatief beïnvloed werd door de antilichaambinding. Deze resultaten 
wijzen op neutraliserende effecten van de antilichamen op de therapeutische werking 
van alglucosidase alfa. In hoofdstuk 3.3 laten we zien dat 71 van de 73 (97%) van de vol-
wassen patiënten antilichamen tegen alglucosidase alfa ontwikkelden. Op groepsniveau 
werd de hoogste antilichaamtiter (1:1259) na 6 maanden ERT gemeten. Daarna daalde 
de titer tot 1:270 bij een behandelduur van 36 maanden. Na een initiële stijging bleef de 
antilichaam titer bij het merendeel (95%) van de patiënten stabiel of daalde gedurende 
de verdere behandeling. Bij de patiënten met de hoogste antilichaam concentraties in 
het bloed trad er significante remming op van de in vitro alglucosidase alfa activiteit. 
Deze bevindingen vertaalden zich echter niet naar de klinische praktijk, omdat er geen 
duidelijke negatieve effecten van hoge antilichaamtiters op het behandelresultaat gezien 
werden. Daarentegen vonden we wel dat er bij patiënten met hogere antilichaamtiters 
een significant hoger risico bestond op het ontwikkelen van infusie-geassocieerde re-
acties. In hoofdstuk 3.4 beschrijven we onze ervaring met ERT tijdens de zwangerschap 
en lactatieperiode van een 40-jarige patiënte met de ziekte van Pompe. Bij een zwan-
gerschapsduur van 37 weken en vijf dagen werd een gezonde jongen geboren middels 
een keizersnede. Er waren geen maternale complicaties en zowel de intra-uteriene ont-
wikkeling als de ontwikkeling van het kind in de eerste levensjaren verliepen normaal. 
Alglucosidase alfa werd in zeer kleine hoeveelheden uitgescheiden in de moedermelk op 
de dag van infusie, maar 24 uur na start van de infusie was de enzym activiteit weer op 
het oude niveau. Op basis hiervan concludeerden we dat het veilig lijkt om behandeling 
met ERT te continueren tijdens de zwangerschap en de borstvoedingsperiode.
Hoofdstuk 4 gaat over vermoeidheid als veel voorkomende klacht bij patiënten met 
neuromusculaire ziekten. In hoofdstuk 4.1 worden de pathofysiologische mechanismen 
en de beperkingen veroorzaakt door vermoeidheid bij patiënten met neuromusculaire 
ziekten beschreven aan de hand van de ziekte van Pompe en het Guillain-Barré syndroom. 
Overmatige vermoeidheid komt even vaak voor bij patiënten met neuromusculaire ziek-
ten als bij patiënten met multiple sclerosis. Vermoeidheid kan onderverdeeld worden in 
vermoeidheid zoals beleefd door de patiënt en fysiologische vermoeidheid. Fysiologische 
vermoeidheid kan vervolgens onderverdeeld worden in centrale en perifere vermoeid-
heid. Bij neuromusculaire ziekten is vermoeidheid meestal van perifere origine. Echter, 
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als reactie op de pathologie in het perifere zenuwstelsel kan centrale vermoeidheid 
ontstaan, dit om verdere schade door overbelasting van het perifere zenuwstelsel te 
voorkomen (central governor model). De ernst van de vermoeidheid is meestal gere-
lateerd aan de ernst van de onderliggende ziekte, met waarschijnlijk als enige uitzon-
dering het monofasische Guillain-Barré syndroom. De behandeling van vermoeidheid 
bij neuromusculaire ziekten bestaat uit symptomatische behandeling van de onderlig-
gende ziekte, oefentherapie en cognitieve gedragstherapie. In hoofdstuk 4.2 beschrijven 
we een patiënte met een bijzondere klinische presentatie: ernstige vermoeidheid en 
spierpijn traden reeds op voor het ontstaan van limb-girdle spierzwakte. Opvallend was 
dat het spierbiopt selectieve aantasting van de type I spiervezels toonde. Mogelijk dat 
deze bevinding bijdraagt aan de bijzondere klinische presentatie van deze patiënte.  In 
hoofdstuk 4.3 wordt de mate van vermoeidheid bij 163 patiënten die deelnamen aan het 
IPA/Erasmus MC Pompe onderzoek gerapporteerd. De gemiddelde follow-up was vier 
jaar voor start van behandeling met ERT en drie jaar gedurende behandeling. Voor start 
van behandeling was er, over de tijd gemeten met behulp van de ‘Fatigue Severity Scale’ 
(FSS score van 5.3), geen verandering in de mate van vermoeidheid op groepsniveau. 
Gedurende de behandelperiode nam de FSS score met 0.13 punten per jaar af (P <0.001). 
In Hoofdstuk 5 – de algemene discussie – worden de meest belangrijkste bevindingen 
beschreven, en worden deze vergeleken met de relevante medische literatuur en vertaald 
naar de implicaties voor de klinische praktijk. Daarnaast worden potentiële methoden 
om ERT te verbeteren, toekomstige behandelingen en suggesties voor verder onderzoek 
besproken. 
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aPPenDiX a | stuDy Design
Version adapted from the study design as described in the thesis written by N.A.M.E. van 
der Beek.
study design and participants
Prospective study on the natural course and effects of enzyme replacement therapy in 
children and adults with Pompe disease 
The Erasmus MC study on the natural course of Pompe disease and the effects of 
enzyme-replacement therapy (ERT) in children and adults with the disease is an ongo-
ing, nationwide, prospective study which was initiated in 2004. All patients are seen 
at regular intervals at Erasmus MC University Medical Center, the designated Centre of 
Excellence for Pompe disease in the Netherlands. Participation is open to all children and 
adults diagnosed with Pompe disease. Patients with classic infantile Pompe disease are 
not included in this study.
Patients are recruited either through neuromuscular centres in the Netherlands 
and Belgium or through the Dutch neuromuscular patient organization (Spierziekten 
Nederland), or are referred to our Center by their treating physicians in the Netherlands 
or abroad. All patients or their parents/guardian gave written informed consent for 
participation in the study. By March 2014, 118 adults and 17 children were taking part 
in the study.
Since the end of 2006, alglucosidase alfa (MyozymeÒ) has officially been reimbursed 
in the Netherlands; from that time on, patients who had been participating in the study 
gradually began treatment with ERT. As the Dutch government had decided that the 
Center for Lysosomal and Metabolic Diseases at Erasmus MC University Medical Center 
would be the only treatment center in the Netherlands, it was not possible to start 
treatment in all patients simultaneously. A special committee comprising neurologists, 
paediatricians, internal medicine specialists and geneticists was therefore instituted 
to decide which patients needed treatment most urgently. This decided that the most 
severely affected patients – meaning those who were mechanically ventilated and 
wheelchair-bound – should be treated first, followed by patients whose pulmonary 
function and muscle strength were declining rapidly. Patients in whom the disease was 
progressing slowly were started on ERT at a later stage. For children, the need for enzyme 
therapy was discussed on a case-by-case basis.
Of the Dutch patients participating in our study, 104 adults and 15 children are now 
being treated with enzyme therapy. Treatment is always started at our center, with all 
patients receiving alglucosidase alfa at a dose of 20 mg/kg every other week. If no severe 
side-effects are apparent within six to twelve months, patients can receive treatment 
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Table I Measurements performed during the natural course phase of our study in patients with Pompe 
disease
Procedure/measurement t = baseline t = every 6 months
Informed consent X
Inclusion/exclusion criteria X
General and neurological examination X X
Muscle strength and muscle function testing
§ Manual muscle testing (MRC score) X X 
§ Hand-Held Dynamometry X X 
§ QMFT X X 
§ AIMSa X X 
§ Griffiths developmental scaleb X X 
Video monitoring of functional outcome measures X X
Pulmonary function testing
§ Spirometry (VC, FVC, FEV1) X X
§ Respiratory muscle strength (MIP, MEP) X X
§ Capnography X X
§ Ventilator use assessmentc X X
Cardiac evaluation
§ Electrocardiogramd X
§ 24-hour Holter ECGd X
§ Echocardiogramd X
Audiometry
§ Pure-tone audiogramd X
§ Tympanographyd X
§ BAEPe X
Blood sample collection
§ CK, AST, ALT, LDH X X
§ Acid α-glucosidase activity in leukocytes X X
§ Blood film (PAS-positive lymphocyte vacuoles) X X
§ DNA mutation analysis X
Urine sample collection
§ Oligosaccharides X X
Skin biopsyf
§ fibroblast culture (acid α-glucosidase activity) X
Self-reported outcome measures
§ Fatigue Severity Scale X X
§ Rotterdam Handicap Scale X X
§ SF-36 / TACQOL X X
§ R-PAct X X
§ HADS X X
§ Health-economic questionnaire X X
See abbreviations on page 251 →
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at home or at a nearby hospital. As of March 2014, 70 adults and 13 children are receiv-
ing home treatment, while 10 adults receive ERT at a hospital other than Erasmus MC 
University Medical Center.
As this is an ongoing study, new data were still being collected when the data from 
the first groups of patients had already been analysed for a specific topic. This explains 
the different numbers of patients described in the different chapters.
clinical assessments and self-reported outcome measures
During the natural-course phase of the study, patients were assessed every six months. 
After the start of treatment, they were assessed every three months. Tables I and II give 
a schematic overview of the measurements performed during the study. The main inves-
tigations are described below.
Muscle strength and muscle function
The first symptoms in children and adults with Pompe disease usually involve mobility 
and limb-girdle weakness. A slowly progressive limb-girdle myopathy is a hallmark of 
the disease.
Muscle strength
Twenty-five different muscle groups were measured by manual muscle testing using 
the Medical Research Council (MRC) grading scale, where grade 5 represents normal 
muscle strength and grade 0 represents paralysis of the muscle group tested.1 The fol-
lowing muscle groups were examined: neck extensors, neck flexors, abdominal muscles, 
trunk muscles, and bilateral sternocleidomastoid muscle, trapezius mu r adductors, 
shoulder abductors, shoulder exorotators, shoulder endorotators, elbow flexors, elbow 
extensors, wrist extensors, wrist flexors, finger extensors, finger flexors, finger abduc-
tors, hip extensors, hip flexors, hip abductors, hip adductors, knee flexors, knee exten-
sors, ankle dorsal flexors, and ankle plantar flexors. 
Abbreviations: MRC=Medical Research Council; QMFT=Quick Motor Function Test; AIMS=Alberta Infant 
Motor Scale; VC=Vital Capacity; FVC=Forced Vital Capacity; FEV1=Forced Expiratory Volume in 1 second; 
MIP=Maximum Inspiratory Pressure; MEP=Maximum Expiratory Pressure; ECG=electrocardiogram; 
BAEP=Brainstem Auditory Evoked Potentials; CK=creatine kinase, AST=aspartate aminotransferase; 
ALT=alanine aminotransferase; LDH=Lactate dehydrogenase; PAS=Periodic Acid Schiff; DNA=Deoxyribonucleic 
acid; SF-36=Medical Outcomes Survey Short Form-36 Health Survey; TACQOL=TNO-AZL Child Quality of Life 
Questionnaire; R-PAct=Rasch-built Pompe-specific Activity scale; HADS=Hospital Anxiety and Depression 
Scale.
a In patients £ 18 months of age, b In patients 3 18 months and £ 7 years, c If applicable, d If abnormalities 
are found at baseline, follow-up will be continued at the next visits, e In patients £ 5 years, f If not performed 
prior to this study.
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Table II Measurements performed during the treatment phase of our study in patients with Pompe 
disease
Procedure / measurement Baseline t = 0
weeks
t = every 2 
weeks
t = 4 
weeks
t = 8 
weeks
t = every 3
 months
t = every 6 
months
t = 2 
years
Informed consent X
Inclusion/exclusion criteria X
General and neurological examination X X X X
Weight X X
Infusion with alglucosidase alfa X X
Vital signs X X X
Adverse events assessment X X
Concomitant medication assessment X X
Muscle strength/muscle function 
testing
§ Manual muscle testing (MRC score) X X
§ Hand-Held Dynamometry/QMT X X
§ Six-minute walk test X X
§ Timed tests X X
§ QMFT X X
§ AIMSa X X
§ Griffiths developmental scaleb X X
Video monitoring of functional 
outcomes
X X
Pulmonary function testing
§ Spirometry (VC, FVC, FEV1) X X
§ Respiratory strength (MIP, MEP) X X
§ Ventilator use assessmentc X X
Cardiac evaluation
§ Electrocardiogramd X X X X
§ Echocardiograme X X X X
Hearing testing
§ Tone audiograme X X
§ Tympanographye X X
§ BAEPe X X
Blood sample collection
§ CK, AST, ALT, LDH X X X X
§ α-glucosidase activity in leukocytes X X X X
§ PAS-positive lymphocyte vacuoles X X X X
§ DNA mutation analysisf X
§ Antibodies against α-glucosidase X X X X
§ PK-analysisg X
Urine sample collection
§ Oligosaccharides X X X X
Skin biopsy (fibroblast culture)f X
§ acid α-glucosidase activity X X
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Hand-held dynamometry (HHD) (Cytec dynamometer, Groningen, the Netherlands)3 
– which measures maximum voluntary contraction – was used to examine the follow-
ing muscle groups: neck extensors, neck flexors and bilateral shoulder abductors, elbow 
flexors, elbow extensors, wrist extensors, hip flexors, hip abductors, knee flexors, knee 
extensors, ankle dorsal flexors, and ankle plantar flexors.
In a subset of patients, quantitative muscle testing (QMT) was performed.4,5 During 
an isometric contraction, force was measured in the following muscle groups: bilateral 
shoulder adductors, elbow flexors, elbow extensors, hip adductors, knee extensors, knee 
flexors. Grip strength was also measured.
Muscle function
The Quick Motor Function Test (QMFT; Appendix B) was developed specifically to mea-
sure functional impairments in children and adults with Pompe disease.6 Comprising 16 
motor skills related to daily activities that require use of the shoulder-girdle musculature, 
Table II Continued
Procedure / measurement Baseline t = 0
weeks
t = every 2 
weeks
t = 4 
weeks
t = 8 
weeks
t = every 3
 months
t = every 6 
months
t = 2 
years
X-ray spineh X
DEXA scani X X
CT/MRI musclei X X
Muscle biopsyi X X
Self-reported outcome measuresj X X
§ Fatigue Severity Scale X X
§ Rotterdam handicap Scale X X
§ SF-36/TACQOLk X X
§ R-PAct X X
§ HADS X X
§ Health-economic questionnaire X X
Abbreviations: MRC= Medical Research Council; QMT= Quantitative Muscle Testing; QMFT= Quick Motor 
Function Test; AIMS= Alberta Infant Motor Scale; VC= Vital Capacity; FVC= Forced Vital Capacity; FEV1= 
Forced Expiratory Volume in 1 second; MIP=Maximum Inspiratory Pressure; MEP= Maximum Expiratory 
Pressure; BAEP=Brainstem Auditory Evoked Potentials; CK= creatine kinase, AST= aspartate aminotransferase; 
ALT=alanine aminotransferase; LDH=Lactate dehydrogenase; PAS= Periodic Acid Schiff; DNA= 
Deoxyribonucleic acid; PK= pharmacokinetics; DEXA= Dual-energy X-ray absorptiometry; CT= Computed 
Tomography; MRI= Magnetic Resonance Imaging; SF-36= Medical Outcomes Survey Short Form-36 Health 
Survey; TACQOL= TNO-AZL Child Quality of Life Questionnaire; R-PAct= Rasch-built Pompe-specific Activity 
scale; HADS= Hospital Anxiety and Depression Scale.
a In patients £ 18 months of age, b In patients 3 18 months and £ 7 years, c If applicable, d If not performed 
prior to this study, or when abnormalities were found at a prior investigation, e In patients £ 5 years, f If not 
performed prior to this study, g Only in patients ³ 18 years. PK analysis will be performed at week 0 and week 
2, h In children or adults with signs of scoliosis in whom corrective surgery is considered, i Not compulsory, j In 
patients 3 16 years unless otherwise indicated, k In patients 3 6 years and £16 years.
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trunk muscles, and pelvic-girdle/proximal lower limb muscles, this test is based on the 
Gross Motor Function Measure7,8 and the IPA/Erasmus MC Pompe Survey.9,10 
As a measure of functional endurance, we used the six-minute walk test (6MWT), 
which is widely regarded as an objective measure for reflecting a patient’s performance 
in the activities of daily living (ADL).7,8,11-13 We recorded the distance walked in six min-
utes. In patients who were unable to complete the full six-minute walk, we recorded the 
time they were able to walk.
To further evaluate the impact of muscle weakness on a patient’s ability to perform 
functional activities in daily life, we performed three additional timed tests: 1) walking 
10 meters; 2) climbing four stairs; and 3) getting up from a supine position on the floor.
Pulmonary function
As well as skeletal-muscle weakness, respiratory dysfunction is one of the main features 
of children and adults with Pompe disease. Severe pulmonary dysfunction may occur 
even in patients with minor mobility problems. We used a Lilly type pneumograph 
(Viasys Healthcare, Würzburg, Germany) or the KoKo spirometry system (Ferraris Respi-
ratory, Louisville, USA) to measure vital capacity (VC), forced vital capacity (FVC), and 
forced expiratory volume in one second (FEV1). Measurements were performed when the 
patient was in supine and upright seated positions.16-18
To obtain the maximum force that can be exerted by the respiratory muscles, we 
recorded maximum static inspiratory (MIP) and expiratory (MEP) pressures using a dif-
ferential pressure transducer (Viasys Healthcare, Würzburg, Germany).19
For information on hypercapnia and alveolar hypoventilation, the carbon dioxide frac-
tion in the expired gas was measured.20 If patients experienced symptoms indicating 
nocturnal hypoventilation, they were referred to a center for home ventilation, where 
further investigations could determine whether mechanical ventilatory support should 
be started. 
safety aspects of treatment with enzyme replacement therapy
Monitoring of Infusion-Associated Reactions
Adverse or infusion-associated reactions (IARs) are any undesirable sign or symptoms ex-
perienced by a patient during the treatment period. As IARs can occur before, during and 
after the infusion, vital signs (blood pressure, heart frequency, breathing frequency, and 
temperature) were measured to guard the safety of the patient. For the first 3 months 
of treatment, the patients had to stay in the hospital for 1 hour after the infusion to 
check if any adverse reactions occur in the phase just after the infusion. After this initial 
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period, the patient may leave the hospital immediately after the infusion if no IARs have 
occurred.
In case IARs occurred the patients was physically examined, and it was judged whether 
the infusion needed to be temporarily interrupted or discontinued. When needed anti-
histamines or corticosteroids were administered to treat the symptoms associated with 
the IAR. With the subsequent infusion, the infusion rates were lowered for prevention 
of IARs. In case IARs were persisting, pre-medication (antihistamines and/or corticoste-
roids) was prescribed. 
New symptoms and signs were documented using the adverse event form provided 
by Genzyme Corps.
Immunogenicity
The majority of patients with Pompe disease who are treated with ERT, developes (IgG) 
antibodies to alglucosidase alfa.21,22,23 Most patients who develop antibodies do so within 
the first 3 months of exposure. There is evidence that classic-infantile patients develop-
ing sustained titers of anti-alglucosidase alfa antibodies have a poorer clinical response 
to treatment, or may lose motor function as antibody titers increase.23,24 Therefore, we 
monitored antibody formation using ELISA in the majority of non-classic patients, who 
were receiving enzyme replacement therapy. In a subset of patients with high antibody 
titers, neutralizing effects of the antibodies on in vitro alglucosidase alfa enzymatic 
activity were determined.
 Pregnancy and lactation
There are no adequate and well-controlled studies in pregnant women or nursing moth-
ers. In other lysosomal storage diseases the experience with continuation of ERT during 
pregnancy, in much lower dosages compared to Pompe disease, did not suggest major 
problems.25-29 Furthermore, the product information of alglucosidase alfa mentions 
normal fetal development in mice and rabbits. Based on this information, we reasoned 
that continuation of ERT during pregnancy was not likely to pose a substantial risk to the 
mother or the fetus.
During each pregnancy of a women with Pompe disease who continued to receive 
ERT, the clinical condition of the mother was regularly checked and fetal growth was 
monitored by regular ultrasound investigations. After birth the newborn baby was care-
fully examined by the pediatrician. Potential transfer of alglucosidase alfa in the breast 
milk was measured during the infusion up to 24 hours thereafter. 
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self-reported outcome measures
Rotterdam 9-items Handicap Scale (RHS)
The RHS was originally developed to measure handicap in patients with immune-
mediated polyneuropathies;30 recently it was also proven to be useful for the evalua-
tion of patients with Pompe disease.10 Suitable for patients age 16 years and older, the 
scale comprises nine questions on the following topics: mobility indoors and outdoors; 
kitchen tasks; domestic tasks indoors and outdoors; leisure activities indoors and out-
doors; travelling; and work/study. The total score ranges from 9 to 36, with higher values 
representing a lower level of handicap.
Fatigue Severity Scale (FSS; Appendix C)
The FSS comprises nine items for determining the severity of fatigue and the impact 
of fatigue on a patient’s life.31 In recent years, it has become clear that fatigue is highly 
prevalent among patients with Pompe disease.32 The total FSS score is the average of the 
9 item scores and ranges from 1 (“no signs of fatigue”) to 7 (“most disabling fatigue”). 
Scores of 4 and higher indicate fatigue, and scores of 5 and higher indicate severe fatigue. 
Fatigue was assessed in patients aged 16 years and older.
Quality of life
Over the last decade, greater emphasis has been placed on “quality of life” as a measure 
which should be included in modern studies. Quality of life in patients over 16 years 
was measured using the Medical Outcomes Survey short-form 36 Health Survey (SF-36; 
see below). The SF-36 is widely used in various health conditions, including lysosomal 
storage disorders.33-35 It comprises 36 items addressing four physical health domains 
(physical functioning, role limitations due to physical problems, bodily pain, and general 
health perceptions); and four mental health domains (vitality, social functioning, role 
limitations due to emotional problems, and mental health). Items are summed per do-
main and subsequently transformed into scores between 0 and 100, with higher values 
representing better functioning. Its usefulness for evaluating the burden of Pompe 
disease was demonstrated recently.36
Hospital Anxiety and Depression Scale (HADS)
The HADS was developed by Zigmond and Snaith to identify anxiety disorders and 
depression among patients in non-psychiatric hospital clinics.37 It is divided into an 
anxiety subscale (HADS-A) and a depression subscale (HADS-D), each containing seven 
intermingled items. All symptoms of anxiety or depression that also related to physical 
disorder, such as dizziness, headaches, insomnia and fatigue were excluded. The HADS 
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has been widely used in different disorders.38 In our study, it was used to distinguish the 
fatigue caused by Pompe disease from that induced by anxiety or depression.
Rasch-built Pompe-specific Activity (R-PAct) scale
Pompe disease strongly affects patients’ functioning in daily life. Although the various 
aspects of this are difficult to measure, it is important to quantify them, both to manage 
individual patients and to evaluate the possible effects of enzyme replacement therapy 
or any other future treatment modality. We therefore constructed a patient-based in-
terval scale using Rasch analysis that is specifically suited to quantifying the effects of 
Pompe disease on a patient’s ability to carry out daily-life activities.39 
Health-economic questionnaire
The direct and indirect costs of treated and untreated Pompe disease were established 
through a self-applicable questionnaire, which included elements from the PROductiv-
ity and DISease Questionnaire (PRODISQ)40, EuroQol-5D41, and Vragenlijst Mantelzorg 
(Department of Public Health, Erasmus MC). We quantified seven aspects of the costs 
associated with medical care: living conditions, home adjustments, use of health care 
facilities, professional and non-professional care (e.g. partner or family), artificial venti-
lation, wheelchair use, and work or loss of productivity. All costs were evaluated against 
the background of the anticipated costs of enzyme-replacement therapy.
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aPPenDiX b | Quick motor function test
1. Raising the torso
Starting position: prone with arms by sides. Examiner may hold the patient’s legs.
Movement: the torso must be completely raised from the mat without using the 
arms.
❑	 initiates no neck extension
❑	 initiates neck extension but cannot raise head from mat
❑	 raises head from mat but torso remains on mat
❑	 partially raises head and torso from the mat
❑	 completely lifts head and torso from the mat (approx. 45°)
2. Neck flexion 
Starting position: supine position, preferably with head in midline and arms  by sides.
Movement: raises head to 45°.
❑	 initiates no neck flexion
❑	 	initiates neck flexion (some movement of the head that indicates neck flexion 
such as lifting or retracting the chin) but does not raise head
❑	 raises head < 45°
❑	 raises head to 45° with difficulty 
❑	 raises head to 45° or more with no difficulty  
3. Hand across midline
Starting position: supine position, preferably with head in the midline and arms by 
sides. Examiner holds hand at level of patient’s chest on L/R sides of the midline. Asks 
patient to reach towards hand.  
Movement: reaches with R/L arm and crosses the midline. 
❑	 makes no attempt to reach towards the midline
❑	 makes attempt to reach towards the midline
❑	 reaches with R/L arm, hand does not cross the midline 
❑	 	reaches with R/L arm, hand crosses the midline with difficulty (slowly, requiring 
effort)
❑	 reaches with R/L arm, hand crosses the midline without difficulty 
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4. Hip and knee flexion
Starting position: supine position, preferably with head in the midline, legs extended 
and arms by sides.
Movement: flexes R/L hip and knee through full range of motion
❑	 unable to initiate flexion in R/L hip and knee
❑	 initiates flexion in R/L hip and knee, but does not move hip more than 10°
❑	 flexes R/L hip and knee through part of full range of motion(<90°)
❑	 	flexes R/L hip and knee through full range of motion but with difficulty (slowly, 
with effort)
❑	 without difficulty flexes R/L hip and knee through full range of motion 
5. Extending the legs 
Starting position: supine position, preferably with head in the midline, legs stretched 
and arms by sides. 
Movement: extends and raises both legs simultaneously. 
❑	 does not attempt to raise legs
❑	 	attempts to raise legs but neither leg leaves the mat (tightens abdominal/leg 
muscles), or raises 1 leg 
❑	 raises legs from mat but does not extend them, or uses arms
❑	 with difficulty extends both legs and lifts them from the mat (e.g. very briefly)
❑	 extends both legs and lifts them from the mat without difficulty  
6. Sit up
Starting position: supine position, preferably with head in the midline, legs in 
comfortable position, arms by sides or crossed over the chest. 
Movement: sit up without support 
❑	 does not attempt to sit up (or initiate neck flexion)
❑	 attempts, but does not achieve sit up (even using the arms)
❑	 does a sit up, but using the arms 
❑	 does a sit up without using arms but with difficulty 
❑	 	does a sit up without using arms without difficulty (quick and controlled 
movement)
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7. Extending the arms 
Starting position: comfortable sitting position (seated on a chair, not leaning on back 
of the chair), arms by sides. 
Movement: raises both arms upwards along the body (180°).
❑	 does not attempt to raise arms
❑	 attempts to raise arms but they do not come above shoulder level  
❑	 raises both arms above shoulder level but arms do not quite reach 180 °
❑	 	raises both arms along the body and hands touch above the head but with 
difficulty (arms are not completely stretched)
❑	 raises both arms along the body and hands touch above the head without 
difficulty (arms remain extended)
8. Standing up from a chair
Starting position: seated in a chair, arms by sides not leaning on the back of the chair.
Movement: stands up from chair without using arms.
❑	 makes no attempt to stand up from chair 
❑	 attempts to stand up from chair but is not able to (even using arms)
❑	 stands up from chair using arms
❑	 	stands up from chair without using arms but with difficulty (slowly, with effort, 
number of attempts are necessary)
❑	 stands up from chair without using arms without difficulty  
9. Standing up from half-knee
Starting position: kneeling without arm support.
Movement: stands by means of half-knee position using L/R knee without using arms. 
❑	 makes no attempt to stand, OR: non-applicable
❑	 attempts to stand up but is not able to (even using arms)
❑	 stands by means of half-knee position using L/R knee and using arms
❑	 	stands by means of half-knee position using L/R knee without using arms but 
with difficulty 
❑	 	stands by means of half-knee position using L/R knee without using arms and 
without any difficulty 
264   |    Chapter 7
Chapter
 7
10.  Squatting
Starting position: standing. 
Movement: squats without using arms.
❑	 does not initiate squat, or: non-applicable
❑	 initiates squat but is unable to bend legs to 90° (even using arms or a support)
❑	 able to squat using arms or holding on
❑	 	able to squat without using arms, but with difficulty (quickly falls over, cannot 
easily maintain position)
❑	 squats with no difficulty without using arms
11.  Standing up from a squatting position
Starting position: squatting:
Movement: stands without using arms.
❑	 unable to stay in squatting position without help, OR: non-applicable
❑	 	attempts to get up from squatting position but is unable to stand (also not 
when using arms)
❑	 able to go from squatting to standing using arms
❑	 able to go from squatting to standing without using arms but with difficulty
❑	 goes from squatting to standing without using arms with no difficulty 
12.  Picking up an object 
Starting position: standing without arm support.
Movement: able to pick up an object from the floor and stand up again without arm 
support. 
❑	 makes no attempt to pick up an object from the floor, OR: non-applicable
❑	 attempts to pick up an object from the floor, put does not pick up the object
❑	 	picks up object from the floor and stands up again using arms (uses arms for 
balance, both on the floor and on the body)
❑	 	able to pick up an object from the floor without arm support and stand up again 
with difficulty 
❑	 	able to pick up an object from the floor without arm support and stand up again 
without difficulty (fast, controlled movement)
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13. Standing on one leg
Starting position: standing without arm support 
Movement: standing without arm support, lift L/R foot up for 10 seconds (and 
remains standing on the same leg).
❑	 lifts L/R foot up without arm support, OR: non-applicable
❑	 stands without arm support, lift L/R foot up for < 3 seconds 
❑	 stands without arm support, lifts L/R foot up for 3-9 seconds 
❑	 stands without arm support, lifts L/R foot up for 10 seconds with difficulty 
❑	 stands without arm support, lifts L/R foot up for 10 seconds without difficulty 
14. Walking ten metres
Starting position: standing without arm support. 
Movement: walks forward for 10 metres without arm support 
❑	 does not attempt to walk, OR: non-applicable
❑	 attempts to, but cannot walk for 10 m, even with support (hands, wall)
❑	 walks 10 m but uses hands or wall for support 
❑	 	walks 10 m without support of hands or wall, but with abnormal gait (e.g. 
staggering)
❑	 walks 10 m without difficulty 
15.  Jumping
Starting position: standing without arm support. 
Movement: jumps forward with both feet simultaneously  
❑	 does not attempt to jump forwards, OR: non-applicable
❑	 	jumps forwards < 10 cm with both feet simultaneously (or falls on jumping or 
landing)
❑	 jumps forwards between 10 and 40 cm with both feet simultaneously 
❑	 jumps forwards between 40 and 100 cm with both feet simultaneously  
❑	 	jumps forwards more than 100 cm with both feet simultaneously and without 
effort 
16. Walking up steps
Starting position: standing without arm support. 
Movement: walks up 4 steps using alternating feet without arm support  
❑	 does not attempt to walk up 4 steps, OR: non-applicable
❑	 walks (alternating or non-alternating feet), up 1 or more step using railing
❑	 walks (alternating or non-alternating feet), up 4 steps using railing
❑	 walks up 4 steps using non-alternating feet without arm support 
❑	 walks up 4 steps using alternating feet without arm support 
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aPPenDiX c | fatigue severity scale 
Individuals are instructed to choose a number from 1 to 7 that indicates their degree 
of agreement with each statement: 1 indicated strongly disagree and 7 strongly agree.
Completely Disagree Completely Agree
1. My motivation is lower when I am fatigued 1 2 3 4 5 6 7
2. Exercise brings on my fatigued 1 2 3 4 5 6 7
3. I am easily fatigued 1 2 3 4 5 6 7
4. Fatigue interferes with my physical functioning 1 2 3 4 5 6 7
5. Fatigue causes frequent problems for me 1 2 3 4 5 6 7
6. My fatigue prevents sustained physical functioning 1 2 3 4 5 6 7
7. Fatigue interferes with carrying out certain duties and 
responsibilities
1 2 3 4 5 6 7
8. Fatigue is among my 3 disabling symptoms 1 2 3 4 5 6 7
9. Fatigue interferes with my work, family or social life 1 2 3 4 5 6 7
Krupp et al. 1989
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DankwoorD
Pieter, ik kan me nog goed herinneren dat je me op 13 juni 2007 op het promotiefeest 
van Janet hebt gevraagd of ik interesse had om onderzoek te gaan doen naar de ziekte 
van Pompe. Dat had ik zeker. Pieter en Ans, ik ben jullie dan ook erg dankbaar voor de 
geboden kans om aan dit promotie avontuur te beginnen. 
In het dankwoord van mijn proefschrift, wil ik graag eenieder - patiënten, promotoren, 
copromotor, commissieleden, coauteurs, collega’s, vrienden en familie – bedanken, jullie 
hebben dit proefschrift mede mogelijk gemaakt.
Patiënten met de ziekte van Pompe
Allereerst wil ik de patiënten met de ziekte van Pompe bedanken voor hun bereidheid 
om deel te nemen aan de verschillende onderzoeken. Jullie komen elke 3 tot 6 maanden 
van heinde en van verre naar het Erasmus MC voor de verschillende testen. In het eerste 
jaar van de behandeling zelfs om de week voor de infusie met enzym therapie op de 
dagbehandeling van het Erasmus MC. Een fijne ontwikkeling is dat de meeste van jullie 
momenteel thuis behandeld worden of in een nabij gelegen ziekenhuis, waardoor jullie 
gelukkig minder tijd kwijt zijn. Ik hoop van harte dat de ontwikkelingen die momenteel 
gaande zijn zullen bijdragen aan een verdere verbetering van jullie kwaliteit van leven 
in de toekomst. 
verwijzende artsen 
J.H.J. Wokke, M. de Visser, B.G.M. van Engelen, J.B.M. Kuks, A.J. van der Kooi, N.C. Noter-
mans, C.G. Faber, J.J.G.M. Verschuuren, W.L. van der Pol, G.J. Biessels, H.J. Schelhaas, A.R. 
Wintzen, W.J.H.M. Grosveld, G. Hageman, A.M. Boon, H. Kerkhof, L.G.F. Sinnige, N.M. 
Vlam, J.T.H. van Asseldonk, A. van der Zwart, E.S.C. Korf, J.C. Doelman, A.J. Breukelman, 
M.F.G. van der Meulen, J. Trip, M.E. Pouwels, G. de Jong, C. Bouwsma, P.R. Schiphof, N. 
Voermans, J. de Bleecker, P.W. Wirtz, H.G.J. Dieks, en M.H.F. Bongers. 
Mijn waardering gaat uit naar alle neurologen en de klinisch geneticus, die patiënten 
naar ons Centrum hebben verwezen. Dankzij jullie kunnen wij deze patiënten een mul-
tidisciplinaire zorg aanbieden, hen op een gestandaardiseerde wijze volgen en indien 
geïndiceerd de behandeling met enzymvervangingstherapie starten. 
spierziekten nederland
De medewerkers van Spierziekten Nederland wil ik bedanken, en in het bijzonder Ria 
Broekgaarden. Het enthousiasme waarmee jullie de patiëntendagen organiseren en de 
belangen behartigen van patiënten met een spierziekte bewonder ik zeer.
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Promotoren en copromotor
Prof.dr. P.A van Doorn, beste Pieter. Heel veel dank voor je enthousiaste begeleiding al 
deze jaren. Ik bewonder je heldere visie als het gaat om het formuleren van onderzoeks-
doelen of het presenteren van wetenschappelijke resultaten. Jij kan als geen ander de 
vertaalslag maken van de kliniek naar wetenschappelijke vraagstukken en weer terug. 
Daarnaast heb ik bewondering voor hoe je je klinische werk, je professorschap en weten-
schappelijk werk combineert. Behalve dat je altijd voor je promovendi klaar staat, sta je 
ook pal achter hen. Ik heb dat als zeer steunend en prettig ervaren.
Naast  het harde werken, is je motto dat er ook hard genoten mag worden. We hebben 
dan ook veel lol gehad op de jaarlijkse terugkerende evenementen, zoals de Babinski 
skireizen, de feestelijke kerstdiners met de neuro-immunologie onderzoeksgroep en de 
zeiluitjes op jouw zeilboot. Zelfs als je onderzoekers je boot aan de grond laten lopen en 
het ze pas bij de zesde poging lukt om aan te meren of wanneer ze een quiche bakken 
waarop je een quiche-geassocieerde reactie ontwikkelt, worden ze het jaar daarop weer 
vriendelijk uitgenodigd. 
Dank voor de leuke en leerzame onderzoekstijd. De komende jaren hoop ik nog veel 
van je te kunnen leren als clinicus. 
Prof.dr. A.T. van der Ploeg, beste Ans. Tankewol dat je me deelgenoot hebt laten zijn van 
jullie levenswerk. Samen met Arnold vorm(de) je de drijvende kracht achter het Pompe 
onderzoek en hebben jullie laten zien hoe belangrijk het is om translationeel onderzoek 
te doen. Ik ben onder de indruk hoe je het voor elkaar krijgt om toegewijde patiëntenzorg 
te combineren met gedegen wetenschappelijk onderzoek. De vlucht die het onderzoek 
heeft genomen in combinatie met de centralisatie van de zorg voor patiënten met de 
ziekte van Pompe in Nederland heeft geresulteerd in de oprichting van ‘Het Centrum 
voor Lysosomale en Metabole Ziekten’. In dit Centrum werken onder jouw leiding nu 
meer dan vijftig mensen die wetenschappelijk onderzoek verrichten en/of betrokken zijn 
bij de zorg voor patiënten met de ziekte van Pompe, Mucopolysaccharidoses en andere 
stofwisselingsziekten. Ik kan me nog goed herinneren dat ik een aantal keer op je ‘vrije’ 
vrijdagen de metro naar Rhoon heb gepakt om daar samen de laatste hand aan het ERT 
artikel te leggen. De heerlijke koffie aldaar verhoogde de productiviteit aanzienlijk. Dank 
voor je begeleiding in de afgelopen jaren.
Dr. A.J.J. Reuser, beste Arnold. Je bent een onderzoeker in hart en nieren met een op-
vallend groot hart voor de patiënten waar je het onderzoek voor doet. Ik heb veel geleerd 
van je jarenlange ervaring in het veld, je kritische blik, je schrijftalent en je diplomatieke 
optreden op congressen. Arnold, ook al heb ik een keer stampvoetend van boosheid in je 
laboratorium gestaan om een of andere opmerking van je, ik ben je erg dankbaar voor 
je begeleiding bij het schrijven van onze gezamenlijke artikelen en bij de afronding van 
het proefschrift.  
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leden van de promotiecommissie
Prof.dr. J.H.J. Wokke, beste John. Hartelijk dank voor het plaatsnemen in de kleine com-
missie en het beoordelen van mijn manuscript. Ik ervaar het als een eer en een bezege-
ling van de jarenlange samenwerking op het gebied van de ziekte van Pompe. Prof.dr. 
E.J.G. Sijbrands, beste Eric. Jou wil ik ook bedanken voor het kritisch doorlezen van mijn 
manuscript en het plaatsnemen in de kleine commissie. Jouw epidemiologische blik 
heeft tot een nuttige discussie geleid en geeft een verdere impuls aan het (toekomstige) 
gezamenlijk onderzoek binnen ons Centrum. Prof.dr. A.G. Vulto, beste Arnold. Ik waardeer 
het zeer dat je plaats wilde nemen in de kleine commissie en de rol van secretaris wilde 
vervullen. En dat ten tijden van je vakantie. 
De overige commissieleden Prof.dr. E.A.P. Steegers en Prof.dr. R. de Groot wil ik be-
danken voor het plaatsnemen in de commissie. Beste Eric, ik wil op deze plek ook van de 
gelegenheid gebruik maken om je te bedanken voor je grote betrokkenheid bij de zorg 
voor de zwangere patiënten met de ziekte van Pompe. Onze eerste casus heeft geleid 
tot een mooie gezamenlijke publicatie over de continuering van enzymtherapie tijdens 
de zwangerschap van een patiënte met de ziekte van Pompe. Beste oom Ronald, het 
is een bijzondere situatie dat een familielid in de promotiecommissie plaatsneemt. Ik 
waardeer het dan ook bijzonder dat je dit voor me wil doen. Onze discussies over het 
doen van wetenschappelijk onderzoek en de toekomst van de zorg onder andere tijdens 
onze hardloopsessies op de Siciliaanse stranden heb ik als zeer inspirerend ervaren. 
mijn paranimfen
Annemarie en Nadine, wat fijn dat jullie mijn steun en toeverlaat wilden zijn in deze 
spannende tijd. Annemarie, ik vind het erg leuk dat je dit voor me wilt doen, temeer daar 
het hele promotieritueel een mysterieus gebeuren voor je is. Ik koester onze vriendschap, 
die op de middelbare school is begonnen. Sindsdien hebben we als best friends lief en 
leed gedeeld en erg leuke tijden beleefd, op naar meer wat mij betreft. Nadine, ik kan 
hier natuurlijk een paar pagina’s volschrijven, maar ik zal er een aantal zaken uitlichten. 
Ten eerste ben ik je erg dankbaar voor het onderzoekspad dat je voor me hebt geplaveid. 
Daarnaast heb ik het als een eer ervaren om je als paranimf terzijde te staan. Aan het 
verzoek van Geert of ik de uiterlijke verzorging van jou als bruid op me wilde nemen, 
hebben we ook veel hilariteit beleefd. Al was het schema van de laatste dag enigszins 
stressvol: je had de make-up, kapper en laatste jurk doorpas sessie op één dag gepland. 
Maar ik heb nog nooit zo’n stralende bruid gezien! Kortom, je bent naast een hele fijne 
collega, ook een hele goede vriendin geworden. 
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collega’s van het centrum voor lysosomale en metabole ziekten
Gezien de snelle groei van het Centrum, is er te weinig ruimte om iedereen persoonlijk te 
noemen. De volgende mensen wil ik in het bijzonder bedanken. 
Promovendi: Nadine, Carine, Linda, Marion, Marein, Deniz, Merel, Stephan, Carin, 
Esther Kuperus, Johanneke, Esmee, Tim, Esther Poelman, Tessel en Chris. Carine en Linda, 
het gezamenlijk promoveren aanstaande juni schept een (onzichtbare) band. Dit is naar 
mijn mening een lotgenoten etentje waard, zodat we samen nog eens terug kunnen 
blikken op de weg ernaar toe. Deniz de leukste herinneringen heb ik aan onze leuke trip 
naar Boston. Na de meeting met Genzyme, hebben we het prachtige in bloei staande 
Boston verkend. Jouw verblijf werd noodgedwongen verlengd door een vulkaanuitbar-
sting. Gelukkig mocht je blijven logeren bij m’n familie (Ivan, Jane en Leo) in Lexington. 
Dat klikte zo goed, dat je ze naderhand nog bent gaan opzoeken in New York. Stephan 
mooi om te zien dat jij een hele eigen weg inslaat met het onderzoek en je meer richt op 
diagnostische technieken en de families binnen ons cohort uitgebreid hebt beschreven. 
Heel veel succes met het afronden van je promotie. Esther, fijn dat je ons team bent 
komen versterken en de zorg voor de volwassenen patiënten op je hebt genomen. Daar-
naast zijn we met z’n allen natuurlijk erg nieuwsgierig naar de lange termijn resultaten 
van ERT. Jij ook heel veel succes met je verdere promotie. Alle anderen natuurlijk ook veel 
succes en plezier gewenst met het verdere onderzoek.
Esther Brusse, erg fijn dat je het Pompe team bent komen versterken als goede neu-
romusculaire dokter. Je bent natuurlijk een van de leukste ‘bazen’ en ik waardeer je inzet 
om ons als neurologen in spe het vak te leren. Hannerieke en René, jullie zijn twee hele 
fijne enthousiaste collega’s en jullie inzet voor patiënten met metabole en neuromuscu-
laire ziekten is bewonderenswaardig. 
Marloes en Michelle, dank voor jullie begeleiding bij het schrijven van de artikelen en 
de gezellige samenwerking. Marloes, daarnaast was het erg leuk om samen paranimf te 
zijn bij de promotie van Nadine. Michelle, naast dat je de flow in het onderzoek houdt 
samen met Iris, ben ik zo blij voor jou en Oscar dat jullie ook zo’n kleine man hebben 
mogen verwelkomen. 
David Alexander, I want to thank you for your critical reading of several of the manus-
cripts. I also very much enjoyed your classes in biomedical English writing, as you have 
the ultimate British sense of humour. I remember that we found out by coincidence that 
you also corrected manuscripts for my father, so in addition to your medical knowledge, 
you also know your way around landscape architecture. 
Marian Kroos, ik heb goede herinneringen aan de snuffelstage die ik bij jullie op het 
lab mocht lopen. Daarnaast wil ik jou, Lale en Marianne bedanken voor al het labwerk dat 
jullie hebben verzet. Pim, goed om te zien hoe het lab met jouw komst en het aantrek-
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ken van nieuwe mensen een nieuwe impuls heeft gekregen. Ik waardeer je enthousiaste 
begeleiding bij het schrijven van het antilichaamstuk. 
Ten aanzien van de klinische zorg voor de volwassen patiënten heb ik de samenwerking 
met de dokters van de interne geneeskunde als prettig ervaren: Adrienne Zandbergen, 
Bart Rövekamp, Janneke Langendonk en François Karsten, bedankt hiervoor. De research 
verpleegkundigen en de verpleegkundigen van de dagbehandeling (5 en 6 midden): Ali, 
Tineke, Wendy, Gonda, Judith, Sjaan, Irma, Belinda, Jacqueline en Rineke, dank voor jullie 
goede zorgen voor de patiënten en de ondersteuning bij de verschillende onderzoeken. 
De medewerkers van Jadim wil ik bedanken voor het faciliteren van de thuisbehandelin-
gen. 
De inzet van de mensen werkzaam in de apotheek speelt zich meer achter de scher-
men af, maar is van cruciaal belang als het gaat om behandeling met enzymtherapie. De 
bereiding in combinatie met de beperkte houdbaarheid van het infuus en de logistieke 
operatie om alle patiënten op tijd en op de juiste plek in Nederland van een infuus te 
voorzien is bepaald geen peanuts. Arnold Vulto, Jan-Dietert en Nicolette, dank voor al 
het werk dat jullie verzet hebben en de prettige en efficiënte samenwerking.  
Marianne en Nathalie, dank voor jullie ondersteunende werkzaamheden en dat het 
jullie vaak toch lukte om een plekje te reserveren in de overvolle agenda van Ans. 
Zenalda en Wilma, bedankt voor het overnemen van de afsprakenplanning voor de 
patiënten. 
Jacqueline Habermehl, je hebt mijn leven een stuk dragelijker gemaakt door je hulp 
bij het zetten van de laatste schreden op het promotiepad. Bedankt hiervoor.
statistische ondersteuning
Wim Hop, bedankt voor je begeleiding bij de ingewikkelde repeated measures analyses. 
Je ging de uitdaging niet uit de weg om met kleine patiëntenaantallen te werken. Dimi-
tris Rizopoulos, ik wil jou bedanken dat je het stokje van Wim Hop hebt overgenomen en 
me geholpen hebt bij het opschrijven van het laatste stuk.
Ewoud Steyerberg en Hester Lingsma, dank voor jullie hulp bij het ontwikkelen van 
een model, waarvan het uiteindelijke doel is om het individuele behandeleffect van 
enzymtherapie te kunnen voorspellen. We hebben de eerste stappen gezet, hopelijk 
resulteert het Europese samenwerkingsproject in een verdere verbetering van dit model 
in de nabije toekomst.
Pathologie
Beste Rob Verdijk, dank voor de kwalitatief goede plaatjes van het myometrium biopt 
in onze publicatie over de eerste zwangere patiënte met de ziekte van Pompe. Ook mijn 
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waardering voor de enthousiaste wijze waarop je alle spierbiopten beoordeeld van onze 
patiënten.
(oud) collega onderzoekers van de 22e en van de neuro-immunologie
Marie-Claire, Liselotte, Karin, Naghmeh, Mark, Sonja, Krista, Christa, Judith, Tessel, Immy, 
Rens, Christine, Joyce, Rinze, Inger, Puck, Bianca, Evita, Daniëlle, Julia, Maaike, Heleen, 
Susanne, Laura, Annemarie, Harro, Wan, Tsz, Carla, Karim, Janneke, Janne en Elise.
Jullie wil ik bedanken voor de geweldige tijd die we samen hebben gehad, in tijden van 
onderzoek deel je veel met elkaar en dat schept een bijzonder fijne band.  
fotografie
Huib Nederhof, duizendmaal dank dat ik jouw prachtige abstracte beeld, waarbij je 
kleurige zeecontainers vanuit de lucht hebt gefotografeerd, ‘zomaar’ voor de cover en 
het binnenwerk van mijn boekje mocht gebruiken.  
Drukkerij ridderprint
Medewerkers van Ridderprint, en in het bijzonder Ben, Lisa, Nikki en Robert, bedankt 
voor de vormgeving en het drukken van mijn proefschrift. Het resultaat mag er wezen! 
vrienden 
Lieve Olga, Janneke, Aafke, Kim, Annemarie, Joepe, Hiske, Jeanine, Floor, Liesbeth, An-
nemieke, Vera, Channa, Annemarijn, Bernadette, Joyce, Caroline, Florian en Emmeken, 
Michiel en Marion, Davy, Yannic, Ineke, Vincent, Edith en Paul: het einde van de sociale 
deprivatie is gelukkig daar, ik heb erg veel zin om met jullie bij te kletsen en te horen wat 
jullie hebben uitgespookt de afgelopen tijd. 
familie
Lieve paps en mams, dank voor jullie liefhebbende support in de afgelopen tijd. Het af-
gelopen jaar is verre van saai geweest, met de verhuizing, onze leuke en te lieve nieuwe 
aanwinst Fedja, het ouderschap voor ons en het grootouderschap voor jullie. Dat doet 
me ook terugdenken aan mijn fijne kindertijd, opgroeien in een woongroep met zulke 
gastvrije, open en liefhebbende ouders was erg fijn. Laura, Marcella en Stan, dank voor al 
jullie aandacht en gezelligheid. 
Lieve mam, lieve Priscil, jij weet ondertussen meer over de ziekte van Pompe dan me-
nig ander, dank dat je anytime mijn Engelse teksten wilde nakijken. Dylan ook al weet 
je geen snars van de ziekte van Pompe, je bent een erg fijne broer. Het enthousiasme 
waarmee jij in het leven staat en de dingen aanpakt, werkt aanstekelijk. Lieve Tess, jij 
bent natuurlijk de beste als het op de ziekte van Pompe aankomt. Je hebt bijna anderhalf 
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jaar tot mijn plezier bij ons gewerkt en zelfs een Pompe Expert Day mede georganiseerd. 
Bovenal ben je natuurlijk de liefste zus die er is. Ik ben erg blij voor je dat je zo gelukkig 
bent met Jip. Jip, bijzonder dat we tegelijkertijd in de afrondende fase van onze promotie 
zitten. 30 juni wordt jouw dag, ik heb er zin in!
Lieve Oma Ger, ik vind het erg leuk dat je zo betrokken bent bij ons en Fedja. En dat je 
als Amsterdamse ons zowaar komt opzoeken in het Rotterdamse.
Lieve Anke en Rob, wat ben ik gezegend met zulke helden van schoonouders. Dank 
voor al jullie hulp rondom de verhuizing, het op orde houden van ons huishouden en 
natuurlijk het verzorgen van het Fedja animatie programma. Iris en Joyce, jullie ook 
bedankt voor de hulp rond de verhuizing. Ik denk jullie ook, maar ik verheug me erg op 
de komst van ons lieve nichtje. 
eric & fedja
Lieve lieve allerliefste Eric, nu is het dan eindelijk echt WE time. Ik ben je héél erg dank-
baar voor je hulp tijdens de afronding van dit proefschrift. Je doet het toch maar ‘even’: 
het combineren van een fulltime baan, het runnen van het huishouden, je vriendin 
zoveel mogelijk stressvrij houden en ook nog de allerleukste pappa uithangen van Fedja. 
In de tussentijd heb je ook nog even een nieuwe baan geregeld. De enthousiaste manier 
waarop je het leven leidt, je trouwheid en bereidheid om de mensen van wie je houdt te 
helpen, je culinaire kwaliteiten en hang naar gezelligheid, maken je tot the love of my 
life! Ik ben erg blij dat er nu meer tijd is om het leven te vieren samen met jou, ons lieve 
ventje en alle fijne mensen om ons heen.
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Biomedical English writing and communication 2010 3.0
International conferences
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World Muscle Society, Almancil (3 poster presentations) 2011 1.5
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presentations)
2009 2.0
Steps Forward in Pompe disease, London (Poster presentation) 2010 0.5
Steps Forward in Pompe disease, Budapest (Oral presentation, 3 poster 
presentations)
2011 2.5
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2010 1.0
Belgisch-Nederlandse neuromusculaire studieclub, Utrecht 2011 0.2
Belgisch-Nederlandse neuromusculaire studieclub, Utrecht 2012 0.2
European NeuroMuscular Centre (ENMC) workshop, Naarden (oral 
presentation)
2010 1.0
Reunião da Primavera da Sociedade Portuguesa de Estudos de Doenças, 
Coimbra (oral presentation)
2011 1.0
National symposium on Pompe disease, Thessaloniki 2011 1.0
In depth courses
International Postgraduate Course on Lysosomal Storage Diseases, Nierstein 2008 1.0
Pompe disease expert day, Rotterdam (3 oral presentations) 2007-2010 3.0
Research conference on Pompe disease, Boston (2 oral presentations) 2010 2.0
Boerhaave Prinses Beatrix Fonds symposium neuromusculaire ziekten 2009-2013 0.8
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Amicus investigators’ meeting POM-CL-201, Enniskerry 2008 0.5
Presentation, media and communication coaching by LionsDen, London 2010 0.5
Teaching activities
Teaching of 2nd year medical students at the Utrecht University Center 2008-2010 3.0
Training homecare nurses, Rotterdam 2011 1.0
Reviewing papers for peer reviewed journals 2010-2013 1.0
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abbreviations
4-MU 4-methylumbelliferyl-α-D-glucopyranoside
6MWT Six-minute walk test
α-Glu Acid α-glucosidase
ACh Acetylcholine
AIMS Alberta infant motor scale
ALT Alanine aminotransferase
AST Aspartate aminotransferase
ANA Antinuclear antibodies
ATPase Adenosine triphosphatase
BAEP Brainstem auditory evoked potentials
BSA Bovine serum albumin 
CAF Central activation failure
CBS Dutch central bureau of statistics
CCMO Central committee on research involving human subjects in the 
Netherlands
CCV Clathrin-coated vesicles
CHO-cells Chinese hamster ovary-cells
CI Confidence interval
CIDP Chronic inflammatory demyelinating polyneuropathy
CIS Checklist individual strength
CK Creatine kinase
CNS Central nervous system
CMT Charcot-Marie-Tooth disease
COX Cytochrome oxidase
CRIM Cross reactive immunogenic material
CT Computed tomography
CTG College tarieven gezondheidszorg
CVZ College voor zorgverzekeringen
DEXA Dual-energy X-ray absorptiometry
DNA Deoxyribonucleic acid
EB Empirical Bayes estimates
ECG Electrocardiogram
ELISA Enzyme-linked immunosorbent assay
EMA European medicines agency
eow Every other week
ERT Enzyme replacement therapy
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FcR Fragment crystallisable receptor
FDA Food and drug administration
FEV1 Forced expiratory volume in 1 second
FIS Fatigue Impact Scale
FSHD Facioscapulohumeral Muscular Dystrophy
FSS Fatigue severity scale
FVC Forced vital capacity
GAA Acid α-glucosidase or gene coding for acid α-glucosidase
GBS Guillain–Barré syndrome
GSD Glycogen storage disease
HADS Hospital anxiety and depression scale
HE Hematoxylin and eosin staining
HHD Hand-held dynamometry
HP-GAA Hyper-mannose-6-phosphorylated variant of recombinant human acid 
α-glucosidase generated by enzymatic engineering
HSCT Hematopoietic stem-cell transplantation
IAR Infusion-associated reaction
ICF International classification of functioning, disability and health
IgE Immunoglobulin E
IGF-2 Insulin growth factor 2
IgG Immunoglobulin G
IPA International Pompe Association
IQR Inter quartile range
ISNO Interuniversitair steunpunt neuromusculair onderzoek (the Dutch 
neuromuscular research center)
IVS1 Common splice-site mutation in non-classic Pompe disease IVS1-13T>G 
(c.-32-13T>G)
LDH Lactate dehydrogenase
kDa Kilo Dalton
LEMS Lambert-Eaton myasthenic syndrome
LGMD Limb-girdle muscular dystrophy
LOTS Late-onset treatment study
M6P Mannose-6-phosphate
MC Medical center
MEP Maximal expiratory pressure
MFI Median fluorescence intensity or multidimensional fatigue inventory
MFM Motor function measure
MIP Maximal inspiratory pressure
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MMT Manual muscle testing
MPS Mucopolysaccharidosis
MRC Medical Research Council
MRI Magnetic resonance imaging
N or n Number of patients
NA Not applicable
NADH Nicotinamide adenine dinucleotide
neo-rhGAA Hyper-mannose-6-phosphorylated variant of recombinant human 
acid α-glucosidase generated by chemical conjugation of synthetic 
oligosaccharides bearing M6P residues
NR Not reported
OMIM Online Mendelian Inheritance in Man
OPMD Oculopharyngeal muscular dystrophy
ORO Oil red O
DM Myotonic dystrophy
PAS Periodic acid-Schiff
PBS Phosphate buffered saline
PCS Physical Component Summary
PEDI Pediatric evaluation of disability inventory
PK Pharmacokinetics
PNS Peripheral nervous system
pp Percentage points
PROMM Proximal myotonic myopathy
QoL Quality of life
QMFT Quick motor function test
QMT Quantitative muscle testing
rAAV Recombinant adeno-associated viruses
R-FSS Rasch-build fatigue severity scale
rhGAA Recombinant human acid α-glucosidase
RHS Rotterdam 9-items handicap scale
RIP Radio-immuno precipitation assay
R-PAct Rasch-built Pompe-specific Activity scale
SD Standard deviation
SDH Succinate dehydrogenase
SEPN1RM Selenoprotein N1-related myopathy
SF-36 Medical outcomes study short-form 36 health survey
sIBM Sporadic inclusion body myositis
SMA Spinal muscular atrophy
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TACQOL TNO-AZL child quality of life questionnaire
TMB 3,3′,5,5′–tetramethylbenzidine
TSH Thyroid-stimulating hormone
VAS-F Visual analogue scale for fatigue
VC Vital capacity
VPRIV Velaglucerase alfa for injection
VSN Vereniging Spierziekten Nederland
WGM Walter Gardner scale
WHO World health organization

